<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2061878-B1" country="EP" doc-number="2061878" kind="B1" date="20140108" family-id="39157898" file-reference-id="312909" date-produced="20180826" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146588349" ucid="EP-2061878-B1"><document-id><country>EP</country><doc-number>2061878</doc-number><kind>B1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-07837971-A" is-representative="NO"><document-id mxw-id="PAPP154850541" load-source="docdb" format="epo"><country>EP</country><doc-number>07837971</doc-number><kind>A</kind><date>20070907</date><lang>EN</lang></document-id><document-id mxw-id="PAPP173218201" load-source="docdb" format="original"><country>EP</country><doc-number>07837971.6</doc-number><date>20070907</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140548896" ucid="US-2007019655-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>2007019655</doc-number><kind>W</kind><date>20070907</date></document-id></priority-claim><priority-claim mxw-id="PPC140556849" ucid="US-84309206-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>84309206</doc-number><kind>P</kind><date>20060908</date></document-id></priority-claim></priority-claims><dates-of-public-availability><intention-to-grant-date><date>20130620</date></intention-to-grant-date><search-report-dispatch-date><date>20090929</date></search-report-dispatch-date></dates-of-public-availability><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1989325352" load-source="docdb">C12N   5/10        20060101AFI20090727BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325353" load-source="docdb">C07H  21/04        20060101ALI20090923BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325354" load-source="docdb">C07H  21/02        20060101ALI20090923BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325355" load-source="docdb">C12P  21/02        20060101ALI20090923BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989622864" load-source="docdb">C12N  15/11        20060101A I20100814RMEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-2059366650" load-source="docdb" scheme="CPC">C12N  15/11        20130101 LI20150504BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2059367791" load-source="docdb" scheme="CPC">C12N   9/93        20130101 LI20150504BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2059369214" load-source="docdb" scheme="CPC">C12P  21/02        20130101 FI20150504BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132369680" lang="DE" load-source="patent-office">HYBRIDUNTERDRÜCKER-TRNA FÜR WIRBELTIERZELLEN</invention-title><invention-title mxw-id="PT132369681" lang="EN" load-source="patent-office">HYBRID SUPPRESSOR TRNA FOR VERTEBRATE CELLS</invention-title><invention-title mxw-id="PT132369682" lang="FR" load-source="patent-office">ARNT SUPPRESSEUR HYBRIDE POUR CELLULES DE VERTÉBRÉS</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR919517633" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>AMBRX INC</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR919505481" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>AMBRX, INC.</last-name></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919518836" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>TIAN FENG</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919525182" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>TIAN, FENG</last-name></addressbook></inventor><inventor mxw-id="PPAR919022688" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>TIAN, FENG</last-name><address><street>9003 Buckwheat Street</street><city>San Diego, CA 92129</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919521909" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>NORMAN THEA</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919541945" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>NORMAN, THEA</last-name></addressbook></inventor><inventor mxw-id="PPAR919022687" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>NORMAN, THEA</last-name><address><street>1729 Bancroft Street</street><city>San Diego, CA 92102</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919517511" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>CHU STEPHANIE</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919545580" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>CHU, STEPHANIE</last-name></addressbook></inventor><inventor mxw-id="PPAR919022689" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>CHU, STEPHANIE</last-name><address><street>4220 Porte De Palmas 34</street><city>San Diego, CA 92122</city><country>US</country></address></addressbook></inventor></inventors><assignees><assignee mxw-id="PPAR919022691" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Ambrx, Inc.</last-name><iid>100788979</iid><address><street>10975 North Torrey Pines Road, Suite 100</street><city>La Jolla CA 92037</city><country>US</country></address></addressbook></assignee></assignees><agents><agent mxw-id="PPAR919022690" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Mercer, Christopher Paul</last-name><suffix>et al</suffix><iid>100022025</iid><address><street>Carpmaels &amp; Ransford LLP One Southampton Row</street><city>London WC1B 5HA</city><country>GB</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="US-2007019655-W"><document-id><country>US</country><doc-number>2007019655</doc-number><kind>W</kind><date>20070907</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2008030613-A2"><document-id><country>WO</country><doc-number>2008030613</doc-number><kind>A2</kind><date>20080313</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549923651" load-source="docdb">AT</country><country mxw-id="DS549891995" load-source="docdb">BE</country><country mxw-id="DS549869326" load-source="docdb">BG</country><country mxw-id="DS549784032" load-source="docdb">CH</country><country mxw-id="DS549878304" load-source="docdb">CY</country><country mxw-id="DS549878305" load-source="docdb">CZ</country><country mxw-id="DS549872655" load-source="docdb">DE</country><country mxw-id="DS549891996" load-source="docdb">DK</country><country mxw-id="DS549892001" load-source="docdb">EE</country><country mxw-id="DS549784764" load-source="docdb">ES</country><country mxw-id="DS549869327" load-source="docdb">FI</country><country mxw-id="DS549869328" load-source="docdb">FR</country><country mxw-id="DS549872656" load-source="docdb">GB</country><country mxw-id="DS549892002" load-source="docdb">GR</country><country mxw-id="DS549878310" load-source="docdb">HU</country><country mxw-id="DS549784046" load-source="docdb">IE</country><country mxw-id="DS549892003" load-source="docdb">IS</country><country mxw-id="DS549869329" load-source="docdb">IT</country><country mxw-id="DS549892004" load-source="docdb">LI</country><country mxw-id="DS549872657" load-source="docdb">LT</country><country mxw-id="DS549923652" load-source="docdb">LU</country><country mxw-id="DS549869334" load-source="docdb">LV</country><country mxw-id="DS549872662" load-source="docdb">MC</country><country mxw-id="DS549923653" load-source="docdb">MT</country><country mxw-id="DS549923654" load-source="docdb">NL</country><country mxw-id="DS549923655" load-source="docdb">PL</country><country mxw-id="DS549784769" load-source="docdb">PT</country><country mxw-id="DS549802135" load-source="docdb">RO</country><country mxw-id="DS549923657" load-source="docdb">SE</country><country mxw-id="DS549872663" load-source="docdb">SI</country><country mxw-id="DS549784047" load-source="docdb">SK</country><country mxw-id="DS549892010" load-source="docdb">TR</country></ep-contracting-states><ep-extended-states><ep-extended-state-data><country>AL</country></ep-extended-state-data><ep-extended-state-data><country>BA</country></ep-extended-state-data><ep-extended-state-data><country>HR</country></ep-extended-state-data><ep-extended-state-data><country>MK</country></ep-extended-state-data><ep-extended-state-data><country>RS</country></ep-extended-state-data></ep-extended-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><description mxw-id="PDES63960772" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001"><b>FIELD OF THE INVENTION</b></heading><p id="p0001" num="0001">The invention pertains to the field of translation biochemistry in vertebrate cells. The invention relates to methods for producing and compositions of orthogonal tRNA's, orthogonal synthetases and pairs thereof, in vertebrate cells. The invention also relates to compositions of unnatural amino acids, proteins and methods of producing proteins in vertebrate cells that include unnatural amino acids.</p><heading id="h0002"><b>BACKGROUND OF THE INVENTION</b></heading><p id="p0002" num="0002">The genetic code of every known organism, from bacteria to humans, encodes the same twenty common amino acids. Different combinations of the same twenty natural amino acids form proteins that carry out virtually all the complex processes of life, from photosynthesis to signal transduction and the immune response. In order to study and modify protein structure and function, scientists have attempted to manipulate both the genetic code and the amino acid sequence of proteins. However, it has been difficult to remove the constraints imposed by the genetic code that limit proteins to twenty genetically encoded standard building blocks (with the rare exception of selenocysteine <i>(see, e.g.,</i> <nplcit id="ncit0001" npl-type="s"><text>A. Bock et al., (1991), Molecular Microbiology 5:515-20</text></nplcit>) and pyrrolysine <i>(see, e.g.,</i> <nplcit id="ncit0002" npl-type="s"><text>G. Srinivasan, et al., (2002), Science 296:1459-62</text></nplcit>).</p><p id="p0003" num="0003">Some progress has been made to remove these constraints, although this progress has been limited and the ability to rationally control protein structure and function is still in its infancy. For example, chemists have developed methods and strategies to synthesize and manipulate the structures of small molecules <i>(see, e.g.,</i> <nplcit id="ncit0003" npl-type="b"><text>E. J. Corey, &amp; X.-M. Cheng, The Logic of Chemical Synthesis (Wiley-Interscience, New York, 1995</text></nplcit>)). Total synthesis <i>(see, e.g.,</i> <nplcit id="ncit0004" npl-type="s"><text>B. Merrifield, (1986), Science 232:341-7 (1986</text></nplcit>)), and semi-synthetic methodologies <i>(see, e.g.,</i> <nplcit id="ncit0005" npl-type="s"><text>D. Y. Jackson et al., (1994) Science 266:243-7</text></nplcit>; and, <nplcit id="ncit0006" npl-type="s"><text>P. E. Dawson, &amp; S. B. Kent, (2000), Annual Review of Biochemistry 69:923-60</text></nplcit>), have made it possible to synthesize peptides and small proteins, but these methodologies have limited utility with proteins over 10 kilo Daltons (kDa). Mutagenesis methods, though powerful, are restricted to a limited number of structural changes. In a number of cases, it has been possible to competitively incorporate close structural analogues of common amino acids throughout proteins. <i>See, e.g.,</i> <nplcit id="ncit0007" npl-type="s"><text>R. Furter, (1998), Protein Science 7:419-26</text></nplcit>; <nplcit id="ncit0008" npl-type="s"><text>K.<!-- EPO <DP n="2"> --> Kirshenbaum, et al., (2002), ChemBioChem 3:235-7</text></nplcit>; and, <nplcit id="ncit0009" npl-type="s"><text>V. Doring et al., (2001), Science 292:501-4</text></nplcit>.</p><p id="p0004" num="0004">In an attempt to expand the ability to manipulate protein structure and function, <i>in vitro</i> methods using chemically acylated orthogonal tRNA's were developed that allowed unnatural amino acids to be selectively incorporated in response to a nonsense codon, <i>in vitro (see, e.g.,</i><nplcit id="ncit0010" npl-type="s"><text> J. A. Ellman, et al., (1992), Science 255:197-200</text></nplcit>). Amino acids with novel structures and physical properties were selectively incorporated into proteins to study protein folding and stability and biomolecular recognition and catalysis. <i>See, e.g.,</i> <nplcit id="ncit0011" npl-type="s"><text>D. Mendel, et al., (1995), Annual Review of Biophysics and Biomolecular Structure 24:435-462</text></nplcit>; and, <nplcit id="ncit0012" npl-type="s"><text>V. W. Cornish, et al. (Mar. 31, 1995), Angewandte Chemie-International Edition in English 34:621-633</text></nplcit>. However, the stoichiometric nature of this process severely limited the amount of protein that could be generated.</p><p id="p0005" num="0005">Unnatural amino acids have been microinjected into cells. For example, unnatural amino acids were introduced into the nicotinic acetylcholine receptor in Xenopus oocytes (e.g., <nplcit id="ncit0013" npl-type="s"><text>M.W. Nowak, et al. (1998), In vivo incorporation of unnatural amino acids into ion channels in Xenopus oocyle expression system, Method Enzymol. 293:504-529</text></nplcit>) by microinjection of a chemically misacylated Tetrahymena thermophila tRNA (e.g., <nplcit id="ncit0014" npl-type="s"><text>M.E. Saks, et al. (1996), An engineered Tetrahymena tRNAGln for in vivo incorporation of unnatural amino acids into proteins by nonsense suppression, J. Biol. Chem. 271:23169-23175</text></nplcit>), and the relevant mRNA. This has allowed detailed biophysical studies of the receptor in oocytes by the introduction of amino acids containing side chains with unique physical or chemical properties. <i>See, e.g.,</i> <nplcit id="ncit0015" npl-type="s"><text>D.A. Dougherty (2000), Unnatural amino acids as probes ofprotein structure and function, Curr. Opin. Chem. Biol. 4:645-652</text></nplcit>. Unfortunately, this methodology is limited to proteins in cells that can be microinjected, and because the relevant tRNA is chemically acylated in vitro, and cannot be re-acylated, the yields of protein are very low.</p><p id="p0006" num="0006">To overcome these limitations, new components were added to the protein biosynthetic machinery of the prokaryote <i>Escherichia coli (E. coli)</i> (e.g., L. Wang, et al., (<nplcit id="ncit0016" npl-type="s"><text>2001), Science 292:498-500</text></nplcit>), which allowed genetic encoding of unnatural amino acids in <i>vivo.</i> A number of new amino acids with novel chemical, physical or biological properties, including photoaffinity labels and photoisomerizable amino acids, keto amino acids, and glycosylated amino acids have been incorporated efficiently and with high fidelity into<!-- EPO <DP n="3"> --> proteins in E. <i>coli</i> in response to the amber codon, TAG, using this methodology. <i>See, e.g.,</i> <nplcit id="ncit0017" npl-type="s"><text>J. W. Chin et al., (2002), Journal of the American Chemical Society 124:9026-9027</text></nplcit>; <nplcit id="ncit0018" npl-type="s"><text>J. W. Chin, &amp; P. G. Schultz, (2002), ChemBioChem 11:1135-1137</text></nplcit>; <nplcit id="ncit0019" npl-type="s"><text>J. W. Chin, et al., (2002), PNAS United States of America 99:11020-11024</text></nplcit>: and, <nplcit id="ncit0020" npl-type="s"><text>L. Wang, &amp; P. G. Schultz, (2002), Chem. Comm.. 1-10</text></nplcit>. However, the translational machinery of prokaryotes and eukaryotes are not highly conserved; thus, components of the biosynthetic machinery added to <i>E. coli</i> cannot often be used to site-specifically incorporate unnatural amino acids into proteins in vertebrate cells. For example, the <i>Methanococcus jannaschii</i> tyrosyl-tRNA synthetase/tRNA pair that was used, in <i>E. coli</i> is not orthogonal in vertebrate cells. In addition, the transcription of tRNA in eukaryotes, but not in prokaryotes, is carried out by RNA Polymerase III and this places restrictions on the primary sequence of the tRNA structural genes that can be transcribed in vertebrate cells. Moreover, in contrast to prokaryotic cells, tRNA's in vertebrate cells need to be exported from the nucleus, where they are transcribed, to the cytoplasm, to function in translation. Finally, the vertebrate 80S ribosome is distinct from the 70S prokaryotic ribosome. Thus, there is a need to develop improved components of the biosynthetic machinery to expand the vertebrate genetic code. This invention fulfills these and other needs, as will be apparent upon review of the following disclosure.</p><heading id="h0003"><u>SUMMARY OF THE INVENTION</u></heading><p id="p0007" num="0007">The invention provides vertebrate cells, wherein the vertebrate cell is not a human embryonic stem cell or an in vivo human cell, with translation components, e.g., pairs of orthogonal aminoacyl-tRNA synthetases (O-RSs) and orthogonal tRNA's (O-tRNA's with a sequence as set forth in SEQ ID NO: 87) and individual components thereof, that are used in vertebrate protein biosynthetic machinery to incorporate an unnatural amino acid in a growing polypeptide chain, in a vertebrate cell.</p><p id="p0008" num="0008">Compositions of the invention include a vertebrate cell (e.g., a mammalian cell, an avian cell, a fish cell, a reptile cell, an amphibian cell, cells derived from non-mammalian animals, etc.) comprising an orthogonal aminoacyl-tRNA synthetase (O-RS) (e.g., derived from a non-vertebrate organism, such as <i>Escherichia coli, Bacillus stearothermophilus,</i> etc.), where the O-RS preferentially aminoacylates the orthogonal tRNA with a sequence as set forth in SEQ ID NO: 87 (O-tRNA) with at least one unnatural amino acid in the vertebrate cell. Optionally, two or more OtRNA's can be aminoacylated in a given vertebrate cell. In one aspect, an O-RS aminoacylates an O-tRNA with the unnatural amino acid, e.g., at least 40%, at least 45%, at<!-- EPO <DP n="4"> --> least 50%, at least 60%, at least 75%, at least 80%, or even 90% or more as efficiently as does an O-RS having an amino acid sequence, e.g., as set forth in SEQ ID NO.: 86 or 45. In one embodiment, an O-RS of the disclosure aminoacylates the O-tRNA with the unnatural amino acid, e.g., at least 10-fold, at least 20-fold, at least 30-fold, etc., more efficiently than the O-RS aminoacylates the O-tRNA with a natural amino acid.</p><p id="p0009" num="0009">In one embodiment, the O-RS or a portion thereof is encoded by a polynucleotide sequence as set forth in any one of SEQ ID NO.: 3-35, or a complementary polynucleotide sequence thereof. In another embodiment, the O-RS comprises an amino acid sequence as set forth in any one of SEQ ID NO.: 36-63, and/or 86, or a conservative variation thereof. In yet another embodiment, the O-RS comprises an amino acid sequence that is, e.g., at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5 % or more, identical to that of a naturally occurring tyrosyl aminoacyl-tRNA synthetase (TyrRS) and comprises two or more amino acids from groups A-E. Group A includes valine, isoleucine, leucine, glycine, serine, alanine, or threonine at a position corresponding to Tyr37 of an E. <i>coli</i> TyrRS. Group B includes aspartate at a position corresponding to Asn126 of an E. <i>coli</i> TyrRS. Group C includes threonine, serine, arginine, asparagine or glycine at a position corresponding to Asp182 of an <i>E, coli</i> TyrRS. Group D includes methionine, alanine, valine, or tyrosine at a position corresponding to Phe183 of an <i>E. coli</i> TyrRS; and, group E includes serine, methionine, valine, cysteine, threonine, or alanine at a position corresponding to Leu186 of an <i>E. coli</i> TyrRS.</p><p id="p0010" num="0010">In another embodiment, the O-RS has one or more improved or enhanced enzymatic properties for the unnatural amino acid as compared to a natural amino acid. For example, the improved or enhanced properties for the unnatural amino acid as compared to a natural amino acid include any of, e.g., a higher Km, a lower Km, a higher kcat, a lower kcat, a lower kcat/km, a higher kcat/km, etc.</p><p id="p0011" num="0011">The vertebrate cell also optionally includes an unnatural amino acid(s). The vertebrate cell also includes an orthogonal tRNA (O-tRNA) with a sequence as set forth in SEQ ID NO: 87, where the O-tRNA recognizes a selector codon and is preferentially aminoacylated with the unnatural amino acid by the O-RS. In one aspect, the O-tRNA mediates the incorporation of the unnatural amino acid into a protein with, e.g., at least 45%, at least 50%, at least 60%, at least 75%, at least 80%, at least 90%, at least 95%, or 99% or the efficiency of a tRNA<!-- EPO <DP n="5"> --> that comprises or is processed in a cell from a polynucleotide sequence as set forth in SEQ ID NO.: 65.</p><p id="p0012" num="0012">In another embodiment, the vertebrate cell comprises a nucleic acid that comprises a polynucleotide that encodes a polypeptide of interest, where the polynucleotide comprises a selector codon that is recognized by the O-tRNA. In one aspect, the yield of the polypeptide of interest comprising the unnatural amino acid is, e.g., at least 2.5%, at least 5%, at least 10%, at least 25%, at least 30%, at least 40%, 50% or more, of that obtained for the naturally occurring polypeptide of interest from a cell in which the polynucleotide lacks the selector codon. In another aspect, the cell produces the polypeptide of interest in the absence of the unnatural amino acid, with a yield that is, e.g., less than 35%, less than 30%, less than 20%, less than 15%, less than 10%, less than 5%, less than 2.5%, etc., of the yield of the polypeptide in the presence of the unnatural amino acid.</p><p id="p0013" num="0013">The invention also provides a vertebrate cell comprising an orthogonal aminoacyl-tRNA synthetase (O-RS), an orthogonal tRNA (O-tRNA with a sequence as set forth in SEQ ID NO: 87), an unnatural amino acid, and a nucleic acid that comprises a polynucleotide that encodes a polypeptide of interest. The polynucleotide comprises a selector codon that is recognized by the O-tRNA. In addition, the O-RS preferentially aminoacylates the orthogonal tRNA (O-tRNA) with the unnatural amino acid in the vertebrate cell, and the cell produces the polypeptide of interest in the absence of the unnatural amino acid, with a yield that is, e.g., less than 30%, less than 20%, less than 15%, less than 10%, less than 5%, less than 2.5%, etc., of the yield of the polypeptide in the presence of the unnatural amino acid.</p><p id="p0014" num="0014">Compositions that include a vertebrate cell comprising an orthogonal tRNA (O-tRNA with a sequence as set forth in SEQ ID NO: 87) are also a feature of the invention. Typically, the O-tRNA mediates incorporation of an unnatural amino acid into a protein that is encoded by a polynucleotide that comprises a selection codon that is recognized by the O-tRNA in vivo. In one embodiment, the O-tRNA mediates the incorporation of the unnatural amino acid into the protein with, e.g., at least 45%, at least 50%, at least 60%, at least 75%, at least 80%, at least 90%, at least 95%, or even 99% or more the efficiency of a tRNA that comprises or is processed in a cell from a polynucleotide sequence as set forth in SEQ ID NO.: 65.<!-- EPO <DP n="6"> --></p><p id="p0015" num="0015">In one aspect of the disclosure, the O-tRNA is post-transcriptionally modified. The disclosure also provides a nucleic acid that encodes an O-tRNA in a vertebrate cell, or a complementary polynucleotide thereof. In one embodiment, the nucleic acid comprises an A box and a B box.<!-- EPO <DP n="7"> --></p><p id="p0016" num="0016">The invention also provides methods for producing, in a vertebrate cell, at least one protein comprising at least one unnatural amino acid (as well as proteins produced by such methods). The methods include, e.g., growing, in an appropriate medium, a vertebrate cell that comprises a nucleic acid that comprises at least one selector codon and encodes the protein. The vertebrate cell also comprises an orthogonal tRNA with a sequence as set forth in SEQ ID NO: 87 or 88 (O-tRNA) that functions in the cell and recognizes the selector codon and an orthogonal aminoacyl tRNA synthetase (O-RS) that preferentially aminoacylates the O-tRNA with the unnatural amino acid, and the medium comprises an unnatural amino acid. In one embodiment, the O-RS aminoacylates the O-tRNA with the unnatural amino acid e.g., at least 45%, at least 50%, at least 60%, at least 75%, at least 90%, at least 90%, at least 95%, or even 99% or more as efficiently as does an O-RS having an amino acid sequence, e.g., as set forth in SEQ ID NO.: 86 or 45. In yet another embodiment, the O-RS comprises an amino acid sequence as set forth in any one of SEQ ID NO.: 36-63, and/or 86.</p><p id="p0017" num="0017">In certain embodiments, the encoded protein comprises a therapeutic protein, a diagnostic protein, an industrial enzyme, or portion thereof. In one embodiment, the protein that is produced by the method is further modified through the unnatural amino acid. For example, the unnatural amino acid is modified through, e.g., a nucleophilic-electrophilic<!-- EPO <DP n="8"> --> reaction, through a [3+2] cycloaddition, etc. In another embodiment, the protein produced by the method is modified by at least one post-translational modification (e.g., N-glycosylation, O-glycosylation, acetylation, acylation, lipid-modification, palmitoylation, palmitate addition, phosphorylation, glycolipid-linkage modification, and the like) in vivo.</p><p id="p0018" num="0018">In certain embodiments, the compositions and the methods of the invention include vertebrate cells. A vertebrate cell of the invention includes any of, e.g., a mammalian cell, a yeast cell, a fungus cell, a plant cell, an insect cell, etc wherein the cell is not a human embryonic stem cell or an in vivo human cell. The translation components of the invention can be derived from a variety of organisms, e.g., non-vertebrate organisms, such as a prokaryotic organism (e.g., <i>E. coli, Bacillus stearothermophilus,</i> or the like), or an archaebacterium, or e.g., a vertebrate organism.</p><p id="p0019" num="0019">A selector codon of the invention expands the genetic codon framework of vertebrate protein biosynthetic machinery. Any of a variety of selector codons can be used in the invention, including stop codons (e.g., an amber codon, an ochre codon, or an opal stop codon), nonsense codons, rare codons, four (or more) base codons, and/or the like.</p><p id="p0020" num="0020">Examples of unnatural amino acids that can be used in the compositions and methods described herein include (but are not limited to): a <i>p</i>-acetyl-L-phenylalanine, a <i>p-</i>iodo-L-phenylalanine,<!-- EPO <DP n="9"> --> an O-methyl-L-tyrosine, a <i>p</i>-propargyloxyphenylalanine, a <i>p-</i>propargyl-phenylalanine, an L-3-(2-naphthyl)alanine, a 3-methyl-phenylalanine, an O-4-allyl-L-tyrosine, a 4-propyl-L-tyrosine, a tri-O-acetyl-GlcNAcβ-serine, an L-Dopa, a fluorinated phenylalanine, an isopropyl-L-phenylalanine, a <i>p</i>-azido-L-phenylalanine, a <i>p-</i>acyl-L-phenylaianine, a <i>p</i>-benzoyl-L-phenylalanine, an L-phosphoserine, a phosphonoserine, a phosphonotyrosine, a <i>p</i>-bromophenylalanine, a <i>p</i>-amino-L-phenylalanine, an isopropyl-L-phenylalanine, an unnatural analogue of a tyrosine amino acid; an unnatural analogue of a glutamine amino acid; an unnatural analogue of a phenylalanine amino acid; an unnatural analogue of a serine amino acid; an unnatural analogue of a threonine amino acid; an alkyl, aryl, acyl, azido, cyano, halo, hydrazine, hydrazide, hydroxyl, alkenyl, alkynl, ether, thiol, sulfonyl, seleno, ester, thioacid, borate, boronate, phospho, phosphono, phosphine, heterocyclic, enone, imine, aldehyde, hydroxylamine, keto, or amino substituted amino acid, or any combination thereof; an amino acid with a photoactivatable cross-linker; a spin-labeled amino acid; a fluorescent amino acid; a metal binding amino acid; a metal-containing amino acid; a radioactive amino acid; a photocaged and/or photoisomerizable amino acid; a biotin or biotin-analogue containing amino acid; a keto containing amino acid; an amino acid comprising polyethylene glycol or polyether; a heavy atom substituted amino acid; a chemically cleavable or photocleavable amino acid; an amino acid with an elongated side chain; an amino acid containing a toxic group; a sugar substituted amino acid; a carbon-linked sugar-containing amino acid; a redox-active amino acid; an α-hydroxy containing acid; an amino thio acid; an α,α disubstituted amino acid; a β-amino acid; a cyclic amino acid other than proline or histidine, an aromatic amino acid other than phenylalanine, tyrosine or tryptophan, and/or the like.</p><p id="p0021" num="0021">Herein described are polypeptides (O-RSs) and polynucleotides, e.g., O-tRNA's, polynucleotides that encode O-RSs or portions thereof (e.g., the active site of the synthetase), oligonucleotides used to construct aminoacyl-tRNA synthetase mutants, polynucleotides that encode a protein or polypeptide of interest that comprise one or more selector codon, etc. For example, a polypeptide includes a polypeptide that comprises an amino acid sequence as set forth in any one of SEQ ID NO.: 36-63, and/or 86, a polypeptide that comprises an amino acid sequence encoded by a polynucleotide sequence as set forth in any one of SEQ ID NO.: 3-35, and a polypeptide that is specifically immunoreactive with an antibody specific for a polypeptide that comprises an amino acid sequence as shown in any one of SEQ ID NO.: 36-63, and/or 86, or a polypeptide that<!-- EPO <DP n="10"> --> comprises an amino acid sequence encoded by a polynucleotide sequence as shown in any one of SEQ ID NO.: 3-35.</p><p id="p0022" num="0022">Also included among the polypeptides described herein is a polypeptide that comprises an amino acid sequence that is at least 90% identical to that of a naturally occurring tyrosyl aminoacyl-tRNA synthetase (TyrRS) (e.g., SEQ ID NO.:2) and comprises two or more amino acids of groups A-E (noted above). Similarly, polypeptides also optionally include a polypeptide that comprises at least 20 contiguous amino acids of any one of SEQ ID NO.: 36-63, and/or 86, and two or more amino acid substitutions as indicated above in groups A-E. An amino acid sequence comprising a conservative variation of any of the above polypeptides is also included as a polypeptide of the invention.<!-- EPO <DP n="11"> --></p><p id="p0023" num="0023">Kits are also a feature of the invention. For example, a kit for producing a protein that comprises at least one unnatural amino acid in a cell is provided, where the kit includes a container containing a polynucleotide sequence as set forth in SEQ ID NO: 87 or 88. In one embodiment, the kit further includes at least one unnatural amino acid. In another embodiment, the kit further comprises instructional materials for producing the protein.</p><heading id="h0004"><u>BRIEF DESCRIPTION OF THE DRAWINGS</u></heading><p id="p0024" num="0024"><ul><li><figref idrefs="f0001">Figure 1</figref> shows increased expression of hGH using the hybrid tRNA.</li></ul><!-- EPO <DP n="12"> --></p><heading id="h0005"><u>DETAILED DESCRIPTION</u></heading><p id="p0025" num="0025">Before describing the present invention in detail, it is to be understood that this invention is not limited to particular devices or biological systems, which can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting. As used in this specification and the appended claims, the singular forms "a", "an" and "the" include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to "a cell" includes a combination of two or more cells; reference to "bacteria" includes mixtures of bacteria, and the like.</p><p id="p0026" num="0026">Unless otherwise defined herein or below in the remainder of the specification, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs.</p><p id="p0027" num="0027"><u>Homologous</u>: Proteins and/or protein sequences are "homologous" when they are derived, naturally or artificially, from a common ancestral protein or protein sequence. Similarly, nucleic acids and/or nucleic acid sequences are homologous when they are derived, naturally or artificially, from a common ancestral nucleic acid or nucleic acid sequence. For example, any naturally occurring nucleic acid can be modified by any available mutagenesis method to include one or more selector codon. When expressed, this mutagenized nucleic acid encodes a polypeptide comprising one or more unnatural amino acid. The mutation process can, of course, additionally alter one or more standard codon, thereby changing one or more standard amino acid in the resulting mutant protein, as well. Homology is generally inferred from sequence similarity between two or more nucleic acids or proteins (or sequences thereof). The precise percentage of similarity between sequences that is useful in establishing homology varies with the nucleic acid and protein at issue, but as little as 25% sequence similarity is routinely used to establish homology. Higher levels of sequence similarity, e.g., 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 99% or more, can also be used to establish homology. Methods for determining sequence similarity percentages (e.g., BLASTP and BLASTN using default parameters) are described herein and are generally available.</p><p id="p0028" num="0028"><u>Orthogonal</u>: As used herein, the term "orthogonal" refers to a molecule (e.g., an orthogonal tRNA (O-tRNA) and/or an orthogonal aminoacyl tRNA synthetase (O-RS)) that functions with endogenous components of a cell with reduced effciency as compared<!-- EPO <DP n="13"> --> to a corresponding molecule that is endogenous to the cell or translation system, or that fails to function with endogenous components of the cell. In the context of tRNA's and aminoacyl-tRNA synthetases, orthogonal refers to an inability or reduced efficiency, e.g., less than 20 % efficient, less than 10 % efficient, less than 5 % efficient, or less than 1% effcient, of an orthogonal tRNA to function with an endogenous tRNA synthetase compared to an endogenous tRNA to function with the endogenous tRNA synthetase, or of an orthogonal aminoacyl-tRNA synthetase to function with an endogenous tRNA compared to an endogenous tRNA synthetase to function with the endogenous tRNA. The orthogonal molecule lacks a functional endogenous complementary molecule in the cell. For example, an orthogonal tRNA in a cell is aminoacylated by any endogenous RS of the cell with reduced or even zero efficiency, when compared to aminoacylation of an endogenous tRNA by the endogenous RS. In another example, an orthogonal RS aminoacylates any endogenous tRNA in a cell of interest with reduced or even zero efficiency, as compared to aminoacylation of the endogenous tRNA by an endogenous RS. A second orthogonal molecule can be introduced into the cell that functions with the first orthogonal molecule. For example, an orthogonal tRNA/RS pair includes introduced complementary components that function together in the cell with an efficiency (e.g., 50% efficiency, 60% efficiency, 70% efficiency, 75% efficiency, 80% efficiency, 90% efficiency, 95% efficiency, or 99% or more efficiency) to that of a corresponding tRNA/RS endogenous pair.</p><p id="p0029" num="0029"><u>Complementary:</u> The term "complementary" refers to components of an orthogonal pair, O-tRNA and O-RS that can function together, e.g., where the O-RS aminoacylates the O-tRNA.</p><p id="p0030" num="0030"><u>Preferentially aminoacylates</u>: The term "preferentially aminoacylates" refers to an efficiency, e.g., 70 % efficient, 75 % efficient, 85% efficient, 90% efficient, 95 % efficient, or 99% or more efficient, at which an O-RS aminoacylates an O-tRNA with an unnatural amino acid as compared to the O-RS aminoacylating a naturally occurring tRNA or a starting material used to generate the O-tRNA. The unnatural amino acid is incorporated into a growing polypeptide chain with high fidelity, e.g., at greater than 75% efficiency for a given selector codon, at greater than about 80% efficiency for a given selector codon, at greater than about 90% efficiency for a given selector codon, at greater than about 95% efficiency for a given selector codon, or at greater than about 99% or more efficiency for a given selector codon.<!-- EPO <DP n="14"> --></p><p id="p0031" num="0031"><u>Selector codon</u>: The term "selector codon" refers to codons recognized by the O-tRNA in the translation process and not recognized by an endogenous tRNA. The O-tRNA anticodon loop recognizes the selector codon on the mRNA and incorporates its amino acid, e.g., an unnatural amino acid, at this site in the polypeptide. Selector codons can include, e.g., nonsense codons, such as, stop codons, e.g., amber, ochre, and opal codons; four or more base codons; rare codons; codons derived from natural or unnatural base pairs and/or the like.</p><p id="p0032" num="0032"><u>Suppressor tRNA</u>: A suppressor tRNA is a tRNA that alters the reading of a messenger RNA (mRNA) in a given translation system, e.g., by providing a mechanism for incorporating an amino acid into a polypeptide chain in response to a selector codon. For example, a suppressor tRNA can read through, e.g., a stop codon, a four base codon, a rare codon, and/or the like.</p><p id="p0033" num="0033"><u>Recyclable tRNA</u>: The term "recyclable tRNA" refers to a tRNA that is aminoacylated and can be repeatedly reaminoacylated with an amino acid (e.g., an unnatural amino acid) for the incorporation of the amino acid (e.g., the unnatural amino acid) into one or more polypeptide chains during translation.</p><p id="p0034" num="0034"><u>Translation system</u>: The term "translation system" refers to the collective set of components that incorporate a naturally occurring amino acid into a growing polypeptide chain (protein). Components of a translation system can include, e.g., ribosomes, tRNA's, synthetases, mRNA, amino acids, and the like. The components of the invention (e.g., ORS, OtRNA's, unnatural amino acids, etc.) can be added to an in vitro or in vivo translation system, e.g., a vertebrate cell, e.g., a yeast cell, a mammalian cell, a plant cell, an algae cell, a fungus cell, an insect cell, and/or the like.</p><p id="p0035" num="0035"><u>Unnatural amino acid:</u> As used herein, the term "unnatural amino acid" refers to any amino acid, modified amino acid, and/or amino acid analogue that is not one of the 20 common naturally occurring amino acids, seleno cysteine or pyrrolysine.</p><p id="p0036" num="0036"><u>Derived from:</u> As used herein, the term "derived from" refers to a component that is isolated from or made using information from a specified molecule or organism.</p><p id="p0037" num="0037"><u>Inactive RS</u>: As used herein, the term "inactive RS" refers to a synthetase that has been mutated so that it no longer can aminoacylate its natural cognate tRNA with an amino acid.<!-- EPO <DP n="15"> --></p><p id="p0038" num="0038"><u>Positive selection or screening marker</u>: As used herein, the term "positive selection or screening marker" refers to a marker that when present, e.g., expressed, activated or the like, results in identification of a cell with the positive selection marker from those without the positive selection marker.</p><p id="p0039" num="0039"><u>Negative selection or screening marker</u>: As used herein, the term "negative selection or screening marker" refers to a marker that when present, e.g., expressed, activated or the like, allows identification of a cell that does not possess the desired property (e.g., as compared to a cell that does possess the desired property).</p><p id="p0040" num="0040"><u>Reporter</u>: As used herein, the term "reporter" refers to a component that can be used to select target components of a system of interest. For example, a reporter can include a fluorescent screening marker (e.g., green fluorescent protein), a luminescent marker (e.g., a firefly luciferase protein), an affinity based screening marker, or selectable marker genes such as his3, ura3, leu2, lys2, lacZ, β-gal/lacZ (β-galactosidase), Adh (alcohol dehydrogenase), or the like.</p><p id="p0041" num="0041"><u>Vertebrate</u>: As used herein, the term "vertebrate" refers to organisms belonging to the phylogenetic domain Eucarya such as animals e.g., mammals, reptiles, birds, etc.</p><p id="p0042" num="0042"><u>Non-eukaryote</u>: As used herein, the term "non-eukaryote" refers to non-vertebrate organisms. For example, a non-vertebrate organism can belong to the Eubacteria (e.g., <i>Escherichia coli, Thermus thermophilus, Bacillus stearothermophilus,</i> etc.) phylogenetic domain, or the Archaea (e.g., <i>Methanococcus jannaschii, Methanobacterium thermoautotrophicum, Halobacterium</i> such as <i>Haloferax volcanii</i> and <i>Halobacterium</i> species <i>NRC-I, Archaeoglobus fulgidus, Pyrococcus furiosus, Pyrococcus horikoshii, Aeuropyrum pernix,</i> etc.) phylogenetic domain.</p><p id="p0043" num="0043"><u>Antibody</u>: The term "antibody," as used herein, includes, but is not limited to a polypeptide substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof, which specifically bind and recognize an analyte (antigen). Examples include polyclonal, monoclonal, chimeric, and single chain antibodies, and the like. Fragments of immunoglobulins, including Fab fragments and fragments produced by an expression library, including phage display, are also included in the term "antibody" as used herein. <i>See, e.g.,</i><nplcit id="ncit0021" npl-type="b"><text>Paul, Fundamental Immunology, 4th Ed., 1999, Raven Press, New York</text></nplcit>, for antibody structure and terminology.<!-- EPO <DP n="16"> --></p><p id="p0044" num="0044"><u>Conservative variant:</u> The term "conservative variant" refers to a translation component, e.g., a conservative variant O-tRNA or a conservative variant O-RS, that functionally performs like the component from which the conservative variant is based, e.g., an O-tRNA or O-RS, but has variations in the sequence. For example, an O-RS will aminoacylate a complementary O-tRNA or a conservative variant O-tRNA with an unnatural amino acid, although the O-tRNA and the conservative variant O-tRNA do not have the same sequence. The conservative variant can have, e.g., one variation, two variations, three variations, four variations, or five or more variations in sequence, as long as the conservative variant is complementary to the corresponding O-tRNA or O-RS.</p><p id="p0045" num="0045"><u>Selection or screening agent</u>: As used herein, the term "selection or screening agent" refers to an agent that, when present, allows for a selection/screening of certain components from a population. For example, a selection or screening agent includes, but is not limited to, e.g., a nutrient, an antibiotic, a wavelength of light, an antibody, an expressed polynucleotide (e.g., a transcriptional modulator protein), or the like. The selection agent can be varied, e.g., by concentration, intensity, etc.</p><p id="p0046" num="0046"><u>Detectable substance</u>: The term "detectable substance," as used herein, refers to an agent that, when activated, altered, expressed or the like, allows for the selection/screening of certain components from a population. For example, the detectable substance can be a chemical agent, e.g., 5-fluroorotic acid (5-FOA), which under certain conditions, e.g., expression of a URA3 reporter, becomes detectable, e.g., a toxic product that kills cells that express the URA3 reporter.</p><p id="p0047" num="0047">The ability to genetically modify the structures of proteins directly in vertebrate cells, beyond the chemical constraints imposed by the genetic code, would provides a powerful molecular tool to both probe and manipulate cellular processes. The invention provides translational components that expand the number of genetically encoded amino acids in vertebrate cells. These include tRNA's (e.g., orthogonal tRNA's (O-tRNA's)), aminoacyl-tRNA synthetases (e.g., orthogonal synthetase (O-RS)), pairs of O-tRNA/O-RSs, and unnatural amino acids.</p><p id="p0048" num="0048">Typically, O-tRNA's of the invention are expressed and processed efficiently, and function in translation in a vertebrate cell, but are not significantly aminoacylated by the host's aminoacyl-tRNA synthetases. In response to a selector codon,<!-- EPO <DP n="17"> --> an O-tRNA of the invention delivers an unnatural amino acid, which does not encode any of the common twenty amino acids, to a growing polypeptide chain during mRNA translation.</p><p id="p0049" num="0049">An O-RS preferentially aminoacylates an O-tRNA of the invention with an unnatural amino acid in a vertebrate cell, but does not aminoacylate any of the cytoplasmic host's tRNA's. Moreover, the specificity of an aminoacyl-tRNA synthetase provides acceptance of an unnatural amino acid while excluding any endogenous amino acids. Polypeptides that include amino acid sequences of example O-RSs, or portions thereof, are also described herein. In addition, polynucleotides that encode translational components, O-tRNA's, O-RSs and portions thereof, are also described herein.</p><p id="p0050" num="0050">The invention further provides methods for producing a protein in a vertebrate cell, where the protein comprises an unnatural amino acid. The protein is produced using the translation components of the invention.<!-- EPO <DP n="18"> --></p><p id="p0051" num="0051">Kits for producing a protein or polypeptide with an unnatural amino acid are also a feature of the invention.</p><heading id="h0006">Orthogonal aminoacyl-TRNA synthetases (O-RS)</heading><p id="p0052" num="0052">In order to specifically incorporate an unnatural amino acid in to a protein or polypeptide of interest, in a vertebrate cell, the substrate specificity of the synthetase is altered so that only the desired unnatural amino acid, but not any of the common 20 amino acids are charged to the tRNA. If the orthogonal synthetase is promiscuous, it will result in mutant proteins with a mixture of natural and unnatural amino acids at the target position. The invention provides compositions of, and methods of, producing orthogonal aminoacyl-tRNA synthetases that have modified substrate specificity for a specific unnatural amino acid.</p><p id="p0053" num="0053">A vertebrate cell or cell line that includes an orthogonal aminoacyl-tRNA synthetase (O-RS) is disclosed.The O-RS preferentially aminoacylates an orthogonal tRNA with a sequence as set forth in SEQ ID NO: 87 (O-tRNA) with an unnatural amino acid in the vertebrate cell. In certain embodiments, the O-RS utilizes more than one unnatural amino acid, e.g., two or more, three or more, etc. Thus, an O-RS of the disclosure can have the capability to preferentially aminoacylate an O-tRNA with a sequence as set forth in SEQ ID NO: 87 with different unnatural amino acids. This allows an additional level of control by selecting which unnatural amino acid or combination of unnatural amino acids are put with the cell and/or by selecting the different amounts of unnatural amino acids that are put with the cell for their incorporation.</p><p id="p0054" num="0054">An O-RS optionally has one or more improved or enhanced enzymatic properties for the unnatural amino acid as compared to a natural amino acid. These properties include, e.g., higher Km, lower Km, higher kcat, lower kcat, lower kcat/km, higher kcat/km, etc., for the unnatural amino acid, as compared to a naturally occurring amino acid, e.g., one of the 20 known common amino acids.</p><p id="p0055" num="0055">Optionally, the O-RS can be provided to the vertebrate cell by a polypeptide that includes an O-RS and/or by a polynucleotide that encodes an O-RS or a portion thereof. For example, an O-RS, or a portion thereof, is encoded by a polynucleotide sequence as set forth in any one of SEQ ID NO.: 3-35, or a complementary polynucleotide sequence<!-- EPO <DP n="19"> --> thereof. In another example, an O-RS comprises an amino acid sequence as set forth in any one of SEQ ID NO.: 36-63, and/or 86, or a conservative variation thereof. <i>See, e.g.,</i> Tables 5, 6 and 8, and Example 6 herein for sequences of exemplary O-RS molecules.</p><p id="p0056" num="0056">An O-RS can also comprise an amino acid sequence that is, e.g., at least 90%, at least 95%, at least 98%, at least 99%, or even at least 99.5 % identical to that of a naturally occurring tyrosyl aminoacyl-tRNA synthetase (TyrRS) (e.g., as set forth in SEQ ID NO.:2) and comprises two or more amino acids of group A-E. Group A includes valine, isoleucine, leucine, glycine, serine, alanine, or threonine at a position corresponding to Tyr37 of E. <i>coli</i> TyrRS; group B includes aspartate at a position corresponding to Asn126 of E. <i>coli</i> TyrRS; group C includes threonine, serine, arginine, asparagine or glycine at a position corresponding to Asp182 of <i>E. coli</i> TyrRS; group D includes methionine, alanine, valine, or tyrosine at a position corresponding to Phe 183 of <i>E. coli</i> TyrRS; and, group E includes serine, methionine, valine, cysteine, threonine, or alanine at a position corresponding to Leu 186 of <i>E. coli</i> TyrRS.</p><p id="p0057" num="0057">Besides the O-RS, a vertebrate cell of the disclosure can include additional components, e.g., an unnatural amino acid(s). The vertebrate cell also includes an orthogonal tRNA (O-tRNA) (e.g., derived from a non-vertebrate organism, such as <i>Escherichia coli, Bacillus stearothermophilus,</i> and/or the like), where the O-tRNA recognizes a selector codon and is preferentially aminoacylated with the unnatural amino acid by the O-RS. A nucleic acid that comprises a polynucleotide that encodes a polypeptide of interest, wherein the polynucleotide comprises a selector codon that is recognized by the O-tRNA, or a combination of one or more of these, can also be present in the cell.</p><p id="p0058" num="0058">In one aspect, the O-tRNA mediates the incorporation of the unnatural amino acid into a protein with, e.g., at least 45%, at least 50%, at least 60%, at least 75%, at least 80%, at least 90%, at least 95%, or 99% or the efficiency of as a tRNA that comprises or is processed from a polynucleotide sequence as set forth in SEQ ID NO.: 65.<!-- EPO <DP n="20"> --></p><heading id="h0007">Orthogonal tRNA's</heading><p id="p0059" num="0059">A vertebrate cell or cell line that include an orthogonal tRNA (O-tRNA) with a sequence as set forth in SEQ ID NO: 87 or 88 are provided by the invention wherein the cell is not a human embryonic stem cell or an in vivo human cell and the cell line is not a human embryonic stem cell line. The orthogonal tRNA mediates incorporation of an unnatural amino acid into a protein that is encoded by a polynucleotide that comprises a selector codon that is recognized by the O-tRNA, in vivo. In certain embodiments, an O-tRNA of the invention mediates the incorporation of an unnatural amino acid into a protein with, e.g., at least 40%, at least 45%, at least 50%, at least 60%, at least 75%, at least 80%, or even 90% or more as efficiently as tRNA that comprises or is processed in a cell from a polynucleotide sequence as set forth in SEQ ID NO.: 65. <i>See,</i> Table 5, herein.<!-- EPO <DP n="21"> --></p><heading id="h0008">Fidelity, Efficiency, and Yield</heading><p id="p0060" num="0060">Fidelity refers to the accuracy with which a desired molecule, e.g., an unnatural amino acid or amino acid, is incorporated into a growing polypeptide at a desired position. The translational components of the invention incorporate unnatural amino acids, with high fidelity, into proteins in response to a selector codon. For example, using the components of the invention, the efficiency of incorporation of a desired unnatural amino acid into a growing polypeptide chain at a desired position (e.g., in response to a selector codon) is, e.g., greater than 75%, greater than 85%, greater than 95%, or even greater than 99% or more as efficient as compared to unwanted incorporation a specific natural amino acid being incorporated into the growing polypeptide chain the desired position.</p><p id="p0061" num="0061">Efficiency can also refer to the degree with which the O-RS aminoacylates the O-tRNA with the unnatural amino acid as compared to a relevant control. O-RSs of the can be defined by their efficiency. In certain embodiments of the disclosure, an O-RS is compared to another O-RS. For example, a O-RS of the disclosure aminoacylates a O-tRNA with an unnatural amino acid, e.g., at least 40%, at least 50%, at least 60%, at least<!-- EPO <DP n="22"> --> 75%, at least 80%, at least 90%, at least 95%, or even 99% or more as efficiently as an O-RS having an amino acid sequence, e.g., as set forth in SEQ ID NO.: 86 or 45 )or another specific RS in Table 5) aminoacylates an O-tRNA. In another embodiment, an O-RS of the disclosure aminoacylates the O-tRNA with the unnatural amino acid at least 10-fold, at least the O-RS aminoacylates the O-tRNA 20-fold, at least 30-fold, etc., more efficiently than the O-RS aminoacylates the O-tRNA with a natural amino acid.</p><p id="p0062" num="0062">Using the translational components of the disclosure, the yield of the polypeptide of interest comprising the unnatural amino acid is, e.g., at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, 50% or more, of that obtained for the naturally occurring polypeptide of interest from a cell in which the polynucleotide lacks the selector codon. In another aspect, the cell produces the polypeptide of interest in the absence of the unnatural amino acid with a yield that is, e.g., less than 30%, less than 20%, less than 15%, less than 10%, less than 5%, less than 2.5%, etc., of the yield of the polypeptide in the presence of the unnatural amino acid.</p><heading id="h0009">Source and Host Organisms</heading><p id="p0063" num="0063">The orthogonal translational components of the disclosure are typically derived from non-vertebrate organisms for use in vertebrate cells or translation systems. For example, the orthogonal O-tRNA can be derived from a non-vertebrate organism, e.g., a eubacterium, such as <i>Escherichia coli, Thermus thermophilus, Bacillus stearothermphilus,</i> or the like, or an archaebacterium, such as <i>Methanococcus jannaschii, Methanobacterium thermoautotrophicum, Halobacterium</i> such as <i>Haloferax volcanii</i> and <i>Halobacterium</i> species <i>NRC-1, Archaeoglobus fulgidus, Pyrococcus furiosus, Pyrococcus horikoshii, A europyrum pernix,</i> or the like, while the orthogonal O-RS can be derived from a non-vertebrate organism, e.g., a eubacterium, such as <i>Escherichia coli, Thermus thermophilus, Bacillus stearothermphilus,</i> or the like, or an archaebacterium, such as <i>Methanococcus jannaschii, Methanobacterium thermoautotrophicum, Halobacterium</i> such as <i>Haloferax volcanii</i> and <i>Halobacterium</i> species <i>NRC-1, Archaeoglobus fulgidus, Pyrococcus furiosus, Pyrococcus horikoshii, Aeuropyrum pernix,</i> or the like. Alternately, vertebrate sources can also be used, e.g., plants, algae, protists, fungi, yeasts, animals (e.g., mammals, insects, arthropods, etc.), or the like, e.g., where the components are orthogonal to a cell or translation system of interest, or where they are modified (e.g., mutated) to be orthogonal to the cell or translation system.<!-- EPO <DP n="23"> --></p><p id="p0064" num="0064">The individual components of an O-tRNA/O-RS pair can be derived from the same organism or different organisms. In one embodiment, the O-tRNA/O-RS pair is from the same organism. For example, the O-tRNA/O-RS pair can be derived from a tyrosyl-tRNA synthetase/tRNA<sub>CUA</sub> pair from <i>E. coli.</i> Alternatively, the O-tRNA and the O-RS of the O-tRNA/O-RS pair are optionally from different organisms.</p><p id="p0065" num="0065">The orthogonal O-tRNA, O-RS or O-tRNA/O-RS pair can be selected or screened and/or used in a vertebrate cell to produce a polypeptide with an unnatural amino acid. A vertebrate cell , wherein the cell is not a human embryonic stem cell or an in vivo human cell, can be from a variety of sources, e.g., any vertebrate animal (e.g., a mammal, an amphibian, birds, reptiles, fish, etc.), or the like. Compositions of vertebrate cells with translational components of the disclosure are also a feature of the disclosure.</p><p id="p0066" num="0066">The disclosure also provides for the efficient screening in one species for in optional use in that species and/or a second species (optionally, without additional selection/screening). For example, the components of the O-tRNA/O-RS are selected or screened in one species, e.g., an easily manipulated species (such as a yeast cell, etc.) and introduced into a second vertebrate species, e.g., a plant (e.g., complex plant such as monocots, or dicots), an algae, a protist, a fungus, a yeast, an animal (e.g., a mammal, an insect, an arthropod, etc.), or the like, for use in the in vivo incorporation of an unnatural amino acid in the second species.</p><p id="p0067" num="0067">For example, <i>Saccharomyces cerevisiae (S. cerevisiae</i>) can be chosen as the vertebrate first species, as it is unicellular, has a rapid generation time, and relatively well-characterized genetics. <i>See, e.g.,</i> <nplcit id="ncit0022" npl-type="b"><text>D. Burke, et al., (2000) Methods in Yeast Genetics, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY</text></nplcit>. Moreover, since the translational machinery of eukaryotes is highly conserved <i>(see, e.g.,</i> (<nplcit id="ncit0023" npl-type="b"><text>1996) Translational Control. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY</text></nplcit>;<nplcit id="ncit0024" npl-type="b"><text> Y. Kwok, &amp; J.T. Wong, (1980), Evolutionary relationship between Halobacterium cutirubrum and eukaryotes determined by use of aminoacyl-tRNA synthetases as phylogenetic probes, Canadian Journal of Biochemistry 58:213-218</text></nplcit>; and, (<nplcit id="ncit0025" npl-type="b"><text>2001) The Ribosome. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY</text></nplcit>), aaRSs genes for the incorporation of unnatural amino acids discovered in <i>S. cerevisiae</i> can be introduced into higher vertebrate organisms and used, in partnership with cognate tRNA's <i>(see, e.g.,</i> <nplcit id="ncit0026" npl-type="s"><text>K. Sakamoto, et al., (2002) Site-specific incorporation of an unnatural amino acid into proteins in mammalian cells, Nucleic Acids Res. 30:4692-4699</text></nplcit>; and, <nplcit id="ncit0027" npl-type="s"><text>C. Kohrer, et al., (2001), Import of amber and ochre suppressor<!-- EPO <DP n="24"> --> tRNA's into mammalian cells: a general approach to site-specific insertion of amino acid analogues into proteins, Proc. Natl. Acad. Sci. U. S. A. 98:14310-14315</text></nplcit>) to incorporate unnatural amino acids.</p><p id="p0068" num="0068">In one example, the method of producing O-tRNA/O-RS in a first species as described herein further includes introducing a nucleic acid that encodes the O-tRNA and a nucleic acid that encodes the O-RS into a vertebrate cell of a second species (e.g., a mammal, an insect, a fungus, an algae, a plant and the like). In another example, a method of producing an orthogonal aminoacyl-tRNA synthetase (O-RS) that preferentially aminoacylates an orthogonal tRNA with an unnatural amino acid in a vertebrate cell includes: (a) subjecting to positive selection, in the presence of an unnatural amino acid, a population of vertebrate cells of a first species (e.g., yeast and the like). Each of the vertebrate cells comprise: i) a member of a library of aminoacyl-tRNA synthetases (RSs), ii) an orthogonal tRNA (O-tRNA), iii) a polynucleotide that encodes a positive selection marker, and iv) a polynucleotide that encodes a negative selection marker. The cells that survive the positive selection comprise an active RS that aminoacylates the orthogonal tRNA (O-tRNA) in the presence of an unnatural amino acid. The cells that survive the positive selection are subjected to negative selection in the absence of the unnatural amino acid to eliminate active RSs that aminoacylate the O-tRNA with a natural amino acid. This provides an O-RS that preferentially aminoacylates the O-tRNA with the unnatural amino acid. A nucleic acid that encodes the O-tRNA and a nucleic acid that encodes the O-RS (or the components O-tRNA and/or O-RS) are introduced into a vertebrate cell of a second species e.g., a mammal, an insect, a fungus, an algae, a plant and/or the like. Typically, the O-tRNA is obtained by subjecting to negative selection a population of vertebrate cells of a first species, where the vertebrate cells comprise a member of a library of tRNA's. The negative selection eliminates cells that comprise a member of the library of tRNA's that is aminoacylated by an aminoacyl-tRNA synthetase (RS) that is endogenous to the vertebrate cells, which provides a pool of tRNA's that are orthogonal to the vertebrate cell of the first species and the second species.</p><heading id="h0010">Selector Codons</heading><p id="p0069" num="0069">Selector codons of the disclosure expand the genetic codon framework of the protein biosynthetic machinery. For example, a selector codon includes, e.g., a unique three base codon, a nonsense codon, such as a stop codon, e.g., an amber codon (UAG), an opal<!-- EPO <DP n="25"> --> codon (UGA), an unnatural codon, at least a four base codon, a rare codon, or the like. A number of selector codons can be introduced into a desired gene, e.g., one or more, two or more, more than three, etc. Once gene can include multiple copies of a given selector codon, or can include multiple different selector codons, or any combination thereof.</p><p id="p0070" num="0070">In one embodiment, the methods involve the use of a selector codon that is a stop codon for the incorporation of unnatural amino acids in vivo in a vertebrate cell. For example, an O-tRNA is produced that recognizes the stop codon, e.g., UAG, and is aminoacylated by an O-RS with a desired unnatural amino acid. This O-tRNA is not recognized by the naturally occurring host's aminoacyl-tRNA synthetases. Conventional site-directed mutagenesis can be used to introduce the stop codon, e.g., TAG, at the site of interest in a polypeptide of interest. <i>See, e.g.,</i> <nplcit id="ncit0028" npl-type="s"><text>Sayers, J.R., et al. (1988), 5',3' Exonuclease in phosphorothioate-based oligonucleotide-directed mutagenesis. Nucleic Acids Res, 791-802</text></nplcit>. When the O-RS, O-tRNA and the nucleic acid that encodes the polypeptide of interest are combined in vivo, the unnatural amino acid is incorporated in response to the UAG codon to give a polypeptide containing the unnatural amino acid at the specified position.</p><p id="p0071" num="0071">The incorporation of unnatural amino acids in vivo can be done without significant perturbation of the vertebrate host cell. For example, because the suppression efficiency for the UAG codon depends upon the competition between the O-tRNA, e.g., the amber suppressor tRNA, and a vertebrate release factor (e.g., eRF) (which binds to a stop codon and initiates release of the growing peptide from the ribosome), the suppression efficiency can be modulated by, e.g., increasing the expression level of O-tRNA, e.g., the suppressor tRNA.</p><p id="p0072" num="0072">Selector codons also comprise extended codons, e.g., four or more base codons, such as, four, five, six or more base codons. Examples of four base codons include, e.g., AGGA, CUAG, UAGA, CCCU and the like. Examples of five base codons include, e.g., AGGAC, CCCCU, CCCUC, CUAGA, CUACU, UAGGC and the like. A feature of the invention includes using extended codons based on frameshift suppression. Four or more base codons can insert, e.g., one or multiple unnatural amino acids into the same protein. For example, in the presence of mutated O-tRNA's, e.g., a special frameshift suppressor tRNA's, with anticodon loops, e.g., with at least 8-10 nt anticodon loops, the four or more base codon is read as single amino acid. In other embodiments, the anticodon loops can decode, e.g., at least a four-base codon, at least a five-base codon, or at least a six-base<!-- EPO <DP n="26"> --> codon or more. Since there are 256 possible four-base codons, multiple unnatural amino acids can be encoded in the same cell using a four or more base codon. <i>See,</i> <nplcit id="ncit0029" npl-type="s"><text>Anderson et al., (2002) Exploring the Limits of Codon and Anticodon Size, Chemistry and Biology, 9:237-244</text></nplcit>; <nplcit id="ncit0030" npl-type="s"><text>Magliery, (2001) Expanding the Genetic Code: Selection of Efficient Suppressors of Four-base Codons and Identification of "Shifty" Four-base Cordons with a Library Approach in Escherichia coli, J. Mol. Biol. 307: 755-769</text></nplcit>.</p><p id="p0073" num="0073">For example, four-base codons have been used to incorporate unnatural amino acids into proteins using in vitro biosynthetic methods. <i>See, e.g.,</i> <nplcit id="ncit0031" npl-type="s"><text>Ma et al., (1993) Biochemistry, 32:7939</text></nplcit>; and <nplcit id="ncit0032" npl-type="s"><text>Hohsaka et al., (1999) J. Am. Chem. Soc., 121:34</text></nplcit>. CGGG and AGGU were used to simultaneously incorporate 2-naphthylalanine and an NBD derivative of lysine into streptavidin in vitro with two chemically acylated frame shift suppressor tRNA's. <i>See, e.g.,</i> <nplcit id="ncit0033" npl-type="s"><text>Hohsaka et al., (1999) J. Am. Chem. Soc., 121:12194</text></nplcit>. In an in vivo study, Moore et al. examined the ability of tRNALeu derivatives with NCUA anticodons to suppress UAGN codons (N can be U, A, G, or C), and found that the quadruplet UAGA can be decoded by a tRNALeu with a UCUA anticodon with an efficiency of 13 to 26% with little decoding in the 0 or -1 frame. <i>See,</i> <nplcit id="ncit0034" npl-type="s"><text>Moore et al., (2000) J. Mol. Biol., 298:195</text></nplcit>. In one embodiment, extended codons based on rare codons or nonsense codons can be used in invention, which can reduce missense readthrough and frameshift suppression at other unwanted sites.</p><p id="p0074" num="0074">For a given system, a selector codon can also include one of the natural three base codons, where the endogenous system does not use (or rarely uses) the natural base codon. For example, this includes a system that is lacking a tRNA that recognizes the natural three-base codon, and/or a system where the three-base codon is a rare codon.</p><p id="p0075" num="0075">Selector codons optionally include unnatural base pairs. These unnatural base pairs further expand the existing genetic alphabet. One extra base pair increases the number of triplet codons from 64 to 125. Properties of third base pairs include stable and selective base pairing, efficient enzymatic incorporation into DNA with high fidelity by a polymerase, and the efficient continued primer extension after synthesis of the nascent unnatural base pair. Descriptions of unnatural base pairs which can be adapted for methods and compositions include, e.g., <nplcit id="ncit0035" npl-type="s"><text>Hirao, et al., (2002) An unnatural base pair for incorporating amino acid analogues into protein, Nature Biotechnology, 20:177-182</text></nplcit>. Other relevant publications are listed below.<!-- EPO <DP n="27"> --></p><p id="p0076" num="0076">For in vivo usage, the unnatural nucleoside is membrane permeable and is phosphorylated to form the corresponding triphosphate. In addition, the increased genetic information is stable and not destroyed by cellular enzymes. Previous efforts by Benner and others took advantage of hydrogen bonding patterns that are different from those in canonical Watson-Crick pairs, the most noteworthy example of which is the iso-C:iso-G pair. <i>See, e.g.,</i> <nplcit id="ncit0036" npl-type="s"><text>Switzer et al., (1989) J. Am. Chem. Soc., 111:8322</text></nplcit>; and<nplcit id="ncit0037" npl-type="s"><text> Piccirilli et al., (1990) Nature, 343:33</text></nplcit>; <nplcit id="ncit0038" npl-type="s"><text>Kool, (2000) Curr. Opin. Chem. Biol., 4:602</text></nplcit>. These bases in general mispair to some degree with natural bases and cannot be enzymatically replicated. Kool and co-workers demonstrated that hydrophobic packing interactions between bases can replace hydrogen bonding to drive the formation of base pair. See, <nplcit id="ncit0039" npl-type="s"><text>Kool, (2000) Curr. Opin. Chem. Biol., 4:602</text></nplcit>; and <nplcit id="ncit0040" npl-type="s"><text>Guckian and Kool, (1998) Angew. Chem. Int. Ed. Engl., 36, 2825</text></nplcit>. In an effort to develop an unnatural base pair satisfying all the above requirements, Schultz, Romesberg and co-workers have systematically synthesized and studied a series of unnatural hydrophobic bases. A PICS:PICS self-pair is found to be more stable than natural base pairs, and can be efficiently incorporated into DNA by Klenow fragment of Escherichia coli DNA polymerase I (KF). <i>See, e.g.,</i> <nplcit id="ncit0041" npl-type="s"><text>McMinn et al., (1999) J. Am. Chem. Soc., 121:11586</text></nplcit>; and <nplcit id="ncit0042" npl-type="s"><text>Ogawa et al., (2000) J. Am. Chem. Soc., 122:3274</text></nplcit>. A 3MN:3MN self-pair can be synthesized by KF with efficiency and selectivity sufficient for biological function. <i>See, e.g.,</i> <nplcit id="ncit0043" npl-type="s"><text>Ogawa et al., (2000) J. Am. Chem. Soc., 122:8803</text></nplcit>. However, both bases act as a chain terminator for further replication. A mutant DNA polymerase has been recently evolved that can be used to replicate the PICS self pair. In addition, a 7AI self pair can be replicated. See, e.g., <nplcit id="ncit0044" npl-type="s"><text>Tae et al., (2001) J. Am. Chem. Soc., 123:7439</text></nplcit>. A novel metallobase pair, Dipic:Py, has also been developed, which forms a stable pair upon binding Cu(II). See, <nplcit id="ncit0045" npl-type="s"><text>Meggers et al., (2000) J. Am. Chem. Soc., 122:10714</text></nplcit>. Because extended codons and unnatural codons are intrinsically orthogonal to natural codons, the methods of the invention can take advantage of this property to generate orthogonal tRNA's for them.</p><p id="p0077" num="0077">A translational bypassing system can also be used to incorporate an unnatural amino acid in a desired polypeptide. In a translational bypassing system, a large sequence is inserted into a gene but is not translated into protein. The sequence contains a structure that serves as a cue to induce the ribosome to hop over the sequence and resume translation downstream of the insertion.</p><heading id="h0011">Unnatural amino acids</heading><!-- EPO <DP n="28"> --><p id="p0078" num="0078">As used herein, an unnatural amino acid refers to any amino acid, modified amino acid, or amino acid analogue other than selenocysteine and/or pyrrolysine and the following twenty genetically encoded alpha-amino acids: alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine. The generic structure of an alpha-amino acid is illustrated by Formula I:
<chemistry id="chem0001" num="0001"><img id="ib0001" file="imgb0001.tif" wi="40" he="22" img-content="chem" img-format="tif"/></chemistry></p><p id="p0079" num="0079">An unnatural amino acid is typically any structure having Formula I wherein the R group is any substituent other than one used in the twenty natural amino acids. See, e.g., <nplcit id="ncit0046" npl-type="b"><text>Biochemistry by L. Stryer, 3rd ed. 1988, Freeman and Company, New York</text></nplcit>, for structures of the twenty natural amino acids. Note that, the unnatural amino acids of the invention can be naturally occurring compounds other than the twenty alpha-amino acids above.</p><p id="p0080" num="0080">Because the unnatural amino acids of the disclosure typically differ from the natural amino acids in side chain, the unnatural amino acids form amide bonds with other amino acids, e.g., natural or unnatural, in the same manner in which they are formed in naturally occurring proteins. However, the unnatural amino acids have side chain groups that distinguish them from the natural amino acids. For example, R in Formula I optionally comprises an alkyl-, aryl-, acyl-, keto-, azido-, hydroxyl-, hydrazine, cyano-, halo-, hydrazide, alkenyl, alkynyl, ether, thiol, seleno-, sulfonyl-, borate, boronate, phospho, phosphono, phosphine, heterocyclic, enone, imine, aldehyde, ester, thioacid, hydroxylamine, amine, and the like, or any combination thereof. Other unnatural amino acids of interest include, but are not limited to, amino acids comprising a photoactivatable cross-linker, spin-labeled amino acids, fluorescent amino acids, metal binding amino acids, metal-containing amino acids, radioactive amino acids, amino acids with novel functional groups, amino acids that covalently or noncovalently interact with other molecules, photocaged and/or photoisomerizable amino acids, biotin or biotin-analogue containing amino acids, keto containing amino acids, amino acids comprising polyethylene glycol or polyether, heavy atom substituted amino acids, chemically cleavable or photocleavable amino acids, amino acids with an elongated side chain as compared to natural amino acids<!-- EPO <DP n="29"> --> (e.g., polyethers or long chain hydrocarbons, e.g., greater than about 5, greater than about 10 carbons, etc.), carbon-linked sugar-containing amino acids, redox-active amino acids, amino thioacid containing amino acids, and amino acids containing one or more toxic moiety. In some embodiments, the unnatural amino acids have a photoactivatable cross-linker that is used, e.g., to link a protein to a solid support. In one embodiment, the unnatural amino acids have a saccharide moiety attached to the amino acid side chain (e.g., glycosylated amino acids) and/or other carbohydrate modification.</p><p id="p0081" num="0081">In addition to unnatural amino acids that contain novel side chains, unnatural amino acids also optionally comprise modified backbone structures, e.g., as illustrated by the structures of Formula II and III:
<chemistry id="chem0002" num="0002"><img id="ib0002" file="imgb0002.tif" wi="48" he="32" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0003" num="0003"><img id="ib0003" file="imgb0003.tif" wi="38" he="25" img-content="chem" img-format="tif"/></chemistry></p><p id="p0082" num="0082">wherein Z typically comprises OH, NH<sub>2</sub>, SH, NH-R', or S-R'; X and Y, which can be the same or different, typically comprise S or O, and R and R', which are optionally the same or different, are typically selected from the same list of constituents for the R group described above for the unnatural amino acids having Formula I as well as hydrogen. For example, unnatural amino acids of the invention optionally comprise substitutions in the amino or carboxyl group as illustrated by Formulas II and III. Unnatural amino acids of this type include, but are not limited to, α-hydroxy acids, α-thioacids α-aminothiocarboxylates, e.g., with side chains corresponding to the common twenty natural amino acids or unnatural side chains. In addition, substitutions at the α-carbon optionally include L, D, or α-α-disubstituted amino acids such as D-glutamate, D-alanine, D-methyl-O-tyrosine,<!-- EPO <DP n="30"> --> aminobutyric acid, and the like. Other structural alternatives include cyclic amino acids, such as proline analogues as well as 3,4,6,7,8, and 9 membered ring proline analogues, β and γ amino acids such as substituted β-alanine and γ-amino butyric acid.For example, many unnatural amino acids are based on natural amino acids, such as tyrosine, glutamine, phenylalanine, and the like. Tyrosine analogs include para-substituted tyrosines, ortho-substituted tyrosines, and meta substituted tyrosines, where the substituted tyrosine comprises, e.g., a keto group (e.g., an acetyl group), a benzoyl group, an amino group, a hydrazine, an hydroxyamine, a thiol group, a carboxy group, an isopropyl group, a methyl group, a C<sub>6</sub> - C<sub>20</sub> straight chain or branched hydrocarbon, a saturated or unsaturated hydrocarbon, an O-methyl group, a polyether group, a nitro group, an alkynyl group or the like. In addition, multiply substituted aryl rings are also contemplated. Glutamine analogs of the invention include, but are not limited to, α-hydroxy derivatives, γ-substituted derivatives, cyclic derivatives, and amide substituted glutamine derivatives. Example phenylalanine analogs include, but are not limited to, para-substituted phenylalanines, ortho-substituted phenyalanines, and meta-substituted phenylalanines, where the substituent comprises, e.g., a hydroxy group, a methoxy group, a methyl group, an allyl group, an aldehyde, an azido, an iodo, a bromo, a keto group (e.g., an acetyl group), a benzoyl, an alkynyl group, or the like. Specific examples of unnatural amino acids include, but are not limited to, a <i>p</i>-acetyl-L- phenylalanine, a <i>p</i>-propargyloxyphenylalanine, O-methyl-L-tyrosine, an L-3-(2-naphthyl)alanine, a 3-methyl-phenylalanine, an O-4-allyl-L-tyrosine, a 4-propyl-L-tyrosine, a tri-O-acetyl-GlcNAcβ-serine, an L-Dopa, a fluorinated phenylalanine, an isopropyl-L-phenylalanine, a <i>p</i>-azido-L-phenylalanine, a <i>p</i>-acyl-L-phenylalanine, a <i>p-</i>benzoyl-L-phenylalanine, an L-phosphoserine, a phosphonoserine, a phosphonotyrosine, a <i>p-</i>iodo-phenylalanine, a <i>p</i>-bromophenylalanine; a <i>p</i>-amino-L-phenylalanine, and an isopropyl-L-phenylalanine, and the like. Additional structures of a variety of unnatural amino acids are provided in, for example, Figures 16, 17, 18, 19,26, and 29 of <patcit id="pcit0001" dnum="WO2002085923A"><text>WO 2002/085923</text></patcit> entitled "In vivo incorporation of unnatural amino acids" See also, <figref idrefs="f0001">figure 1</figref> structures 2-5 of <nplcit id="ncit0047" npl-type="s"><text>Kiick et al., (2002) Incorporation of azides into recombinant proteins for chemoselective modification by the Staudinger ligtation, PNAS 99:19-24</text></nplcit>, for additional methionine analogs.</p><p id="p0083" num="0083">Compositions that include an unnatural amino acid (such as <i>p</i>-(propargyloxy)-phenyalanine) are described herein. Various compositions comprisingp-(propargyloxy)-phenyalanine and, e.g., proteins and/or cells, are also provided. In one<!-- EPO <DP n="31"> --> aspect, a composition that includes the <i>p</i>-(propargyloxy)-phenyalanine unnatural amino acid further includes an orthogonal tRNA. The unnatural amino acid can be bonded (e.g., covalently) to the orthogonal tRNA, e.g., covalently bonded to the orthogonal tRNA though an amino-acyl bond, covalently bonded to a 3'OH or a 2'OH of a terminal ribose sugar of the orthogonal tRNA, etc.</p><p id="p0084" num="0084">The chemical moieties via unnatural amino acids that can be incorporated into proteins offer a variety of advantages and manipulations of the protein. For example, the unique reactivity of a keto functional group allows selective modification of proteins with any of a number of hydrazine- or hydroxylamine-containing reagents in vitro and in vivo. A heavy atom unnatural amino acid, for example, can be useful for phasing x-ray structure data. The site-specific introduction of heavy atoms using unnatural amino acids also provides selectivity and flexibility in choosing positions for heavy atoms. Photoreactive unnatural amino acids (e.g., amino acids with benzophenone and arylazides (e.g., phenylazide) side chains), for example, allow for efficient in vivo and in vitro photocrosslinking of proteins. Examples of photoreactive unnatural amino acids include, but are not limited to, e.g., p-azido-phenylalanine and p-benzoyl-phenylalanine. The protein with the photoreactive unnatural amino acids can then be crosslinked at will by excitation of the photoreactive group-providing temporal (and/or spatial) control. In one example, the methyl group of an unnatural amino can be substituted with an isotopically labelled, e.g., methyl group, as a probe of local structure and dynamics, e.g., with the use of nuclear magnetic resonance and vibrational spectroscopy. Alkynyl or azido functional groups, for example, allow the selective modification of proteins with molecules through a [3+2] cycloaddition reaction.</p><heading id="h0012">Chemical Synthesis of Unnatural Amino Acids</heading><p id="p0085" num="0085">Many of the unnatural amino acids provided above are commercially available, e.g., from Sigma (USA) or Aldrich (Milwaukee, WI, USA). Those that are not commercially available are optionally synthesized as provided herein or as provided in various publications or using standard methods known to those of skill in the art. For organic synthesis techniques, see, e.g., <nplcit id="ncit0048" npl-type="b"><text>Organic Chemistry by Fessendon and Fessendon, (1982, Second Edition, Willard Grant Press, Boston Mass</text></nplcit>.); <nplcit id="ncit0049" npl-type="b"><text>Advanced Organic Chemistry by March (Third Edition, 1985, Wiley and Sons, New York</text></nplcit>); and<nplcit id="ncit0050" npl-type="b"><text> Advanced Organic Chemistry by Carey and Sundberg (Third Edition, Parts A and B, 1990, Plenum Press, New<!-- EPO <DP n="32"> --> York</text></nplcit>). Additional publications describing the synthesis of unnatural amino acids include, e.g., <patcit id="pcit0002" dnum="WO2002085923A"><text>WO 2002/085923</text></patcit> entitled "In vivo incorporation of Unnatural Amino Acids;" <nplcit id="ncit0051" npl-type="s"><text>Matsoukas et al., (1995) J. Med. Chem., 38, 4660-4669</text></nplcit>; <nplcit id="ncit0052" npl-type="s"><text>King, F.E. &amp; Kidd, D.A.A. (1949) A New Synthesis of Glutamine and of γ-Dipeptides of Glutamic Acid from Phthylated Intermediated. J. Chem. Soc., 3315-3319</text></nplcit>; <nplcit id="ncit0053" npl-type="s"><text>Friedman, O.M. &amp; Chatterrji, R. (1959) Synthesis of Derivatives of Glutamine as Model Substrates jor Anti-Tumor Agents. J. Am. Chem. Soc. 81, 3750-3752</text></nplcit>;<nplcit id="ncit0054" npl-type="s"><text> Craig, J.C. et al. (1988) Absolute Configuration of the Enantiomers of 7-Chloro-4 [[4-(diethylamino)-1-methylbutyl]amino]quinoline (Chloroquine). J. Org. Chem. 53, 1167-1170</text></nplcit>; <nplcit id="ncit0055" npl-type="s"><text>Azoulay, M., Vilmont, M. &amp; Frappier, F. (1991) Glutamine analogues as Potential Antimalarials,. Eur. J. Med. Chem. 26, 201-5</text></nplcit>; <nplcit id="ncit0056" npl-type="s"><text>Koskinen, A.M.P. &amp; Rapoport, H. (1989) Synthesis of 4-Substituted Prolines as Conformationally Constrained Amino Acid Analogues. J. Org. Chem. 54, 1859-1866</text></nplcit>; <nplcit id="ncit0057" npl-type="s"><text>Christie, B.D. &amp; Rapoport, H. (1985) Synthesis of Optically Pure Pipecolates from L-Asparagine. Application to the Total Synthesis of (+)-Apovincamine through Amino Acid Decarbonylation and Iminium Ion Cyclization. J. Org. Chem. 1989:1859-1866</text></nplcit>; <nplcit id="ncit0058" npl-type="s"><text>Barton et al., (1987) Synthesis of Novel a-Amino-Acids and Derivatives Using Radical Chemistry: Synthesis of L- and D-a-Amino-Adipic Acids, L-a-aminopimelic Acid and Appropriate Unsaturated Derivatives. Tetrahedron Lett. 43:4297-4308</text></nplcit>; and, <nplcit id="ncit0059" npl-type="s"><text>Subasinghe et al., (1992) Quisqualic acid analogues: synthesis of beta-heterocyclic 2-aminopropanoic acid derivatives and their activity at a novel quisqualate-sensitized site. J. Med. Chem. 35:4602-7</text></nplcit>.</p><heading id="h0013">Cellular uptake of unnatural amino acids</heading><p id="p0086" num="0086">Unnatural amino acid uptake by a vertebrate cell is one issue that is typically considered when designing and selecting unnatural amino acids, e.g., for incorporation into a protein. For example, the high charge density of α-amino acids suggests that these compounds are unlikely to be cell permeable. Natural amino acids are taken up into the vertebrate cell via a collection of protein-based transport systems. A rapid screen can be done which assesses which unnatural amino acids, if any, are taken up by cells. <i>See, e.g.,</i> the toxicity assays in, e.g., the application entitled "Protein Arrays," attorney docket number P1001US00 filed on December 22, 2002; and<nplcit id="ncit0060" npl-type="s"><text> Liu, D.R. &amp; Schultz, P.G. (1999) Progress toward the evolution of an organism with an expanded genetic code. PNAS United States 96:4780-4785</text></nplcit>. Although uptake is easily analyzed with various assays, an alternative to designing unnatural amino acids that are amenable to cellular uptake pathways is to provide biosynthetic pathways to create amino acids <i>in vivo.</i><!-- EPO <DP n="33"> --></p><heading id="h0014">Biosynthesis of Unnatural Amino Acids</heading><p id="p0087" num="0087">Many biosynthetic pathways already exist in cells for the production of amino acids and other compounds. While a biosynthetic method for a particular unnatural amino acid may not exist in nature, e.g., in a vertebrate cell, the invention provides such methods. For example, biosynthetic pathways for unnatural amino acids are optionally generated in host cell by adding new enzymes or modifying existing host cell pathways. Additional new enzymes are optionally naturally occurring enzymes or artificially evolved enzymes. For example, the biosynthesis of <i>p</i>-aminophenylalanine (as presented in an example in <patcit id="pcit0003" dnum="WO2002085923A"><text>WO 2002/085923</text></patcit> entitled "In vivo incorporation of unnatural amino acids") relies on the addition of a combination of known enzymes from other organisms. The genes for these enzymes can be introduced into a vertebrate cell by transforming the cell with a plasmid comprising the genes. The genes, when expressed in the cell, provide an enzymatic pathway to synthesize the desired compound. Examples of the types of enzymes that are optionally added are provided in the examples below. Additional enzymes sequences are found, e.g., in Genbank. Artificially evolved enzymes are also optionally added into a cell in the same manner. In this manner, the cellular machinery and resources of a cell are manipulated to produce unnatural amino acids.</p><p id="p0088" num="0088">A variety of methods are available for producing novel enzymes for use in biosynthetic pathways or for evolution of existing pathways. For example, recursive recombination, e.g., as developed by Maxygen, Inc. (available on the world wide web at www.maxygen.com), is optionally used to develop novel enzymes and pathways. <i>See, e.g.,</i> <nplcit id="ncit0061" npl-type="s"><text>Stemmer (1994), Rapid evolution of a protein in vitro by DNA shuffling, Nature 370(4):389-391</text></nplcit>; and, <nplcit id="ncit0062" npl-type="s"><text>Stemmer, (1994), DNA shuffling by random fragmentation and reassembly: In vitro recombination for molecular evolution, Proc. Natl. Acad. Sci. USA., 91:10747-10751</text></nplcit>. Similarly DesignPath™, developed by Genencor (available on the world wide web at genencor.com) is optionally used for metabolic pathway engineering, e.g., to engineer a pathway to create O-methyl-L-tyrosine in a cell. This technology reconstructs existing pathways in host organisms using a combination of new genes, e.g., identified through functional genomics, and molecular evolution and design. Diversa Corporation (available on the world wide web at diversa.com) also provides technology for rapidly screening libraries of genes and gene pathways, e.g., to create new pathways.<!-- EPO <DP n="34"> --></p><p id="p0089" num="0089">Typically, the unnatural amino acid produced with an engineered biosynthetic pathway of the invention is produced in a concentration sufficient for efficient protein biosynthesis, e.g., a natural cellular amount, but not to such a degree as to affect the concentration of the other amino acids or exhaust cellular resources. Typical concentrations produced <i>in vivo</i> in this manner are about 10 mM to about 0.05 mM. Once a cell is transformed with a plasmid comprising the genes used to produce enzymes desired for a specific pathway and an unnatural amino acid is generated, <i>in vivo</i> selections are optionally used to further optimize the production of the unnatural amino acid for both ribosomal protein synthesis and cell growth.</p><heading id="h0015">Polypeptides with Unnatural Amino Acids</heading><p id="p0090" num="0090">Proteins or polypeptides of interest with at least one unnatural amino acid are described herein. The disclosure also includes polypeptides or proteins with at least one unnatural amino acid produced using the compositions and methods of the invention. An excipient (e.g., a pharmaceutically acceptable excipient) can also be present with the protein.</p><p id="p0091" num="0091">By producing proteins or polypeptides of interest with at least one unnatural amino acid in vertebrate cells, proteins or polypeptides will typically include vertebrate posttranslational modifications. A protein may include at least one unnatural amino acid and at least one post-translational modification that is made in vivo by a vertebrate cell, where the post-translational modification is not made by a prokaryotic cell. For example, the post-translation modification includes, e.g., acetylation, acylation, lipid-modification, palmitoylation, palmitate addition, phosphorylation, glycolipid-linkage modification, glycosylation, and the like. In one aspect, the post-translational modification includes attachment of an oligosaccharide (e.g., (GlcNAc-Man)<sub>2</sub>-Man-GlcNAc-GlcNAc)) to an asparagine by a GlcNAc-asparagine linkage. See also, Table 7, which lists some examples of N-linked oligosaccharides of vertebrate proteins (additional residues can also be present, which are not shown). In another aspect, the post-translational modification includes attachment of an oligosaccharide (e.g., Gal-GalNAc, Gal-GlcNAc, etc.) to a serine or threonine by a GalNAc-serine or GalNAc-threonine linkage, or a GlcNAc-serine or a GlcNAc-threonine linkage.<!-- EPO <DP n="35"> -->
<tables id="tabl0001" num="0001"><table frame="all"><title><u>TABLE 7: EXAMPLES OF OLIGOSACCHARIDES THROUGH GlcNAc-LINKAGE</u></title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="28mm"/><colspec colnum="2" colname="col2" colwidth="128mm"/><thead><row><entry align="center" valign="middle"><b>Type</b></entry><entry align="center" valign="middle"><b>Base Structure</b></entry></row></thead><tbody><row><entry align="center" valign="middle"><b>High-mannose</b></entry><entry valign="middle"><chemistry id="chem0004" num="0004"><img id="ib0004" file="imgb0004.tif" wi="123" he="20" img-content="chem" img-format="tif"/></chemistry></entry></row><row><entry align="center" valign="middle"><b>Hybrid</b></entry><entry valign="middle"><chemistry id="chem0005" num="0005"><img id="ib0005" file="imgb0005.tif" wi="123" he="13" img-content="chem" img-format="tif"/></chemistry></entry></row><row><entry align="center" valign="middle"><b>Complex</b></entry><entry valign="middle"><chemistry id="chem0006" num="0006"><img id="ib0006" file="imgb0006.tif" wi="124" he="14" img-content="chem" img-format="tif"/></chemistry></entry></row><row><entry align="center" valign="middle"><b>Xylose</b></entry><entry valign="middle"><chemistry id="chem0007" num="0007"><img id="ib0007" file="imgb0007.tif" wi="94" he="14" img-content="chem" img-format="tif"/></chemistry></entry></row></tbody></tgroup></table></tables></p><p id="p0092" num="0092">In yet another aspect, the post-translation modification includes proteolytic processing of precursors (e.g., calcitonin precursor, calcitonin gene-related peptide precursor, preproparathyroid hormone, preproinsulin, proinsulin, prepro-opiomelanocortin, pro-opiomelanocortin and the like), assembly into a multisubunit protein or macromolecular assembly, translation to another site in the cell (e.g., to organelles, such as the endoplasmic reticulum, the golgi apparatus, the nucleus, lysosomes, peroxisomes, mitochondria, chloroplasts, vacuoles, etc., or through the secretory pathway). In certain embodiments, the protein comprises a secretion or localization sequence, an epitope tag, a FLAG tag, a polyhistidine tag, a GST fusion, or the like.</p><p id="p0093" num="0093">One advantage of an unnatural amino acid is that it presents additional chemical moieties that can be used to add additional molecules. These modifications can be made in vivo in a vertebrate cell, or in vitro. Thus, in certain embodiments, the post-translational modification is through the unnatural amino acid. For example, the post-translational modification can be through a nucleophilic-electrophilic reaction. Most reactions currently used for the selective modification of proteins involve covalent bond<!-- EPO <DP n="36"> --> formation between nucleophilic and electrophilic reaction partners, e.g. the reaction of α-haloketones with histidine or cysteine side chains. Selectivity in these cases is determined by the number and accessibility of the nucleophilic residues in the protein. In proteins of the invention, other more selective reactions can be used, such as the reaction of an unnatural keto-amino acid with hydrazides or aminooxy compounds, in vitro and in vivo. <i>See, e.g.,</i> <nplcit id="ncit0063" npl-type="s"><text>Cornish, et al., (1996) Am. Chem. Soc., 118:8150-8151</text></nplcit>;<nplcit id="ncit0064" npl-type="s"><text> Mahal, et al., (1997) Science, 276:1125-1128</text></nplcit>; <nplcit id="ncit0065" npl-type="s"><text>Wang, et al., (2001) Science 292:498-500</text></nplcit>; <nplcit id="ncit0066" npl-type="s"><text>Chin, et al., (2002) Am. Chem. Soc. 124:9026-9027</text></nplcit>; <nplcit id="ncit0067" npl-type="s"><text>Chin, et al., (2002) Proc. Natl. Acad. Sci., 99:11020-11024</text></nplcit>; <nplcit id="ncit0068" npl-type="s"><text>Wang, et al., (2003) Proc. Natl. Acad. Sci., 100:56-61</text></nplcit>; <nplcit id="ncit0069" npl-type="s"><text>Zhang, et al., (2003) Biochemistry, 42:6735-6746</text></nplcit>; and, <nplcit id="ncit0070" npl-type="s"><text>Chin, et al., (2003) Science, in press</text></nplcit>. This allows the selective labeling of virtually any protein with a host of reagents including fluorophores, crosslinking agents, saccharide derivatives and cytotoxic molecules. <i>See also,</i> patent application <patcit id="pcit0004" dnum="USSN10686944A"><text>USSN 10/686,944</text></patcit> entitled "Glycoprotein synthesis" filed October 15, 2003. Post-translational modifications, e.g., through an azido amino acid, can also made through the Staudinger ligation (e.g., with triarylphosphine reagents). <i>See, e.g.,</i> <nplcit id="ncit0071" npl-type="s"><text>Kiick et al., (2002) Incorporation of azides into recombinant proteins for chemoselective modification by the Staudinger ligtation, PNAS 99:19-24</text></nplcit>.<!-- EPO <DP n="37"> --></p><p id="p0094" num="0094">A vertebrate cell of the disclosure provides the ability to synthesize proteins that comprise unnatural amino acids in large useful quantities. In one aspect, the composition optionally includes, e.g., at least 10 micrograms, at least 50 micrograms, at least 75 micrograms, at least 100 micrograms, at least 200 micrograms, at least 250 micrograms, at least 500 micrograms, at least I milligram, at least 10 milligrams or more of the protein that comprises an unnatural amino acid, or an amount that can be achieved with in vivo protein production methods (details on recombinant protein production and purification are provided herein). In another aspect, the protein is optionally present in the composition at a concentration of, e.g., at least 10 micrograms of protein per liter, at least 50 micrograms of protein per liter, at least 75 micrograms of protein per liter, at least 100 micrograms of protein per liter, at least 200 micrograms of protein per liter, at least 250 micrograms of protein per liter, at least 500 micrograms of protein per liter, at least 1 milligram of protein per liter, or at least 10 milligrams of protein per liter or more, in, e.g., a cell lysate, a buffer, a pharmaceutical buffer, or other liquid suspension (e.g., in a volume<!-- EPO <DP n="38"> --> of, <i>e.g.,</i> anywhere from about 1 nl to about 100 L). The production of large quantities (e.g., greater that that typically possible with other methods, e.g., in vitro translation) of a protein in a vertebrate cell including at least one unnatural amino acid is a feature of the invention.</p><p id="p0095" num="0095">The incorporation of an unnatural amino acid can be done to, e.g., tailor changes in protein structure and/or function, e.g., to change size, acidity, nucleophilicity, hydrogen bonding, hydrophobicity, accessibility of protease target sites, target to a moiety (e.g., for a protein array), etc. Proteins that include an unnatural amino acid can have enhanced or even entirely new catalytic or physical properties. For example, the following properties are optionally modified by inclusion of an unnatural amino acid into a protein: toxicity, biodistribution, structural properties, spectroscopic properties, chemical and/or photochemical properties, catalytic ability, half-life (e.g., serum half-life), ability to react with other molecules, e.g., covalently or noncovalently, and the like. The compositions including proteins that include at least one unnatural amino acid are useful for, e.g., novel therapeutics, diagnostics, catalytic enzymes, industrial enzymes, binding proteins (e.g., antibodies), and e.g., the study of protein structure and function. <i>See, e.g.,</i> Dougherty, (<nplcit id="ncit0072" npl-type="s"><text>2000) Unnatural Amino Acids as Probes of Protein Structure and Function, Current Opinion in Chemical Biology, 4:645-652</text></nplcit>.</p><p id="p0096" num="0096">In one aspect described herein a protein includes at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten or more unnatural amino acids. The unnatural amino acids can be the same or different, e.g., there can be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more different sites in the protein that comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more different unnatural amino acids. In another aspect, described herein a protein with at least one, but fewer than all, of a particular amino acid present in the protein is substituted with the unnatural amino acid. For a given protein with more than one unnatural amino acid, the unnatural amino acids can be identical or different (e.g., the protein can include two or more different types of unnatural amino acids, or can include two of the same unnatural amino acid). For a given protein with more than two unnatural amino acids, the unnatural amino acids can be the same, different or a combination of a multiple unnatural amino acid of the same kind with at least one different unnatural amino acid.</p><p id="p0097" num="0097">Essentially any protein (or portion thereof) that includes an unnatural amino acid (and any corresponding coding nucleic acid, e.g., which includes one or more selector<!-- EPO <DP n="39"> --> codons) can be produced using the compositions and methods herein. No attempt is made to identify the hundreds of thousands of known proteins, any of which can be modified to include one or more unnatural amino acid, e.g., by tailoring any available mutation methods to include one or more appropriate selector codon in a relevant translation system. Common sequence repositories for known proteins include GenBank EMBL, DDBJ and the NCBI. Other repositories can easily be identified by searching the internet.</p><p id="p0098" num="0098">Typically, the proteins are, e.g., at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, or at least 99% or more identical to any available protein (e.g., a therapeutic protein, a diagnostic protein, an industrial enzyme, or portion thereof, and the like), and they comprise one or more unnatural amino acid. Examples of therapeutic, diagnostic, and other proteins that can be modified to comprise one or more unnatural amino acids include, but are not limited to, e.g., Alpha-1 antitrypsin, Angiostatin, Antihemolytic factor, antibodies (further details on antibodies are found below), Apolipoprotein, Apoprotein, Atrial natriuretic factor, Atrial natriuretic polypeptide, Atrial peptides, C-X-C chemokines (e.g., T39765, NAP-2, ENA-78, Gro-a, Gro-b, Gro-c, IP-10, GCP-2, NAP-4, SDF-1, PF4, MIG), Calcitonin, CC chemokines (e.g., Monocyte chemoattractant protein-1, Monocyte chemoattractant protein-2, Monocyte chemoattractant protein-3, Monocyte inflammatory protein-1 alpha, Monocyte inflammatory protein-1 beta, RANTES, I309, R83915, R91733, HCC1. T58847, D31065, T64262), CD40 ligand, C-kit Ligand, Collagen, Colony stimulating factor (CSF), Complement factor 5a, Complement inhibitor, Complement receptor 1, cytokines, (e.g., epithelial Neutrophil Activating Peptide-78, GROα/MGSA, GROβ, GROγ, MIP-1α, MIP-1δ, MCP-I), Epidermal Growth Factor (EGF), Erythropoietin ("EPO", representing a preferred target for modification by the incorporation of one or more unnatural amino acid), Exfoliating toxins A and B, Factor IX, Factor VII, Factor VIII, Factor X, Fibroblast Growth Factor (FGF), Fibrinogen, Fibronectin, G-CSF, GM-CSF, Glucocerebrosidase, Gonadotropin, growth factors, Hedgehog proteins (e.g., Sonic, Indian, Desert), Hemoglobin, Hepatocyte Growth Factor (HGF), Hirudin, Human serum albumin, Insulin, Insulin-like Growth Factor (IGF), interferons (e.g., IFN-α, IFN-β, IFN-γ), interleukins (e.g., IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, etc.), Keratinocyte Growth Factor (KGF), Lactoferrin, leukemia inhibitory factor, Luciferase, Neurturin, Neutrophil inhibitory factor (NIF), oncostatin M, Osteogenic protein, Parathyroid hormone, PD-ECSF, PDGF, peptide hormones (e.g., Human Growth Hormone), Pleiotropin, Protein A, Protein G, Pyrogenic exotoxins A, B, and C, Relaxin,<!-- EPO <DP n="40"> --> Renin, SCF, Soluble complement receptor I, Soluble I-CAM 1, Soluble interleukin receptors (IL-1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15), Soluble TNF receptor, Somatomedin, Somatostatin, Somatotropin, Streptokinase, Superantigens, i.e., Staphylococcal enterotoxins (SEA, SEB, SEC1, SEC2, SEC3, SED, SEE), Superoxide dismutase (SOD), Toxic shock syndrome toxin (TSST-1), Thymosin alpha 1, Tissue plasminogen activator, Tumor necrosis factor beta (TNF beta), Tumor necrosis factor receptor (TNFR), Tumor necrosis factor-alpha (TNF alpha), Vascular Endothelial Growth Factor (VEGEF), Urokinase, and many others.</p><p id="p0099" num="0099">One class of proteins that can be made using the compositions and methods for in vivo incorporation of unnatural amino acids described herein includes transcriptional modulators or portions thereof. Example transcriptional modulators include genes and transcriptional modulator proteins that modulate cell growth, differentiation, regulation, or the like. Transcriptional modulators are found in prokaryotes, viruses, and eukaryotes, including fungi, plants, yeasts, insects, and animals, including mammals, providing a wide range of therapeutic targets. It will be appreciated that expression and transcriptional activators regulate transcription by many mechanisms, e.g., by binding to receptors, stimulating a signal transduction cascade, regulating expression of transcription factors, binding to promoters and enhancers, binding to proteins that bind to promoters and enhancers, unwinding DNA, splicing pre-mRNA, polyadenylating RNA, and degrading RNA. For example, compositions of GAL4 protein or portion thereof in a vertebrate cell are also a feature of the invention. Typically, the GAL4 protein or portion thereof comprises at least one unnatural amino acid. See also the section herein entitled "Orthogonal aminoacyl-tRNA synthetases."</p><p id="p0100" num="0100">One class of proteins of described herein (e.g., proteins with one or more unnatural amino acids) include expression activators such as cytokines, inflammatory molecules, growth factors, their receptors, and oncogene products, e.g., interleukins (e.g., IL-1, IL-2, IL-8, etc.), interferons, FGF, IGF-1, IGF-II, FGF, PDGF, TNF, TGF-α, TGF-β, EGF, KGF, SCF/c-Kit, CD40L/CD40, VLA-4/VCAM-1, ICAM-1/LFA-1, and hyalurin/CD44; signal transduction molecules and corresponding oncogene products, e.g., Mos, Ras, Raf, and Met; and transcriptional activators and suppressors, e.g., p53, Tat, Fos, Myc, Jun, Myb, Rel, and steroid hormone receptors such as those for estrogen, progesterone, testosterone, aldosterone, the LDL receptor ligand and corticosterone.<!-- EPO <DP n="41"> --></p><p id="p0101" num="0101">Enzymes (e.g., industrial enzymes), or portions thereof with at least one unnatural amino acid, are also provided by the invention. Examples of enzymes include, but are not limited to, e.g., amidases, amino acid racemases, acylases, dehalogenases, dioxygenases, diarylpropane peroxidases, epimerases, epoxide hydrolases, esterases, isomerases, kinases, glucose isomerases, glycosidases, glycosyl transferases, haloperoxidases, monooxygenases (e.g., p450s), lipases, lignin peroxidases, nitrile hydratases, nitrilases, proteases, phosphatases, subtilisins, transaminase, and nucleases.</p><p id="p0102" num="0102">Many of these proteins are commercially available (<i>See.</i> e.g., the Sigma BioSciences 2002 catalogue and price list), and the corresponding protein sequences and genes and, typically, many variants thereof, are well-known <i>(see,</i> e.g., Genbank). Any of them can be modified by the insertion of one or more unnatural amino acid according to the invention, e.g., to alter the protein with respect to one or more therapeutic, diagnostic or enzymatic properties of interest. Examples of therapeutically relevant properties include serum half-life, shelf half-life, stability, immunogenicity, therapeutic activity, detectability (e.g., by the inclusion of reporter groups (e.g., labels or label binding sites) in the unnatural amino acids), reduction of LD<sub>50</sub> or other side effects, ability to enter the body through the gastric tract (e.g., oral availability), or the like. Examples of diagnostic properties include shelf half-life, stability, diagnostic activity, detectability, or the like. Examples of relevant enzymatic properties include shelf half-life, stability, enzymatic activity, production capability, or the like.</p><p id="p0103" num="0103">A variety of other proteins can also be modified to include one or more unnatural amino acid. For example, substituting one or more natural amino acids in one or more vaccine proteins with an unnatural amino acid, e.g., in proteins from infectious fungi, e.g., <i>Aspergillus, Candida</i> species; bacteria, particularly E. <i>coli,</i> which serves a model for pathogenic bacteria, as well as medically important bacteria such as <i>Staphylococci</i> (e.g., <i>aureus),</i> or <i>Streptococci</i> (e.g., <i>pneumoniae);</i> protozoa such as sporozoa (e.g., <i>Plasmodia), rhizopods (e.g., Entamoeba)</i> and flagellates <i>(Trypanosoma, Leishmania, Trichomonas, Giardia,</i> etc.); viruses such as (+) RNA viruses (examples include Poxviruses e.g., <i>vaccinia;</i> Picornaviruses, e.g. <i>polio;</i> Togaviruses, e.g., <i>rubella;</i> Flaviviruses, e.g., HCV; and Coronaviruses), (-) RNA viruses (e.g., Rhabdoviruses, e.g., VSV; Paramyxovimses, e.g., RSV; Orthomyxovimses, e.g., influenza; Bunyaviruses; and Arenaviruses), dsDNA viruses (Reoviruses, for example), RNA to DNA<!-- EPO <DP n="42"> --> viruses, i.e., Retroviruses, e.g., HIV and HTLV, and certain DNA to RNA viruses such as Hepatitis B is described herein.</p><p id="p0104" num="0104">Agriculturally related proteins such as insect resistance proteins (e.g., the Cry proteins), starch and lipid production enzymes, plant and insect toxins, toxin-resistance proteins, Mycotoxin detoxification proteins, plant growth enzymes (e.g., Ribulose 1,5-Bisphosphate Carboxylase/Oxygenase, "RUBISCO"), lipoxygenase (LOX), and Phosphoenolpyruvate (PEP) carboxylase are also suitable targets for unnatural amino acid modification.</p><p id="p0105" num="0105">The invention also provides methods for producing in a vertebrate cell at least one protein comprising at least one unnatural amino acid (and proteins produced by such methods). For example, a method includes: growing, in an appropriate medium, a vertebrate cell that comprises a nucleic acid that comprises at least one selector codon and encodes the protein. The vertebrate cell also comprises: an orthogonal tRNA having a nucleotide sequence as set forth in SEQ ID NO: 87 (O-tRNA) that functions in the cell and recognizes the selector codon; and an orthogonal aminoacyl tRNA synthetase (O-RS) that preferentially aminoacylates the O-tRNA with the unnatural amino acid, and the medium comprises an unnatural amino acid.</p><p id="p0106" num="0106">In one embodiment, the method further includes incorporating into the protein the unnatural amino acid, where the unnatural amino acid comprises a first reactive group; and contacting the protein with a molecule (e.g., a dye, a polymer, e.g., a derivative of polyethylene glycol, a photocrosslinker, a cytotoxic compound, an affinity label, a derivative of biotin, a resin, a second protein or polypeptide, a metal chelator, a cofactor, a fatty acid, a carbohydrate, a polynucleotide (e.g., DNA, RNA, etc.), and the like) that comprises a second reactive group. The first reactive group reacts with the second reactive group to attach the molecule to the unnatural amino acid through a [3+2] cycloaddition. In one embodiment, the first reactive group is an alkynyl or azido moiety and the second reactive group is an azido or alkynyl moiety. For example, the first reactive group is the alkynyl moiety (e.g., in unnatural amino acid p-propargyloxyphenylalanine) and the second reactive group is the azido moiety. In another example, the first reactive group is the azido moiety (e.g., in the unnatural amino acid p-azido-L-phenylalanine) and the second reactive group is the alkynyl moiety.</p><p id="p0107" num="0107">In one embodiment, the O-RS aminoacylates the O-tRNA with the unnatural amino acid at least 50% as efficiently as does an O-RS having an amino acid sequence, e.g.,<!-- EPO <DP n="43"> --> as set forth in SEQ ID NO.: 86 or 45. In yet another embodiment, the O-RS comprises an amino acid set forth in any one of SEQ ID NO.: 36-63 and/or 86.</p><p id="p0108" num="0108">The encoded protein can comprise, e.g., a therapeutic protein, a diagnostic protein, an industrial enzyme, or portion thereof. Optionally, the protein that is produced by the method is further modified through the unnatural amino acid. For example, the protein produced by the method is optionally modified by at least one post-translational modification in vivo.</p><p id="p0109" num="0109">Methods of producing a screening or selecting transcriptional modulator protein are also described (and screening or selecting transcriptional modulator proteins produced by such methods). For example, a method includes: selecting a first polynucleotide sequence, where the polynucleotide sequence encodes a nucleic acid binding domain; and mutating the first polynucleotide sequence to include at least one selector codon. This provides a screening or selecting polynucleotide sequence. The method also includes: selecting a second polynucleotide sequence, where the second polynucleotide sequence encodes a transcriptional activation domain; providing a construct that comprises the screening or selecting polynucleotide sequence operably linked to the second polynucleotide sequence; and, introducing the construct, an unnatural amino acid, an orthogonal tRNA synthetase (O-RS) and an orthogonal tRNA (O-tRNA) into a cell. With these components, the O-RS preferentially aminoacylates the O-tRNA with the unnatural amino acid and the O-tRNA recognizes the selector codon and incorporates the unnatural amino acid into the nucleic acid binding domain, in response to the selector codon in the screening or selecting polynucleotide sequence, thereby providing the screening or selecting transcriptional modulator protein.</p><p id="p0110" num="0110">In certain embodiments, the protein or polypeptide of interest (or portion thereof) in the methods of the invention is encoded by a nucleic acid. Typically, the nucleic acid comprises at least one selector codon, at least two selector codons, at least three selector codons, at least four selector codons, at least five selector codons, at least six selector codons, at least seven selector codons, at least eight selector codons, at least nine selector codons, ten or more selector codons.<!-- EPO <DP n="44"> --></p><p id="p0111" num="0111">Genes coding for proteins or polypeptides of interest can be mutagenized using methods well-known to one of skill in the art and described herein under "Mutagenesis and Other Molecular Biology Techniques" to include, e.g., one or more selector codon for the incorporation of an unnatural amino acid. For example, a nucleic acid for a protein of interest is mutagenized to include one or more selector codon, providing for the insertion of the one or more unnatural amino acids. The disclosure includes any such variant, e.g., mutant, versions of any protein, e.g., including at least one unnatural amino acid. Similarly, the invention also includes corresponding nucleic acids, i.e., any nucleic acid with one or more selector codon that encodes one or more unnatural amino acid.</p><p id="p0112" num="0112">Purifying recombinant proteins comprising unnatural amino acids</p><p id="p0113" num="0113">Proteins comprising unnatural amino acids, antibodies to proteins comprising unnatural amino acids, etc., can be purified, either partially or substantially to homogeneity, according to standard procedures known to and used by those of skill in the art. Accordingly, polypeptides can be recovered and purified by any of a number of methods well known in the art, including, e.g., ammonium sulfate or ethanol precipitation, acid or base extraction, column chromatography, affinity column chromatography, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, hydroxylapatite chromatography, lectin chromatography, gel electrophoresis and the like. Protein refolding steps can be used, as desired, in making correctly folded mature proteins. High performance liquid chromatography (HPLC), affinity chromatography or other suitable methods can be employed in final purification steps where high purity is desired. Antibodies made against unnatural amino acids (or proteins comprising unnatural amino acids) are used as purification reagents, e.g., for affinity-based purification of proteins comprising one or more unnatural amino acid(s). Once purified, partially or to homogeneity, as desired, the polypeptides are optionally used e.g., as assay components, therapeutic reagents or as immunogens for antibody production.</p><p id="p0114" num="0114">In addition to other references noted herein, a variety of purification/protein folding methods are well known in the art, including, e.g., those set forth in <nplcit id="ncit0073" npl-type="b"><text>R. Scopes, Protein Purification, Springer-Verlag, N.Y. (1982</text></nplcit>); <nplcit id="ncit0074" npl-type="b"><text>Deutscher, Methods in Enzymology<!-- EPO <DP n="45"> --> Vol. 182; Guide to Protein Purification, Academic Press, Inc. N.Y. (1990</text></nplcit>); <nplcit id="ncit0075" npl-type="b"><text>Sandana (1997) Bioseparation of Proteins, Academic Press, Inc.</text></nplcit>; <nplcit id="ncit0076" npl-type="b"><text>Bollag et al. (1996) Protein Methods, 2nd Edition Wiley-Liss, NY</text></nplcit>; <nplcit id="ncit0077" npl-type="b"><text>Walker (1996) The Protein Protocols Handbook Humana Press, NJ</text></nplcit>, <nplcit id="ncit0078" npl-type="b"><text>Harris and Angal (1990) Protein Purification Applications: A Practical Approach IRL Press at Oxford, Oxford, Engl</text></nplcit>and; <nplcit id="ncit0079" npl-type="b"><text>Harris and Angal Protein Purification Methods: A Practical Approach IRL Press at Oxford, Oxford, Engl</text></nplcit>and; <nplcit id="ncit0080" npl-type="b"><text>Scopes (1993) Protein Purification: Principles and Practice 3rd Edition Springer Verlag, NY</text></nplcit>; <nplcit id="ncit0081" npl-type="b"><text>Janson and Ryden (1998) Protein Purification: Principles, High Resolution Methods and Applications, Second Edition Wiley-VCH, NY</text></nplcit>; and<nplcit id="ncit0082" npl-type="b"><text> Walker (1998) Protein Protocols on CD-ROM Humana Press, NJ</text></nplcit>; and the references cited therein.</p><p id="p0115" num="0115">One advantage of producing a protein or polypeptide of interest with an unnatural amino acid in a vertebrate cell is that typically the proteins or polypeptides will be folded in their native conformations. However, those of skill in the art will recognize that, after synthesis, expression and/or purification, proteins can possess a conformation different from the desired conformations of the relevant polypeptides. In one aspect of the invention, the expressed protein is optionally denatured and then renatured. This is accomplished, e.g., by adding a chaperonin to the protein or polypeptide of interest, and/or by solubilizing the proteins in a chaotropic agent such as guanidine HCl, etc.</p><p id="p0116" num="0116">In general, it is occasionally desirable to denature and reduce expressed polypeptides and then to cause the polypeptides to re-fold into the preferred conformation. For example, guanidine, urea, DTT, DTE, and/or a chaperonin can be added to a translation product of interest. Methods of reducing, denaturing and renaturing proteins are well known to those of skill in the art (see, the references above, and <nplcit id="ncit0083" npl-type="s"><text>Debinski, et al. (1993) J. Biol. Chem., 268: 14065-14070</text></nplcit>; <nplcit id="ncit0084" npl-type="s"><text>Kreitman and Pastan (1993) Bioconjug. Chem.,4: 581-585</text></nplcit>; and <nplcit id="ncit0085" npl-type="s"><text>Buchner, et al., (1992) Anal. Biochem.. 205: 263-270</text></nplcit>). Debinski, et al., for example, describe the denaturation and reduction of inclusion body proteins in guanidine-DTE. The proteins can be refolded in a redox buffer containing, e.g., oxidized glutathione and L-arginine. Refolding reagents can be flowed or otherwise moved into contact with the one or more polypeptide or other expression product, or vice-versa.<!-- EPO <DP n="46"> --></p><heading id="h0016">Antibodies</heading><p id="p0117" num="0117">Herein described are antibodies to molecules of the disclosure, e.g., synthetases, tRNA, and proteins comprising unnatural amino acids. Antibodies to molecules of the disclosure are useful as purification reagents, e.g., for purifying the molecules of the disclosure. In addition, the antibodies can be used as indicator reagents to indicate the presence of a synthetase, a tRNA, or protein comprising an unnatural amino acid, e.g., to track the presence or location (e.g., in vivo or in situ) of the molecule.</p><p id="p0118" num="0118">An antibody can be a protein comprising one or more polypeptides substantially or partially encoded by immunoglobulin genes or fragments of immunoglobulingenes. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively. A typical immunoglobulin (e.g., antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kD) and one "heavy" chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (VL) and variable heavy chain (V<sub>H</sub>) refer to these light and heavy chains, respectively.</p><p id="p0119" num="0119">Antibodies exist as intact immunoglobulins or as a number of well-characterized fragments produced by digestion with various peptidases. Thus, for example, pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab')<sub>2</sub>, a dimer of Fab which itself is a light chain joined to V<sub>H</sub>-C<sub>H</sub>l by a disulfide bond. The F(ab')<sub>2</sub> may be reduced under mild conditions to break the disulfide linkage in the hinge region thereby converting the F(ab')<sub>2</sub>dimer into an Fab' monomer. The Fab' monomer is essentially an Fab with part of the hinge region (see,<nplcit id="ncit0086" npl-type="b"><text> Fundamental Immunology, 4th addition, W.E. Paul, ed., Raven Press, N.Y. (1999</text></nplcit>), for a more detailed description of other antibody fragments). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such Fab' fragments, etc. may be synthesized de novo either chemically or by utilizing recombinant DNA<!-- EPO <DP n="47"> --> methodology. Thus, the term antibody, as used herein, also optionally includes antibody fragments either produced by the modification of whole antibodies or synthesized <i>de novo</i> using recombinant DNA methodologies. Antibodies include single chain antibodies, including single chain Fv (sFv or scFv) antibodies in which a variable heavy and a variable light chain are joined together (directly or through a peptide linker) to form a continuous polypeptide. Antibodies of the invention can be, e.g., polyclonal, monoclonal, chimeric, humanized, single chain, Fab fragments, fragments produced by an Fab expression library, or the like.</p><p id="p0120" num="0120">In general, antibodies are valuable, both as general reagents and as therapeutic reagents in a variety of molecular biological or pharmaceutical processes. Methods of producing polyclonal and monoclonal antibodies are available, and can be applied to making the antibodies of the invention. A number of basic texts describe standard antibody production processes, including, e.g., <nplcit id="ncit0087" npl-type="b"><text>Borrebaeck (ed) (1995) Antibody Engineering, 2nd Edition Freeman and Company, NY (Borrebaeck</text></nplcit>); <nplcit id="ncit0088" npl-type="b"><text>McCafferty et al. (1996) Antibody Engineering, A Practical Approach IRL at Oxford Press, Oxford, England (McCafferty</text></nplcit>), and <nplcit id="ncit0089" npl-type="b"><text>Paul (1995) Antibody Engineering Protocols Humana Press, Towata, NJ (Paul</text></nplcit>); <nplcit id="ncit0090" npl-type="b"><text>Paul (ed.), (1999) Fundamental Immunology, Fifth edition Raven Press, N.Y</text></nplcit>.; <nplcit id="ncit0091" npl-type="b"><text>Coligan (1991) Current Protocols in Immunology Wiley/Greene, NY</text></nplcit>; <nplcit id="ncit0092" npl-type="b"><text>Harlow and Lane (1989) Antibodies: A Laboratory Manual Cold Spring Harbor Press, NY</text></nplcit>; <nplcit id="ncit0093" npl-type="b"><text>Stites et al. (eds.) Basic and Clinical Immunology (4th ed.) Lange Medical Publications, Los Altos, CA</text></nplcit>, and references cited therein; <nplcit id="ncit0094" npl-type="b"><text>Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed.) Academic Press, New York, NY</text></nplcit>; and <nplcit id="ncit0095" npl-type="s"><text>Kohler and Milstein (1975) Nature 256: 495-497</text></nplcit>.</p><p id="p0121" num="0121">A variety of recombinant techniques for antibody preparation which do not rely on, e.g., injection of an antigen into an animal have been developed and can be used in the context of the present invention. For example, it is possible to generate and select libraries of recombinant antibodies in phage or similar vectors. <i>See,</i> e.g., <nplcit id="ncit0096" npl-type="s"><text>Winter et al. (1994) Making Antibodies by Phage Display Technology Annu. Rev. Immunol. 12:433-55</text></nplcit> and the references cited therein for a review. <i>See also,</i><nplcit id="ncit0097" npl-type="s"><text> Griffiths and Duncan (1998) Strategies for selection of antibodies by phage display Curr Opin Biotechnol 9: 102-8</text></nplcit>; <nplcit id="ncit0098" npl-type="s"><text>Hoogenboom et al. (1998) Antibody phage display technology and its applications Immunotechnology 4: 1-20</text></nplcit>; <nplcit id="ncit0099" npl-type="s"><text>Gram et al. (1992) in vitro selection and affinity maturation of antibodies from a naïve combinatorial immunoglobulin library PNAS 89:3576-3580</text></nplcit>; <nplcit id="ncit0100" npl-type="s"><text>Huse et al. (1989) Science 246: 1275-1281</text></nplcit>; and <nplcit id="ncit0101" npl-type="s"><text>Ward, et al. (1989) Nature 341: 544-546</text></nplcit>.<!-- EPO <DP n="48"> --></p><p id="p0122" num="0122">Antibody libraries can include repertoires of V genes (e.g., harvested from populations of lymphocytes or assembled in vitro) which are cloned for display of associated heavy and light chain variable domains on the surface of filamentous bacteriophage. Phage are selected by binding to an antigen. Soluble antibodies are expressed from phage infected bacteria and the antibody can be improved, e.g., via mutagenesis. <i>See</i> e.g., <nplcit id="ncit0102" npl-type="s"><text>Balint and Larrick (1993) Antibody Engineering by Parsimonious Mutagenesis Gene 137:109-118</text></nplcit>; <nplcit id="ncit0103" npl-type="s"><text>Stemmer et al. (1993) Selection of an Active Single Chain Fv Antibody From a Protein Linker Library Prepared by Enzymatic Inverse PCR Biotechniques 14(2):256-65</text></nplcit>; <nplcit id="ncit0104" npl-type="s"><text>Crameri et al. (1996) Construction and evolution of antibody-phage libraries by DNA shuffling Nature Medicine 2:100-103</text></nplcit>; and <nplcit id="ncit0105" npl-type="s"><text>Crameri and Stemmer (1995) Combinatorial multiple cassette mutagenesis creates all the permutations of mutant and wildtype cassettes BioTechniques 18:194-195</text></nplcit>.</p><p id="p0123" num="0123">Kits for cloning and expression of recombinant antibody phage systems are also known and available, e.g., the "recombinant phage antibody system, mouse ScFv module," from Amersham-Pharmacia Biotechnology (Uppsala, Sweden). Bacteriophage antibody libraries have also been produced for making high affinity human antibodies by chain shuffling (<i>See,</i> e.g., <nplcit id="ncit0106" npl-type="s"><text>Marks et al. (1992) By- Passing Immunization: Building High Affinity Human Antibodies by Chain Snuffling Biotechniques 10:779-782</text></nplcit>. It will also be recognized that antibodies can be prepared by any of a number of commercial services (e.g., Bethyl Laboratories (Montgomery, TX), Anawa (Switzerland), Eurogentec (Belgium and in the US in Philadelphia, PA, etc.) and many others.</p><p id="p0124" num="0124">In certain cases, it is useful to "humanize" antibodies, e.g., where the antibodies are to be administered therapeutically. The use of humanized antibodies tends to reduce the incidence of unwanted immune responses against the therapeutic antibodies (e.g., when the patient is a human). The antibody references above describe humanization strategies. In addition to humanized antibodies, human antibodies are also a feature of the invention. Human antibodies consist of characteristically human immunoglobulin sequences. Human antibodies can be produced in using a wide variety of methods <i>(see, e.g.,</i> <patcit id="pcit0005" dnum="US5001065A"><text>Larrick et al., U.S. Pat. No. 5,001,065</text></patcit>, for a review). A general approach for producing human antibodies by trioma technology is described by <nplcit id="ncit0107" npl-type="s"><text>Ostberg et al. (1983), Hybridoma 2: 361-367</text></nplcit>, <patcit id="pcit0006" dnum="US4634664A"><text>Ostberg, U.S. Pat. No. 4,634,664</text></patcit>, and <patcit id="pcit0007" dnum="US4634666A"><text>Engelman et al., U.S. Pat. No. 4,634,666</text></patcit>.<!-- EPO <DP n="49"> --></p><p id="p0125" num="0125">A variety of methods of using antibodies in the purification and detection of proteins are known and can be applied to detecting and purifying proteins comprising unnatural amino acids as noted herein. In general, antibodies are useful reagents for ELISA, western blotting, immunochemistry, affinity chromatograpy methods, SPR, and many other methods. The references noted above provide details on how to perform ELISA assays, western blots, surface plasmon resonance (SPR) and the like.</p><p id="p0126" num="0126">In one aspect, antibodies themselves include unnatural amino acids, providing the antibodies with properties of interest (e.g., improved half-life, stability, toxicity, or the like). See also, the section herein entitled "Polypeptides with unnatural amino acids." Antibodies account for nearly 50% of all compounds currently in clinical trials (<nplcit id="ncit0108" npl-type="s"><text>Wittrup, (1999) Phage on display Tibtech 17: 423-424</text></nplcit> and antibodies are used ubiquitously as diagnostic reagents. Accordingly, the ability to modify antibodies with unnatural amino acids provides an important tool for modifying these valuable reagents.</p><p id="p0127" num="0127">For example, there are many applications of MAbs to the field of diagnostics. Assays range from simple spot tests to more involved methods such as the radio-labeled NR-LU-10 MAb from DuPont Merck Co. used for tumor imaging (<nplcit id="ncit0109" npl-type="s"><text>Rusch et al. (1993) NR-LU-10 monoclonal antibody scanning. A helpful new adjunct to computed tomography in evaluating non-small-cell lung cancer. J Thorac Cardiovasc Surg 106: 200-4</text></nplcit>). As noted, MAbs are central reagents for ELISA, western blotting, immunochemistry, affinity chromatograpy methods and the like. Any such diagnostic antibody can be modified to include one or more unnatural amino acid, altering, e.g., the specificity or avidity of the Ab for a target, or altering one or more detectable property, e.g., by including a detectable label (e.g., spectrographic, fluorescent, luminescent, etc.) in the unnatural amino acid.</p><p id="p0128" num="0128">One class of valuable antibody reagents are therapeutic Abs. For example, antibodies can be tumor-specific MAbs that arrest tumor growth by targeting tumor cells for destruction by antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-mediated lysis (CML) (these general types of Abs are sometimes referred to as "magic bullets"). One example is Rituxan, an anti-CD20 MAb for the treatment of Non-Hodgkins lymphoma (<nplcit id="ncit0110" npl-type="s"><text>Scott (1998) Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma Cancer Pract 6: 195-7</text></nplcit>). A second example relates to antibodies which<!-- EPO <DP n="50"> --> interfere with a critical component of tumor growth. Herceptin is an anti-HER-2 monoclonal antibody for treatment of metastatic breast cancer, and provides an example of an antibody with this mechanism of action (<nplcit id="ncit0111" npl-type="s"><text>Baselga et al. (1998) Recombinant humanized arrti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts [published erratum appears in Cancer Res (1999) 59(8):2020</text></nplcit>], <nplcit id="ncit0112" npl-type="s"><text>Cancer Res 58: 2825-31</text></nplcit>). A third example relates to antibodies for delivery of cytotoxic compounds (toxins, radionuclides, etc.) directly to a tumor or other site of interest. For example, one application Mab is CYT-356, a 90Y-linked antibody that targets radiation directly to prostate tumor cells (<nplcit id="ncit0113" npl-type="s"><text>Deb et al. (1996) Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody Clin Cancer Res 2: 1289-97</text></nplcit>. A fourth application is antibody-directed enzyme prodrug therapy, where an enzyme co-localized to a tumor activates a systemically-administered pro-drug in the tumor vicinity. For example, an anti-Ep-CAM1 antibody linked to carboxypeptidase A is being developed for treatment of colorectal cancer (<nplcit id="ncit0114" npl-type="s"><text>Wolfe et al. (1999) Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843 Bioconjug Chem 10: 38-48</text></nplcit>). Other Abs (e.g., antagonists) are designed to specifically inhibit normal cellular functions for therapeutic benefit. An example is Orthoclone OKT3, an anti-CD3 MAb offered by Johnson and Johnson for reducing acute organ transplant rejection (<nplcit id="ncit0115" npl-type="s"><text>Strate et al. (1990) Orthoclone OKT3 as first-line therapy in acute renal allograft rejection Transplant Proc 22: 219-20</text></nplcit>. Another class of antibody products are agonists. These Mabs are designed to specifically enhance normal cellular functions for therapeutic benefit. For example, Mab-based agonists of acetylcholine receptors for neurotherapy are under development (<nplcit id="ncit0116" npl-type="s"><text>Xie et al. (1997) Direct demonstration of MuSK involvement in acetylcholine receptor clustering through identification of agonist ScFv Nat. Biotechnol. 15: 768-71</text></nplcit>. Any of these antibodies can be modified to include one or more unnatural amino acid to enhance one or more therapeutic property (specificity, avidity, serum-half-life, etc.).</p><p id="p0129" num="0129">Another class of antibody products provide novel functions. The main antibodies in this group are catalytic antibodies such as Ig sequences that have been engineered to mimic the catalytic abilities of enzymes (<nplcit id="ncit0117" npl-type="s"><text>Wentworth and Janda (1998) Catalytic antibodies Curr Opin Chem Biol 2: 138-44</text></nplcit>. For example, an interesting application involves using the catalytic antibody mAb-15A10 to hydrolyze cocaine <i>in vivo</i><!-- EPO <DP n="51"> --> for addiction therapy (<nplcit id="ncit0118" npl-type="s"><text>Mets et al. (1998) A catalytic antibody against cocaine prevents cocaine's reinforcing and toxic effects in rats Proc Natl Acad Sci U S A 95: 10176-81</text></nplcit>). Catalytic antibodies can also be modified to include one or more unnatural amino acid to improve one or more property of interest.<!-- EPO <DP n="52"> --></p><heading id="h0017">Nucleic acid and polypeptide sequence and variants</heading><!-- EPO <DP n="53"> --><p id="p0130" num="0130">As described above and below, the disclosure provides for nucleic acid polynucleotide sequences and polypeptide amino acid sequences, e.g., O-tRNA's and O-RSs, and, e.g., compositions and methods comprising said sequences. Examples of said sequences, e.g., O-tRNA's and O-RSs are disclosed herein (see, Table 5, e.g., SEQ ID NO. 3-65, 86, 87 and 88, and other than SEQ ID NO.: 1 and 2).<!-- EPO <DP n="54"> --></p><heading id="h0018">Mutagenesis and Other Molecular Biology Techniques</heading><p id="p0131" num="0131">General texts which describe molecular biological techniques include <nplcit id="ncit0119" npl-type="b"><text>Berger and Kimmel, Guide to Molecular Cloning Techniques,_Methods in Enzymology volume 152 Academic Press, Inc., San Diego, CA (Berger</text></nplcit>);<nplcit id="ncit0120" npl-type="b"><text> Sambrook et al., Molecular Cloning - A Laboratory Manual (2nd Ed.), Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989 ("Sambrook</text></nplcit>") and <nplcit id="ncit0121" npl-type="b"><text>Current Protocols in Molecular Biology, F.M. Ausubel et al., eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley &amp; Sons, Inc., (supplemented through 1999) ("Ausubel</text></nplcit>")). These texts describe mutagenesis, the use of vectors, promoters and many other relevant topics related to, e.g., the generation of genes that include selector codons for production of proteins that include unnatural amino acids, orthogonal tRNA's, orthogonal synthetases, and pairs thereof.</p><p id="p0132" num="0132">Various types of mutagenesis are used in the disclosure, e.g., to produce libraries of tRNA's, to produce libraries of synthetases, to insert selector codons that encode unnatural amino acids in a protein or polypeptide of interest. They include but are not limited to site-directed, random point mutagenesis, homologous recombination, DNA shuffling or other recursive mutagenesis methods, chimeric construction, mutagenesis using uracil containing templates, oligonucleotide-directed mutagenesis, phosphorothioate-modified DNA mutagenesis, mutagenesis using gapped duplex DNA or the like, or any combination thereof. Additional suitable methods include point mismatch repair, mutagenesis using repair-deficient host strains, restriction-selection and restriction-purification, deletion mutagenesis, mutagenesis by total gene synthesis, double-strand break repair, and the like. Mutagenesis, e.g., involving chimeric constructs, are also included in<!-- EPO <DP n="55"> --> the present disclosure. In one embodiment, mutagenesis can be guided by known information of the naturally occurring molecule or altered or mutated naturally occurring molecule, e.g., sequence, sequence comparisons, physical properties, crystal structure or the like.</p><p id="p0133" num="0133">The above texts and examples found herein describe these procedures. Additional information is found in the following publications and references cited within: <nplcit id="ncit0122" npl-type="s"><text>Ling et al., Approaches to DNA mutagenesis: an overview, Anal Biochem. 254(2): 157-178 (1997</text></nplcit>);<nplcit id="ncit0123" npl-type="s"><text> Dale et al., Oligonucleotide-directed random mutagenesis using the phosphorothioate method, Methods Mol. Biol. 57:369-374 (1996</text></nplcit>); <nplcit id="ncit0124" npl-type="s"><text>Smith, In vitro mutagenesis, Ann. Rev. Genet. 19:423-462(1985</text></nplcit>); <nplcit id="ncit0125" npl-type="s"><text>Botstein &amp; Shortle, Strategies and applications of in vitro mutagenesis, Science 229:1193-1201(1985</text></nplcit>); <nplcit id="ncit0126" npl-type="s"><text>Carter, Site-directed mutagenesis, Biochem. J. 237:1-7 (1986</text></nplcit>); <nplcit id="ncit0127" npl-type="b"><text>Kunkel, The efficiency of oligonucleotide directed mutagenesis, in Nucleic Acids &amp; Molecular Biology (Eckstein, F. and Lilley, D.M.J. eds., Springer Verlag, Berlin)) (1987</text></nplcit>); <nplcit id="ncit0128" npl-type="s"><text>Kunkel, Rapid and efficient site-specific mutagenesis without phenotypic selection, Proc. Natl. Acad. Sci. USA 82:488-492 (1985</text></nplcit>); <nplcit id="ncit0129" npl-type="s"><text>Kunkel et al., Rapid and efficient site-specific mutagenesis without phenotypic selection, Methods in Enzymol. 154, 367-382 (1987</text></nplcit>); <nplcit id="ncit0130" npl-type="s"><text>Bass et al., Mutant Trp repressors with new DNA-binding specificities, Science 242:240-245 (1988</text></nplcit>); <nplcit id="ncit0131" npl-type="s"><text>Methods in Enzymol. 100: 468-500 (1983</text></nplcit>); <nplcit id="ncit0132" npl-type="s"><text>Methods in Enzymol. 154: 329-350 (1987</text></nplcit>); <nplcit id="ncit0133" npl-type="s"><text>Zoller &amp; Smith, Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutations in any DNA fragment, Nucleic Acids Res. 10:6487-6500 (1982</text></nplcit>); <nplcit id="ncit0134" npl-type="s"><text>Zoller &amp; Smith, Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors, Methods in Enzymol. 100:468-500 (1983</text></nplcit>); <nplcit id="ncit0135" npl-type="s"><text>Zoller &amp; Smith, Oligonucleotide-directed mutagenesis: a simple method using two oligonucleotide primers and a single-stranded DNA template, Methods in Enzymol. 154:329-350 (1987</text></nplcit>); <nplcit id="ncit0136" npl-type="s"><text>Taylor et al., The use of phosphorothioate-modified DNA in restriction enzyme reactions to prepare nicked DNA, Nucl. Acids Res. 13: 8749-8764 (1985</text></nplcit>); <nplcit id="ncit0137" npl-type="s"><text>Taylor et al., The rapid generation of oligonucleotide-directed mutations at high frequency using phosphorothioate-modified DNA, Nucl. Acids Res. 13: 8765-8787 (1985</text></nplcit>); <nplcit id="ncit0138" npl-type="s"><text>Nakamaye &amp; Eckstein, Inhibition of restriction endonuclease Nci I cleavage by phosphorothioate groups and its application to oligonucleotide-directed mutagenesis, Nucl. Acids Res. 14: 9679-9698 (1986</text></nplcit>); <nplcit id="ncit0139" npl-type="s"><text>Sayers et al., Y-T Exonucleases in phosphorothioate-based oligonucleotide-directed mutagenesis, Nucl. Acids Res. 16:791-802 (1988</text></nplcit>);<nplcit id="ncit0140" npl-type="s"><text> Sayers et al., Strand specific cleavage of phosphorothioate-containing<!-- EPO <DP n="56"> --> DNA by reaction with restriction endonucleases in the presence of ethidium bromide, (1988) Nucl. Acids Res. 16: 803-814</text></nplcit>;<nplcit id="ncit0141" npl-type="s"><text> Kramer et al., The gapped duplex DNA approach to oligonucleotide-directed mutation construction, Nucl. Acids Res. 12: 9441-9456 (1984</text></nplcit>); <nplcit id="ncit0142" npl-type="s"><text>Kramer &amp; Fritz Oligonucleotide-directed construction of mutations via gapped duplex DNA, Methods in Enzymol. 154:350-367 (1987</text></nplcit>); <nplcit id="ncit0143" npl-type="s"><text>Kramer et al., Improved enzymatic in vitro reactions in the gapped duplex DNA approach to oligonucleotide-directed construction ofmutations, Nucl. Acids Res. 16: 7207 (1988</text></nplcit>); <nplcit id="ncit0144" npl-type="s"><text>Fritz et al., Oligonucleotide-directed construction of mutations: a gapped duplex DNA procedure without enzymatic reactions in vitro, Nucl. Acids Res. 16: 6987-6999 (1988</text></nplcit>); <nplcit id="ncit0145" npl-type="s"><text>Kramer et al., Point Mismatch Repair, Cell 38:879-887 (1984</text></nplcit>); <nplcit id="ncit0146" npl-type="s"><text>Carter et al., Improved oligonucleotide site-directed mutagenesis using M13 vectors, Nucl. Acids Res. 13: 4431-4443 (1985</text></nplcit>); <nplcit id="ncit0147" npl-type="s"><text>Carter, Improved oligonucleotide-directed mutagenesis using M13 vectors, Methods in Enzymol. 154: 382-403 (1987</text></nplcit>); <nplcit id="ncit0148" npl-type="s"><text>Eghtedarzadeh &amp; Henikoff, Use of oligonucleotides to generate large deletions, Nucl. Acids Res. 14: 5115 (1986</text></nplcit>); <nplcit id="ncit0149" npl-type="s"><text>Wells et al., Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin, Phil. Trans. R. Soc. Lond. A 317: 415-423 (1986</text></nplcit>); <nplcit id="ncit0150" npl-type="s"><text>Nambiar et al., Total synthesis and cloning of a gene coding for the ribonuclease S protein, Science 223: 1299-1301 (1984</text></nplcit>); <nplcit id="ncit0151" npl-type="s"><text>Sakamar and Khorana, Total synthesis and expression of a gene for the α-subunit of bovine rod outer segment guanine nucleotide-binding protein (transducin), Nucl. Acids Res. 14: 6361-6372 (1988</text></nplcit>); <nplcit id="ncit0152" npl-type="s"><text>Wells et al., Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites, Gene 34:315-323 (1985</text></nplcit>); <nplcit id="ncit0153" npl-type="s"><text>Grundström et al., Oligonucleotide-directed mutagenesis by microscale 'shot-gun'gene synthesis, Nucl. Acids Res. 13: 3305-3316 (1985</text></nplcit>);<nplcit id="ncit0154" npl-type="s"><text> Mandecki, Oligonucleotide-directed double-strand break repair in plasmids of Escherichia coli: a method for site-specific mutagenesis, Proc. Natl. Acad. Sci. USA, 83:7177-7181 (1986</text></nplcit>); <nplcit id="ncit0155" npl-type="s"><text>Arnold, Protein engineering for unusual environments, Current Opinion in Biotechnology 4:450-455 (1993</text></nplcit>); <nplcit id="ncit0156" npl-type="s"><text>Sieber, et al., Nature Biotechnology, 19:456-460 (2001</text></nplcit>). <nplcit id="ncit0157" npl-type="s"><text>W. P. C. Stemmer, Nature 370, 389-91 (1994</text></nplcit>); and,<nplcit id="ncit0158" npl-type="s"><text> I. A. Lorimer, I. Pastan, Nucleic Acids Res. 23, 3067-8 (1995</text></nplcit>). Additional details on many of the above methods can be found <u>in</u> <nplcit id="ncit0159" npl-type="s"><text>Methods in Enzymology Volume 154</text></nplcit>, which also describes useful controls for trouble-shooting problems with various mutagenesis methods.</p><p id="p0134" num="0134">The disclosure also relates to vertebrate host cells wherein the cells are not human embryonic cells or in vivo human cells and organisms for the in vivo incorporation of an unnatural amino acid via orthogonal tRNA/RS pairs. Host cells are genetically engineered (e.g., transformed, transduced or transfected) with the<!-- EPO <DP n="57"> --> polynucleotides of the disclosure or constructs which include a polynucleotide of the disclosure e.g., a vector of the disclosure, which can be, for example, a cloning vector or an expression vector. The vector can be, for example, in the form of a plasmid, a bacterium, a virus, a naked polynucleotide, or a conjugated polynucleotide. The vectors are introduced into cells and/or microorganisms by standard methods including electroporation (<nplcit id="ncit0160" npl-type="s"><text>From et al., Proc. Natl. Acad. Sci. USA 82, 5824 (1985</text></nplcit>), infection by viral vectors, high velocity ballistic penetration by small particles with the nucleic acid either within the matrix of small beads or particles, or on the surface (<nplcit id="ncit0161" npl-type="s"><text>Klein et al., Nature 327, 70-73 (1987</text></nplcit>)).</p><p id="p0135" num="0135">The engineered host cells can be cultured in conventional nutrient media modified as appropriate for such activities as, for example, screening steps, activating promoters or selecting transformants. These cells can optionally be cultured into transgenic organisms. Other useful references, e.g. for cell isolation and culture (e.g., for subsequent nucleic acid isolation) include <nplcit id="ncit0162" npl-type="b"><text>Freshney (1994) Culture of Animal Cells, a Manual of Basic Technique, third edition, Wiley- Liss, New York</text></nplcit> and the references cited therein; <nplcit id="ncit0163" npl-type="b"><text>Payne et al. (1992) Plant Cell and Tissue Culture in liquid Systems John Wiley &amp; Sons, Inc. New York, NY</text></nplcit>; <nplcit id="ncit0164" npl-type="b"><text>Gamborg and Phillips (eds) (1995) Plant Cell, Tissue and Organ Culture; Fundamental Methods Springer Lab Manual, Springer-Verlag (Berlin Heidelberg New York</text></nplcit>) and <nplcit id="ncit0165" npl-type="b"><text>Atlas and Parks (eds) The Handbook of Microbiological Media (1993) CRC Press, Boca Raton, FL</text></nplcit>.</p><p id="p0136" num="0136">The invention also relates to vertebrate cell lines wherein the cell line is not a human embryonic stem cell line with the ability to incorporate an unnatural amino acid or acids via orthogonal tRNA/RS pairs wherein the tRNA comprises a sequence as set forth in SEQ ID NO: 87. These cell lines can be established using cell culture techniques known in the art on host cells which have been transformed, transduced, or transfected with the polynucleotides of the invention or constructs which include a polynucleotide of the invention. The methods of introducing exogenous nucleic acids into host cells are well known in the art, and will vary with the host cell used. Techniques include, but are not limited to, dextran-mediated transfection, calcium phosphate precipitation, calcium chloride treatment, polybrene mediated transfection, protoplast fusion, electroporation, viral or phage infection, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection.</p><p id="p0137" num="0137">Cells may be transformed or transfected in a manner to allow either transient or stable incorporation of DNA. For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the<!-- EPO <DP n="58"> --> antibody molecule may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the antibody molecule. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule. Alternatively, other techniques, such as some viral-mediated vector transfection techniques, well known to those in the art, can permit transient transfection of cells.</p><p id="p0138" num="0138">Several well-known methods of introducing target nucleic acids into cells are available, any of which can be used in the invention. These include: fusion of the recipient cells with bacterial protoplasts containing the DNA, electroporation, projectile bombardment (for more stable expression), and infection with viral vectors (which can be used for stable or transient transfection and which is also discussed further, below), etc. Bacterial cells can be used to amplify the number of plasmids containing DNA constructs of this invention. The bacteria are grown to log phase and the plasmids within the bacteria can be isolated by a variety of methods known in the art <i>(see,</i> for instance, Sambrook). In addition, a plethora of kits are commercially available for the purification of plasmids from bacteria, (see, e.g., EasyPrep™, FlexiPrep™, both from Pharmacia Biotech; StrataClean™, from Stratagene; and, QIAprep™ from Qiagen). The isolated and purified plasmids are then further manipulated to produce other plasmids, used to transfect cells or incorporated into related vectors to infect organisms. Typical vectors contain transcription and translation terminators, transcription and translation initiation sequences, and promoters useful for regulation of the expression of the particular target nucleic acid. The vectors optionally comprise generic expression cassettes containing at least one independent terminator sequence, sequences permitting replication of the cassette in eukaryotes, or prokaryotes, or both, (e.g., shuttle vectors) and selection markers for both prokaryotic and vertebrate systems. Vectors are suitable for replication and integration in prokaryotes, eukaryotes, or preferably both. See, <nplcit id="ncit0166" npl-type="s"><text>Giliman &amp; Smith, Gene 8:81 (1979</text></nplcit>); <nplcit id="ncit0167" npl-type="s"><text>Roberts, et al.,<!-- EPO <DP n="59"> --> Nature, 328:731 (1987</text></nplcit>); <nplcit id="ncit0168" npl-type="s"><text>Schneider, B., el a/., Protein Expr. Purif. 6435:10 (1995</text></nplcit>); Ausubel, Sambrook, Berger (<i>all supra</i>)<i>.</i> A catalogue of Bacteria and Bacteriophages useful for cloning is provided, e.g., by the ATCC, e.g., <nplcit id="ncit0169" npl-type="b"><text>The ATCC Catalogue of Bacteria and Bacteriophage (1992) Ghema et al. (eds) published by the ATCC</text></nplcit>. Additional basic procedures for sequencing, cloning and other aspects of molecular biology and underlying theoretical considerations are also found in<nplcit id="ncit0170" npl-type="b"><text> Watson et al. (1992) Recombinant DNA Second Edition Scientific American Books, NY</text></nplcit>. In addition, essentially any nucleic acid (and virtually any labeled nucleic acid, whether standard or non-standard) can be custom or standard ordered from any of a variety of commercial sources, such as the Midland Certified Reagent Company (Midland, TX mcrc.com), The Great American Gene Company (Ramona, CA available on the World Wide Web at genco.com), ExpressGen Inc. (Chicago, IL available on the World Wide Web at expressgen.com), Operon Technologies Inc. (Alameda, CA) and many others.</p><heading id="h0019">Kits</heading><p id="p0139" num="0139">Kits are also a feature of the disclosure. For example, a kit for producing a protein that comprises at least one unnatural amino acid in a cell is provided, where the kit includes a container containing a polynucleotide sequence encoding an O-tRNA with the sequence as set forth in SEQ ID NO: 87, and/or an O-tRNA with the sequence as set forth in SEQ ID NO: 87, and/or a polynucleotide sequence encoding an O-RS, and/or an O-RS. In one embodiment, the kit further includes at least one unnatural amino acid. In another embodiment, the kit further comprises instructional materials for producing the protein.</p><heading id="h0020">EXAMPLES</heading><heading id="h0021">Example 1: Methods of producing and compositions of Aminoacyl-tRNA synthetases that Incorporate unnatural amino acids in vertebrate cells</heading><p id="p0140" num="0140">The expansion of the vertebrate genetic code to include unnatural amino acids with novel physical, chemical or biological properties would provide powerful tools for analyzing and controlling protein function in these cells. Towards this goal, a general approach for the isolation of aminoacyl-tRNA synthetases that incorporate unnatural amino acids with high fidelity into proteins in response to an amber codon in Saccharomyces<!-- EPO <DP n="60"> --> cerevisiae (S. cerevisiae) is described. The method is based on the activation of GAL4 responsive reporter genes, HIS3, URA3 or LacZ, by suppression of amber codons between the DNA binding domain and transcriptional activation domain of GAL4. The optimization of a GAL4 reporter for positive selection of active <i>Escherichia coli</i> tyrosyl-tRNA synthetase (EcTyrRS) variants is described. A negative selection of inactive EcTyrRS variants has also been developed with the URA3 reporter by use of a small molecule (5-fluroorotic acid (5-FOA)) added to the growth media as a 'toxic allele.' Importantly both positive and negative selections can be performed on a single cell and with a range of stringencies. This can facilitate the isolation of a range of aminoacyl-tRNA synthetase (aaRS) activities from large libraries of mutant synthetases. The power of the method for isolating desired aaRS phenotypes is demonstrated by model selections.</p><heading id="h0022">Example 2</heading><heading id="h0023"><i>E. coli</i> and <i>B stearothermophilus</i> Tyr tRNA hybrid tRNA Construction</heading><p id="p0141" num="0141">It is known from work in Saccharomyces cerevisiae, that the E. coli Tyr tRNA/RS pairs are orthogonal to endogenous tRNA/RS pairs and supports unnatural amino acid suppression. However, efforts to transcribe functional E. coli tRNA<sup>Tyr</sup> <i>in vivo</i> in mammalian cells have been challenging. Because of this, interest has turned to <i>B</i>. <i>stearothermophilus</i> as a source of tRNA sequence that can support unnatural amino acid suppression in mammalian cells. Though <i>B. stearothermophilus</i> tRNA is a substrate for <i>E</i>. <i>coli</i> tRNA<sup>Tyr</sup> synthetase, further engineering of tRNA is needed to improve the tRNA aminoacylation efficiency. Improved tRNA aminoacylation will improve suppression efficiency. The acceptor stem of the tRNA is a key determinant for tRNA synthetase recognition. In this example, a hybrid tRNA was constructed by combining different structural components of <i>E</i>. <i>coli</i> and <i>B. stearothermophilus</i> tRNA<sup>Tyr</sup>. This hybrid tRNA has the acceptor stem <i>of E. coli</i> tRNA<sup>Tyr</sup>, and the D arm, TψC arm, variable loop and anticodon stem of <i>B</i>. <i>stearothermophilus</i> tRNA<sup>Tyr</sup>. The new hybrid tRNA, having an acceptor stem that derives from <i>E. coli,</i> is a better substrate for <i>E. coli</i> tRNA<sup>Tyr</sup>synthetase. We show in the experiment below that improved amber suppression efficiency was obtained when the newly created hybrid amber-suppressing tRNA was used. For comparison, the hybrid tRNA was tested alongside the <i>B</i>. <i>stearothermophilus</i> tRNA<sup>Tyr</sup> from which it was derived.</p><heading id="h0024">Experimental:</heading><p id="p0142" num="0142">Construction of plasmid encoding hybrid tRNA:<!-- EPO <DP n="61"> -->
<ul><li>Single-copy hybrid amber-suppressing tRNA expression insert which includes 5' restriction sites (EcoR I and Bgl II), 5' flanking sequence of human tRNA<sup>Tyr</sup>
<img id="ib0008" file="imgb0008.tif" wi="161" he="12" img-content="dna" img-format="tif"/></li><li>the hybrid <i>tRNA</i> amber suppression mutant lacking 3'-CCA (The nucleotide sequence of the hybrid tRNA is as follows:
<img id="ib0009" file="imgb0009.tif" wi="161" he="12" img-content="dna" img-format="tif"/>
and the DNA sequence encoding the tRNA is as follows:
<img id="ib0010" file="imgb0010.tif" wi="159" he="12" img-content="dna" img-format="tif"/>
3' flanking sequence of human tRNA<sup>Tyr</sup> (GACAAGTGCGGTTTTTTTCTCCAGCTCCCGATGACTTATGGC (SEQ ID NO: 90)) and 3' restriction sites (BamH I and Hind III), was constructed by overlap PCR using primers:
<ul><li>FTam 73: forward primer with EcoR I and Bgl <b>II</b> site
<img id="ib0011" file="imgb0011.tif" wi="160" he="12" img-content="dna" img-format="tif"/></li><li>FTam 115: reverse primer:
<img id="ib0012" file="imgb0012.tif" wi="160" he="11" img-content="dna" img-format="tif"/></li><li>FTam 116: forward primer for picec 2:
<img id="ib0013" file="imgb0013.tif" wi="161" he="12" img-content="dna" img-format="tif"/></li><li>FTam 117: reverse primer for piece 2:
<img id="ib0014" file="imgb0014.tif" wi="160" he="12" img-content="dna" img-format="tif"/></li></ul></li></ul>
The insert was ligated into pUC19 at EcoR I and Hind III sites.</p><p id="p0143" num="0143">Amber suppression experiment with hybrid tRNA (<figref idrefs="f0001">Figure 1</figref>):
<ul><li>Plasmids encoding the hGH E88 amber mutant, <i>E. coli</i> tRNA synthetase and either the single-copy amber-suppressing <i>B</i>. <i>stearothermophilus</i> tRNA or the single-copy amber-suppressing hybrid tRNA were co-transfected into CHO K1 cells. The expression of hGH was assayed 42 hours after transfection. When the hybrid tRNA (hb1) was used, amber<!-- EPO <DP n="62"> --> suppression efficiency increased approximately 30% relative to that obtained when the <i>B</i>. <i>stearothermophilus</i> amber suppressing tRNA was used.</li></ul></p><heading id="h0025">Example 3</heading><p id="p0144" num="0144">Addition of molecules to proteins with an unnatural amino acid.<br/>
In one aspect, the invention provides methods and related compositions of proteins comprising unnatural amino acids coupled to additional substituent molecules.</p><p id="p0145" num="0145">It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims.</p><p id="p0146" num="0146">While the foregoing invention has been described in some detail for purposes of clarity and understanding, it will be clear to one skilled in the art from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention. For example, all the techniques and apparatus described herein can be used in various combinations.<!-- EPO <DP n="63"> -->
<tables id="tabl0002" num="0002"><table frame="all"><title><u>TABLE 5</u></title><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="27mm"/><colspec colnum="2" colname="col2" colwidth="79mm"/><colspec colnum="3" colname="col3" colwidth="136mm"/><thead><row><entry valign="top"><b>SEQ ID NO.:</b></entry><entry valign="top"><b>Label</b></entry><entry valign="top"><b>SEQUENCE</b></entry></row></thead><tbody><row><entry>SEQ ID NO.: 1</entry><entry>E. coli wild-type TyrRS (synthetase) polynucleotide</entry><entry><img id="ib0015" file="imgb0015.tif" wi="123" he="101" img-content="dna" img-format="tif"/></entry></row><row><entry>SEQ ID NO.: 2</entry><entry>E. coli wild-type TyrRS (synthetase) Amino acid (aa)</entry><entry><img id="ib0016" file="imgb0016.tif" wi="123" he="33" img-content="dna" img-format="tif"/></entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 3</entry><entry>pOMe-I</entry><entry morerows="1" rowsep="1"><img id="ib0017" file="imgb0017.tif" wi="123" he="48" img-content="dna" img-format="tif"/><img id="ib0018" file="imgb0018.tif" wi="123" he="53" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><!-- EPO <DP n="64"> --><row><entry morerows="1" rowsep="1">SEQ ID NO.: 4</entry><entry>pOMe-2</entry><entry morerows="1" rowsep="1"><img id="ib0019" file="imgb0019.tif" wi="123" he="100" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 5</entry><entry>pOMe-3</entry><entry morerows="1" rowsep="1"><img id="ib0020" file="imgb0020.tif" wi="123" he="67" img-content="dna" img-format="tif"/><img id="ib0021" file="imgb0021.tif" wi="123" he="34" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><!-- EPO <DP n="65"> --><row><entry morerows="1" rowsep="1">SEQ ID NO.: 6</entry><entry>pOMe-4</entry><entry morerows="1" rowsep="1"><img id="ib0022" file="imgb0022.tif" wi="124" he="100" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 7</entry><entry>pOMe-5</entry><entry morerows="1" rowsep="1"><img id="ib0023" file="imgb0023.tif" wi="123" he="82" img-content="dna" img-format="tif"/><img id="ib0024" file="imgb0024.tif" wi="124" he="19" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><!-- EPO <DP n="66"> --><row><entry morerows="1" rowsep="1">SEQ ID NO.: 8</entry><entry>pOMe-6 (active site)</entry><entry morerows="1" rowsep="1"><img id="ib0025" file="imgb0025.tif" wi="124" he="45" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 9</entry><entry>pOMe-7 (active site)</entry><entry morerows="1" rowsep="1"><img id="ib0026" file="imgb0026.tif" wi="124" he="45" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 10</entry><entry>pOMe-8 (active site)</entry><entry morerows="1" rowsep="1"><img id="ib0027" file="imgb0027.tif" wi="124" he="44" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 11</entry><entry>pOMe-9 (active site)</entry><entry morerows="1" rowsep="1"><img id="ib0028" file="imgb0028.tif" wi="124" he="45" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 12</entry><entry>pOMe-10 (active site)</entry><entry morerows="1" rowsep="1"><img id="ib0029" file="imgb0029.tif" wi="124" he="19" img-content="dna" img-format="tif"/><img id="ib0030" file="imgb0030.tif" wi="126" he="27" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><!-- EPO <DP n="67"> --><row><entry morerows="1" rowsep="1">SEQ ID NO.: 13</entry><entry>pOMe-11 (active site)</entry><entry morerows="1" rowsep="1"><img id="ib0031" file="imgb0031.tif" wi="126" he="46" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 14</entry><entry>pOMe-12 (active site)</entry><entry morerows="1" rowsep="1"><img id="ib0032" file="imgb0032.tif" wi="126" he="45" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 15</entry><entry>pOMe-13 (active site)</entry><entry morerows="1" rowsep="1"><img id="ib0033" file="imgb0033.tif" wi="123" he="44" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 16</entry><entry>pOMe-14 (active site)</entry><entry morerows="1" rowsep="1"><img id="ib0034" file="imgb0034.tif" wi="123" he="45" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 17</entry><entry>p-acetylPhe-1 (active site)</entry><entry morerows="1" rowsep="1"><img id="ib0035" file="imgb0035.tif" wi="123" he="15" img-content="dna" img-format="tif"/><img id="ib0036" file="imgb0036.tif" wi="123" he="34" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><!-- EPO <DP n="68"> --><row><entry morerows="1" rowsep="1">SEQ ID NO.: 18</entry><entry>pBenzophenon -1 (active site)</entry><entry morerows="1" rowsep="1"><img id="ib0037" file="imgb0037.tif" wi="124" he="48" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 19</entry><entry>pBenzophenon e-2 (active site)</entry><entry morerows="1" rowsep="1"><img id="ib0038" file="imgb0038.tif" wi="124" he="48" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 20</entry><entry>pAzidoPhe-1 (active site)</entry><entry morerows="1" rowsep="1"><img id="ib0039" file="imgb0039.tif" wi="123" he="48" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 21</entry><entry>pAzidoPhe-2 (active site)</entry><entry morerows="1" rowsep="1"><img id="ib0040" file="imgb0040.tif" wi="123" he="38" img-content="dna" img-format="tif"/><img id="ib0041" file="imgb0041.tif" wi="126" he="12" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><!-- EPO <DP n="69"> --><row><entry morerows="1" rowsep="1">SEQ ID NO.: 22</entry><entry>pAzidoPhe-3 (active site)</entry><entry morerows="1" rowsep="1"><img id="ib0042" file="imgb0042.tif" wi="126" he="51" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 23</entry><entry>pAzidoPhe-4 (active site)</entry><entry morerows="1" rowsep="1"><img id="ib0043" file="imgb0043.tif" wi="126" he="49" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 24</entry><entry>pAzidoPhe-5 (active site)</entry><entry morerows="1" rowsep="1"><img id="ib0044" file="imgb0044.tif" wi="126" he="49" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 25</entry><entry>pAzidoPhe-6 (active site)</entry><entry morerows="1" rowsep="1"><img id="ib0045" file="imgb0045.tif" wi="128" he="46" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><row><entry>SEQ ID NO.: 26</entry><entry>pPR-EcRS-1 (propargyloxy phenylalanine synthetase) (active site)</entry><entry><img id="ib0046" file="imgb0046.tif" wi="125" he="20" img-content="dna" img-format="tif"/></entry></row><!-- EPO <DP n="70"> --><row><entry/><entry>Synthetase polynucleotide</entry><entry><img id="ib0047" file="imgb0047.tif" wi="126" he="31" img-content="dna" img-format="tif"/></entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 27</entry><entry>pPR-EcRS-2 (active site)</entry><entry morerows="1" rowsep="1"><img id="ib0048" file="imgb0048.tif" wi="123" he="48" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 28</entry><entry>pPR-EcRS-3 (active site)</entry><entry morerows="1" rowsep="1"><img id="ib0049" file="imgb0049.tif" wi="123" he="48" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 29</entry><entry>pPR-EcRS-4 (active site)</entry><entry morerows="1" rowsep="1"><img id="ib0050" file="imgb0050.tif" wi="123" he="48" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 30</entry><entry>pPR-EcRS-5 (active site)</entry><entry morerows="1" rowsep="1"><img id="ib0051" file="imgb0051.tif" wi="123" he="45" img-content="dna" img-format="tif"/><img id="ib0052" file="imgb0052.tif" wi="100" he="4" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><!-- EPO <DP n="71"> --><row><entry morerows="1" rowsep="1">SEQ ID NO.: 31</entry><entry>pPR-EcRS-6 (active site)</entry><entry morerows="1" rowsep="1"><img id="ib0053" file="imgb0053.tif" wi="123" he="49" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.:32</entry><entry>pPR-EcRS-7 (active site)</entry><entry morerows="1" rowsep="1"><img id="ib0054" file="imgb0054.tif" wi="123" he="48" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 33</entry><entry>pPR-EcRS-8 (active site)</entry><entry morerows="1" rowsep="1"><img id="ib0055" file="imgb0055.tif" wi="123" he="48" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 34</entry><entry>pPR-EcRS-9 (active site)</entry><entry morerows="1" rowsep="1"><img id="ib0056" file="imgb0056.tif" wi="123" he="48" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 35</entry><entry>pPR-EcRS-10 (active site)</entry><entry morerows="1" rowsep="1"><img id="ib0057" file="imgb0057.tif" wi="123" he="22" img-content="dna" img-format="tif"/><img id="ib0058" file="imgb0058.tif" wi="123" he="27" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase polynucleotide</entry></row><!-- EPO <DP n="72"> --><row><entry morerows="1" rowsep="1">SEQ ID NO.: 36</entry><entry>p-iodoPheRS-1</entry><entry morerows="1" rowsep="1"><img id="ib0059" file="imgb0059.tif" wi="124" he="34" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase Amino acid (aa)</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 37</entry><entry>p-iodoPheRS-2</entry><entry morerows="1" rowsep="1"><img id="ib0060" file="imgb0060.tif" wi="124" he="33" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase Amino acid (aa)</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 38</entry><entry>p-iodoPheRS-3</entry><entry morerows="1" rowsep="1"><img id="ib0061" file="imgb0061.tif" wi="124" he="33" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase Amino acid (aa)</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 39</entry><entry>OMeTyrRS-1</entry><entry morerows="1" rowsep="1"><img id="ib0062" file="imgb0062.tif" wi="124" he="33" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase Amino acid (aa)</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 40</entry><entry>OMeTyrRS-2</entry><entry morerows="1" rowsep="1"><img id="ib0063" file="imgb0063.tif" wi="124" he="33" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase Amino acid (aa)</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 41</entry><entry>OMeTyrRS-3</entry><entry morerows="1" rowsep="1"><img id="ib0064" file="imgb0064.tif" wi="123" he="27" img-content="dna" img-format="tif"/><img id="ib0065" file="imgb0065.tif" wi="126" he="9" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase Amino acid (aa)</entry></row><!-- EPO <DP n="73"> --><row><entry morerows="1" rowsep="1">SEQ ID NO.: 42</entry><entry>OMeTyrRS-4</entry><entry morerows="1" rowsep="1"><img id="ib0066" file="imgb0066.tif" wi="126" he="35" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase Amino acid (aa)</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 43</entry><entry>OMeTyrRS-5</entry><entry morerows="1" rowsep="1"><img id="ib0067" file="imgb0067.tif" wi="126" he="35" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase Amino acid (aa)</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 44</entry><entry>OMeTyrRS-6</entry><entry morerows="1" rowsep="1"><img id="ib0068" file="imgb0068.tif" wi="126" he="34" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase Amino acid (aa)</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 45</entry><entry>p-acetylPheRS-1</entry><entry morerows="1" rowsep="1"><img id="ib0069" file="imgb0069.tif" wi="126" he="33" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase Amino acid (aa)</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 46</entry><entry>p-benzoylPheRS -1</entry><entry morerows="1" rowsep="1"><img id="ib0070" file="imgb0070.tif" wi="124" he="33" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase Amino acid (aa)</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 47</entry><entry>p-benzoylPheRS -2</entry><entry morerows="1" rowsep="1"><img id="ib0071" file="imgb0071.tif" wi="126" he="34" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase Amino acid (aa)</entry></row><row><entry>SEQ ID NO.: 48</entry><entry>p-azidoPheRS-1<br/>
Synthetase Amino acid (aa)</entry><entry><img id="ib0072" file="imgb0072.tif" wi="125" he="12" img-content="dna" img-format="tif"/></entry></row><!-- EPO <DP n="74"> --><row><entry/><entry/><entry><img id="ib0073" file="imgb0073.tif" wi="123" he="23" img-content="dna" img-format="tif"/></entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 49</entry><entry>p-azidoPheRS-2</entry><entry morerows="1" rowsep="1"><img id="ib0074" file="imgb0074.tif" wi="123" he="34" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase Amino acid (aa)</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 50</entry><entry>p-azidoPheRS-3</entry><entry morerows="1" rowsep="1"><img id="ib0075" file="imgb0075.tif" wi="123" he="33" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase Amino acid (aa)</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.:51</entry><entry>p-azidoPheRS-4</entry><entry morerows="1" rowsep="1"><img id="ib0076" file="imgb0076.tif" wi="123" he="33" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase Amino acid (aa)</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 52</entry><entry>p-azidoPheRS-5</entry><entry morerows="1" rowsep="1"><img id="ib0077" file="imgb0077.tif" wi="123" he="33" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase Amino acid (aa)</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 53</entry><entry>p-azidoPheRS-6</entry><entry morerows="1" rowsep="1"><img id="ib0078" file="imgb0078.tif" wi="123" he="33" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase Amino acid (aa)</entry></row><row><entry morerows="2" rowsep="1">SEQ ID NO.: 54</entry><entry>pPR-EcRS-1</entry><entry morerows="2" rowsep="1"><img id="ib0079" file="imgb0079.tif" wi="123" he="30" img-content="dna" img-format="tif"/><img id="ib0080" file="imgb0080.tif" wi="48" he="4" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase Amino acid (aa)</entry></row><row><entry><i>p-propargyloxyp henylalanine synthetase</i></entry></row><!-- EPO <DP n="75"> --><row><entry morerows="1" rowsep="1">SEQ ID NO.: 55</entry><entry>pPR-EcRS-2</entry><entry morerows="1" rowsep="1"><img id="ib0081" file="imgb0081.tif" wi="123" he="34" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase Amino acid (aa)</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 56</entry><entry>pPR-EcRS-3</entry><entry morerows="1" rowsep="1"><img id="ib0082" file="imgb0082.tif" wi="123" he="34" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase Amino acid (aa)</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 57</entry><entry>pPR-EcRS-4</entry><entry morerows="1" rowsep="1"><img id="ib0083" file="imgb0083.tif" wi="123" he="33" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase Amino acid (aa)</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.:58</entry><entry>pPR-EcRS-5</entry><entry morerows="1" rowsep="1"><img id="ib0084" file="imgb0084.tif" wi="123" he="33" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase Amino acid (aa)</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 59</entry><entry>pPR-EcRS-6</entry><entry morerows="1" rowsep="1"><img id="ib0085" file="imgb0085.tif" wi="123" he="33" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase Amino acid (aa)</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 60</entry><entry>pPR-EcRS-7</entry><entry morerows="1" rowsep="1"><img id="ib0086" file="imgb0086.tif" wi="123" he="33" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase Amino acid (aa)</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 61</entry><entry>pPR-EcRS-8</entry><entry morerows="1" rowsep="1"><img id="ib0087" file="imgb0087.tif" wi="123" he="15" img-content="dna" img-format="tif"/><img id="ib0088" file="imgb0088.tif" wi="123" he="19" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase Amino acid (aa)</entry></row><!-- EPO <DP n="76"> --><row><entry morerows="1" rowsep="1">SEQ ID NO.: 62</entry><entry>pPR-EcRS-9</entry><entry morerows="1" rowsep="1"><img id="ib0089" file="imgb0089.tif" wi="123" he="34" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase Amino acid (aa)</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 63</entry><entry>pPR-EcRS-10</entry><entry morerows="1" rowsep="1"><img id="ib0090" file="imgb0090.tif" wi="123" he="34" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase Amino acid (aa)</entry></row><row><entry>SEQ ID NO.: 64</entry><entry>tRNA/Tyr polynucleotide</entry><entry><img id="ib0091" file="imgb0091.tif" wi="122" he="11" img-content="dna" img-format="tif"/></entry></row><row><entry>SEQ ID NO.: 65</entry><entry>tRNA/Tyr</entry><entry><img id="ib0092" file="imgb0092.tif" wi="122" he="11" img-content="dna" img-format="tif"/></entry></row><row><entry>SEQ ID NO.: 66</entry><entry>Amber Mutants L3TAG</entry><entry>5'-ATGAAGTAGCTGTCTTCTATCGAACAAGCATGCG-3'</entry></row><row><entry>SEQ ID NO.: 67</entry><entry>Amber Mutants 113TAG</entry><entry>5'-CGAACAAGCATGCGATTAGTGCCGACTTAAAAAG-3'</entry></row><row><entry>SEQ ID NO.: 68</entry><entry>Amber Mutants T44TAG</entry><entry>5'-CGCTACTCTCCCAAATAGAAAAGGTCTCCGCTG-3'</entry></row><row><entry>SEQ ID NO.: 69</entry><entry>Amber Mutants F68TAG</entry><entry>5'-CTGGAACAGCTATAGCTACTGATTTTTCCTCG-3'</entry></row><row><entry>SEQ ID NO.: 70</entry><entry>Amber Mutants R110TAG</entry><entry>5'-GCCGTCACAGATTACTTGGCTTCAGTGGAGACTC-3'</entry></row><row><entry>SEQ ID NO.: 71</entry><entry>Amber Mutants V114TAG</entry><entry>5'-GATTGGCTTCATAGGAGACTGATATGCTCTAAC-3'</entry></row><row><entry>SEQ ID NO.:72</entry><entry>Amber Mutants T121TAG</entry><entry>5'-GCCTCTATAGTTGAGACAGCATAGAATAATGCG-3'</entry></row><row><entry>SEQ ID NO.: 73</entry><entry>Amber Mutants I127TAG</entry><entry>5'-GAGACAGCATAGATAGAGTGCGACATCATCATCGG-3'</entry></row><row><entry>SEQ ID NO.: 74</entry><entry>Amber Mutants S131TAG</entry><entry>5'-GAATAAGTGCGACATAGTCATCGGAAGAGAGTAGTAG-3'</entry></row><row><entry>SEQ ID NO.: 75</entry><entry>Amber Mutants T145TAG</entry><entry>5'-GGTCAAAGACAGTTGTAGGTATCGATTGACTCGGC-3'</entry></row><!-- EPO <DP n="77"> --><row><entry>SEQ ID NO.: 76</entry><entry>Permissive Site Mutants T44F</entry><entry>5'-CGCTACTCTCCCCAAATTTAAAAGGTCTCCGCTG-3'</entry></row><row><entry>SEQ ID NO.: 77</entry><entry>Permissive Site Mutants T44Y</entry><entry>5'-CGCTACTCTCCCCAAATATAAAAGGTCTCCGCTG-3'</entry></row><row><entry>SEQ ID NO.: 78</entry><entry>Permissive Site Mutants T44W</entry><entry>5'-CGCTACTCTCCCCAAATGGAAAAGGTCTCCGCTG-3'</entry></row><row><entry>SEQ ID NO.:79</entry><entry>Permissive Site Mutants T44D</entry><entry>5'-CGCTACTCTCCCCAAAGATAAAAGGTCTCCGCTG-3'</entry></row><row><entry>SEQ ID NO.:80</entry><entry>Permissive Site Mutants T44K</entry><entry>5'-CGCTACTCTCCCCAAAAAAAAAAGGTCTCCGCTG-3'</entry></row><row><entry>SEQ ID NO.: 81</entry><entry>Permissive Site Mutants R110F</entry><entry>5'-GCCGTCACAGATTTTTTGGCTTCAGTGGAGACTG-3'</entry></row><row><entry>SEQ ID NO.: 82</entry><entry>Permissive Site Mutants R110Y</entry><entry>5'-GCCGTCACAGATTATTTGGCTTCAGTGGAGACTG-3'</entry></row><row><entry>SEQ ID NO.: 83</entry><entry>Permissive Site Mutants R110W</entry><entry>5'-GCCGTCACAGATTGGTTGGCTTCAGTGGAGACTG-3'</entry></row><row><entry>SEQ ID NO.: 84</entry><entry>Permissive Site Mutants R110D</entry><entry>5'-GCCGTCACAGATGATTTGGCTTCAGTGGAGACTG-3'</entry></row><row><entry>SEQ ID NO.: 85</entry><entry>Permissive Site Mutants R110K</entry><entry>5'-GCCGTCACAGATAAATTGGCTTCAGTGGAGACTG-3'</entry></row><row><entry morerows="1" rowsep="1">SEQ ID NO.: 86</entry><entry>p-acetylPheRS-1</entry><entry morerows="1" rowsep="1"><img id="ib0093" file="imgb0093.tif" wi="123" he="33" img-content="dna" img-format="tif"/></entry></row><row><entry>Synthetase Amino acid (aa)<sup>a</sup></entry></row><row><entry>SEQ ID NO:87</entry><entry>Hybrid tRNA</entry><entry><img id="ib0094" file="imgb0094.tif" wi="122" he="8" img-content="dna" img-format="tif"/></entry></row><row><entry>SEQ ID NO: 88</entry><entry>cDNA for Hybrid tRNA</entry><entry><img id="ib0095" file="imgb0095.tif" wi="122" he="8" img-content="dna" img-format="tif"/></entry></row><row><entry>SEQ ID NO: 89</entry><entry>amber-suppressing tRNA expression insert</entry><entry><img id="ib0096" file="imgb0096.tif" wi="122" he="8" img-content="dna" img-format="tif"/></entry></row><row><entry>SEQ ID NO: 90</entry><entry>3' flanking sequence of human tRNA<sup>Tyr</sup></entry><entry>GACAAGTGCGGTTTTTTTCTCCAGCTCCCGATGACTTATGGC</entry></row><row><entry>SEQ ID NO: 91</entry><entry>FTam 73: forward primer</entry><entry><img id="ib0097" file="imgb0097.tif" wi="122" he="8" img-content="dna" img-format="tif"/></entry></row><row><entry>SEQ ID NO: 92</entry><entry>FTam 115 : reverse primer</entry><entry><img id="ib0098" file="imgb0098.tif" wi="121" he="8" img-content="dna" img-format="tif"/></entry></row><row><entry>SEQ ID NO: 93</entry><entry>FTam116: forward primer</entry><entry>GTGGCTAAACGCGGCGGACTCTAAATCCGCTCCCTTTGGGTTCGGCGGT</entry></row><!-- EPO <DP n="78"> --><row><entry/><entry/><entry>TCGAATCCGTCCCCCACCAGACAAGTG</entry></row><row><entry>SEQ ID NO: 94</entry><entry>FTam117: reverse primer</entry><entry><img id="ib0099" file="imgb0099.tif" wi="123" he="8" img-content="dna" img-format="tif"/></entry></row><row><entry/><entry>A Box Sequence</entry><entry>TRGCNNAGY</entry></row><row><entry>SEQ ID NO: 95</entry><entry>B Box Sequence</entry><entry>CGTTCGANTCC</entry></row></tbody></tgroup><tgroup cols="3" rowsep="0"><colspec colnum="1" colname="col1" colwidth="27mm"/><colspec colnum="2" colname="col2" colwidth="79mm"/><colspec colnum="3" colname="col3" colwidth="136mm"/><tbody><row><entry namest="col1" nameend="col3" align="justify"><sup>a</sup> These clones also contain a Asp165Gly mutation</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="79"> --></p><heading id="h0026">SEQUENCE LISTING</heading><p id="p0147" num="0147"><ul><li>&lt;110&gt; Feng, Tian Norman, Thea chu, Stephanie</li><li>&lt;120&gt; HYBRID SUPPRESSOR TRNA FOR VERTEBRATE CELLS</li><li>&lt;130&gt; AMBX-0125.00US</li><li>&lt;150&gt; <patcit id="pcit0008" dnum="US60843092B"><text>60/843,092</text></patcit><br/>
&lt;151&gt; 2006-09-08</li><li>&lt;160&gt; 95</li><li>&lt;170&gt; PatentIn version 3.4</li><li>&lt;210&gt; 1<br/>
&lt;211&gt; 1275<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Escherichia coli</li><li>&lt;400&gt; 1
<img id="ib0100" file="imgb0100.tif" wi="157" he="140" img-content="dna" img-format="tif"/><!-- EPO <DP n="80"> --></li><li>&lt;210&gt; 2<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Escherichia coli</li><li>&lt;400&gt; 2
<img id="ib0101" file="imgb0101.tif" wi="139" he="189" img-content="dna" img-format="tif"/><!-- EPO <DP n="81"> -->
<img id="ib0102" file="imgb0102.tif" wi="138" he="150" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 3<br/>
&lt;211&gt; 1275<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 3
<img id="ib0103" file="imgb0103.tif" wi="157" he="31" img-content="dna" img-format="tif"/><!-- EPO <DP n="82"> -->
<img id="ib0104" file="imgb0104.tif" wi="157" he="109" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 4<br/>
&lt;211&gt; 1275<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 4
<img id="ib0105" file="imgb0105.tif" wi="157" he="69" img-content="dna" img-format="tif"/><!-- EPO <DP n="83"> -->
<img id="ib0106" file="imgb0106.tif" wi="157" he="70" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 5<br/>
&lt;211&gt; 1275<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 5
<img id="ib0107" file="imgb0107.tif" wi="157" he="114" img-content="dna" img-format="tif"/><!-- EPO <DP n="84"> -->
<img id="ib0108" file="imgb0108.tif" wi="157" he="26" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 6<br/>
&lt;211&gt; 1275<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 6
<img id="ib0109" file="imgb0109.tif" wi="157" he="140" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 7<br/>
&lt;211&gt; 1275<br/>
&lt;212&gt; DNA<br/>
<!-- EPO <DP n="85"> -->&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; Artificial synthetase</li><li>&lt;400&gt; 7
<img id="ib0110" file="imgb0110.tif" wi="158" he="141" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 8<br/>
&lt;211&gt; 540<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 8
<img id="ib0111" file="imgb0111.tif" wi="157" he="24" img-content="dna" img-format="tif"/><!-- EPO <DP n="86"> -->
<img id="ib0112" file="imgb0112.tif" wi="158" he="31" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 9<br/>
&lt;211&gt; 540<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 9
<img id="ib0113" file="imgb0113.tif" wi="158" he="57" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 10<br/>
&lt;211&gt; 540<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 10
<img id="ib0114" file="imgb0114.tif" wi="158" he="56" img-content="dna" img-format="tif"/><!-- EPO <DP n="87"> --></li><li>&lt;210&gt; 11<br/>
&lt;211&gt; 540<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 11
<img id="ib0115" file="imgb0115.tif" wi="158" he="56" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 12<br/>
&lt;211&gt; 540<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 12
<img id="ib0116" file="imgb0116.tif" wi="158" he="56" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 13<br/>
&lt;211&gt; 540<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 13
<img id="ib0117" file="imgb0117.tif" wi="157" he="5" img-content="dna" img-format="tif"/><!-- EPO <DP n="88"> -->
<img id="ib0118" file="imgb0118.tif" wi="158" he="51" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 14<br/>
&lt;211&gt; 540<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 14
<img id="ib0119" file="imgb0119.tif" wi="158" he="56" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 15<br/>
&lt;211&gt; 540<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 15
<img id="ib0120" file="imgb0120.tif" wi="157" he="37" img-content="dna" img-format="tif"/><!-- EPO <DP n="89"> -->
<img id="ib0121" file="imgb0121.tif" wi="158" he="18" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 16<br/>
&lt;211&gt; 540<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 16
<img id="ib0122" file="imgb0122.tif" wi="158" he="56" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 17<br/>
&lt;211&gt; 624<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 17
<img id="ib0123" file="imgb0123.tif" wi="157" he="69" img-content="dna" img-format="tif"/><!-- EPO <DP n="90"> --></li><li>&lt;210&gt; 18<br/>
&lt;211&gt; 609<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 18
<img id="ib0124" file="imgb0124.tif" wi="158" he="70" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 19<br/>
&lt;211&gt; 591<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 19
<img id="ib0125" file="imgb0125.tif" wi="158" he="63" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 20<br/>
&lt;211&gt; 621<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial<!-- EPO <DP n="91"> --></li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (26)..(26)<br/>
&lt;223&gt; n is a, c, g, or t</li><li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (612)..(612)<br/>
&lt;223&gt; n is a, c, g, or t</li><li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (618)..(618)<br/>
&lt;223&gt; n is a, c, g, or t</li><li>&lt;400&gt; 20
<img id="ib0126" file="imgb0126.tif" wi="158" he="69" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 21<br/>
&lt;211&gt; 588<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 21
<img id="ib0127" file="imgb0127.tif" wi="157" he="50" img-content="dna" img-format="tif"/><!-- EPO <DP n="92"> -->
<img id="ib0128" file="imgb0128.tif" wi="158" he="12" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 22<br/>
&lt;211&gt; 600<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (403)..(403)<br/>
&lt;223&gt; n is a, c, g, or t</li><li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (513)..(513)<br/>
&lt;223&gt; n is a, c, g, or t</li><li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (515)..(515)<br/>
&lt;223&gt; n is a, c, g, or t</li><li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (518)..(518)<br/>
&lt;223&gt; n is a, c, g, or t</li><li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (531)..(531)<br/>
&lt;223&gt; n is a, c, g, or t</li><li>&lt;400&gt; 22
<img id="ib0129" file="imgb0129.tif" wi="158" he="62" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 23<br/>
&lt;211&gt; 591<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial<!-- EPO <DP n="93"> --></li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (588)..(588)<br/>
&lt;223&gt; n is a, c, g, or t</li><li>&lt;400&gt; 23
<img id="ib0130" file="imgb0130.tif" wi="158" he="63" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 24<br/>
&lt;211&gt; 600<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 24
<img id="ib0131" file="imgb0131.tif" wi="158" he="63" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 25<br/>
&lt;211&gt; 579<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
<!-- EPO <DP n="94"> -->&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 25
<img id="ib0132" file="imgb0132.tif" wi="157" he="63" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 26<br/>
&lt;211&gt; 624<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (13)..(13)<br/>
&lt;223&gt; n is a, c, g, or t</li><li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (599)..(599)<br/>
&lt;223&gt; n is a, c, g, or t</li><li>&lt;400&gt; 26
<img id="ib0133" file="imgb0133.tif" wi="157" he="69" img-content="dna" img-format="tif"/><!-- EPO <DP n="95"> --></li><li>&lt;210&gt; 27<br/>
&lt;211&gt; 625<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (600)..(600)<br/>
&lt;223&gt; n is a, c, g, or t</li><li>&lt;400&gt; 27
<img id="ib0134" file="imgb0134.tif" wi="158" he="69" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 28<br/>
&lt;211&gt; 624<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 28
<img id="ib0135" file="imgb0135.tif" wi="158" he="63" img-content="dna" img-format="tif"/><!-- EPO <DP n="96"> -->
<img id="ib0136" file="imgb0136.tif" wi="157" he="5" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 29<br/>
&lt;211&gt; 624<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 29
<img id="ib0137" file="imgb0137.tif" wi="157" he="70" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 30<br/>
&lt;211&gt; 624<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 30
<img id="ib0138" file="imgb0138.tif" wi="157" he="69" img-content="dna" img-format="tif"/><!-- EPO <DP n="97"> --></li><li>&lt;210&gt; 31<br/>
&lt;211&gt; 624<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 31
<img id="ib0139" file="imgb0139.tif" wi="157" he="69" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 32<br/>
&lt;211&gt; 606<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 32
<img id="ib0140" file="imgb0140.tif" wi="157" he="69" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 33<br/>
&lt;211&gt; 624<br/>
&lt;212&gt; DNA<br/>
<!-- EPO <DP n="98"> -->&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 33
<img id="ib0141" file="imgb0141.tif" wi="158" he="70" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 34<br/>
&lt;211&gt; 624<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (13)..(13)<br/>
&lt;223&gt; n is a, c, g, or t</li><li>&lt;400&gt; 34
<img id="ib0142" file="imgb0142.tif" wi="157" he="69" img-content="dna" img-format="tif"/><!-- EPO <DP n="99"> --></li><li>&lt;210&gt; 35<br/>
&lt;211&gt; 624<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 35
<img id="ib0143" file="imgb0143.tif" wi="157" he="69" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 36<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 36
<img id="ib0144" file="imgb0144.tif" wi="138" he="82" img-content="dna" img-format="tif"/><!-- EPO <DP n="100"> -->
<img id="ib0145" file="imgb0145.tif" wi="139" he="211" img-content="dna" img-format="tif"/><!-- EPO <DP n="101"> -->
<img id="ib0146" file="imgb0146.tif" wi="139" he="47" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 37<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 37
<img id="ib0147" file="imgb0147.tif" wi="143" he="134" img-content="dna" img-format="tif"/><!-- EPO <DP n="102"> -->
<img id="ib0148" file="imgb0148.tif" wi="138" he="211" img-content="dna" img-format="tif"/><!-- EPO <DP n="103"> --></li><li>&lt;210&gt; 38<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 38
<img id="ib0149" file="imgb0149.tif" wi="138" he="185" img-content="dna" img-format="tif"/><!-- EPO <DP n="104"> -->
<img id="ib0150" file="imgb0150.tif" wi="138" he="160" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 39<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 39
<img id="ib0151" file="imgb0151.tif" wi="138" he="20" img-content="dna" img-format="tif"/><!-- EPO <DP n="105"> -->
<img id="ib0152" file="imgb0152.tif" wi="139" he="213" img-content="dna" img-format="tif"/><!-- EPO <DP n="106"> -->
<img id="ib0153" file="imgb0153.tif" wi="138" he="108" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 40<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 40
<img id="ib0154" file="imgb0154.tif" wi="138" he="72" img-content="dna" img-format="tif"/><!-- EPO <DP n="107"> -->
<img id="ib0155" file="imgb0155.tif" wi="139" he="212" img-content="dna" img-format="tif"/><!-- EPO <DP n="108"> -->
<img id="ib0156" file="imgb0156.tif" wi="139" he="57" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 41<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 41
<img id="ib0157" file="imgb0157.tif" wi="139" he="123" img-content="dna" img-format="tif"/><!-- EPO <DP n="109"> -->
<img id="ib0158" file="imgb0158.tif" wi="143" he="212" img-content="dna" img-format="tif"/><!-- EPO <DP n="110"> -->
<img id="ib0159" file="imgb0159.tif" wi="9" he="4" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 42<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 42
<img id="ib0160" file="imgb0160.tif" wi="143" he="175" img-content="dna" img-format="tif"/><!-- EPO <DP n="111"> -->
<img id="ib0161" file="imgb0161.tif" wi="139" he="164" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 43<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 43
<img id="ib0162" file="imgb0162.tif" wi="138" he="8" img-content="dna" img-format="tif"/><!-- EPO <DP n="112"> -->
<img id="ib0163" file="imgb0163.tif" wi="138" he="214" img-content="dna" img-format="tif"/><!-- EPO <DP n="113"> -->
<img id="ib0164" file="imgb0164.tif" wi="138" he="111" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 44<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 44
<img id="ib0165" file="imgb0165.tif" wi="139" he="59" img-content="dna" img-format="tif"/><!-- EPO <DP n="114"> -->
<img id="ib0166" file="imgb0166.tif" wi="138" he="214" img-content="dna" img-format="tif"/><!-- EPO <DP n="115"> -->
<img id="ib0167" file="imgb0167.tif" wi="138" he="62" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 45<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 45
<img id="ib0168" file="imgb0168.tif" wi="138" he="110" img-content="dna" img-format="tif"/><!-- EPO <DP n="116"> -->
<img id="ib0169" file="imgb0169.tif" wi="138" he="214" img-content="dna" img-format="tif"/><!-- EPO <DP n="117"> -->
<img id="ib0170" file="imgb0170.tif" wi="69" he="8" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 46<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 46
<img id="ib0171" file="imgb0171.tif" wi="146" he="162" img-content="dna" img-format="tif"/><!-- EPO <DP n="118"> -->
<img id="ib0172" file="imgb0172.tif" wi="138" he="175" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 47<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 47<!-- EPO <DP n="119"> -->
<img id="ib0173" file="imgb0173.tif" wi="139" he="214" img-content="dna" img-format="tif"/><!-- EPO <DP n="120"> -->
<img id="ib0174" file="imgb0174.tif" wi="139" he="124" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 48<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 48
<img id="ib0175" file="imgb0175.tif" wi="138" he="46" img-content="dna" img-format="tif"/><!-- EPO <DP n="121"> -->
<img id="ib0176" file="imgb0176.tif" wi="148" he="215" img-content="dna" img-format="tif"/><!-- EPO <DP n="122"> -->
<img id="ib0177" file="imgb0177.tif" wi="138" he="73" img-content="dna" img-format="tif"/>
*&lt;210&gt; 49<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 49
<img id="ib0178" file="imgb0178.tif" wi="138" he="97" img-content="dna" img-format="tif"/><!-- EPO <DP n="123"> -->
<img id="ib0179" file="imgb0179.tif" wi="138" he="214" img-content="dna" img-format="tif"/><!-- EPO <DP n="124"> -->
<img id="ib0180" file="imgb0180.tif" wi="138" he="21" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 50<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 50
<img id="ib0181" file="imgb0181.tif" wi="138" he="149" img-content="dna" img-format="tif"/><!-- EPO <DP n="125"> -->
<img id="ib0182" file="imgb0182.tif" wi="140" he="188" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 51<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase<!-- EPO <DP n="126"> --></li><li>&lt;400&gt; 51
<img id="ib0183" file="imgb0183.tif" wi="138" he="202" img-content="dna" img-format="tif"/><!-- EPO <DP n="127"> -->
<img id="ib0184" file="imgb0184.tif" wi="140" he="137" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 52<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 52
<img id="ib0185" file="imgb0185.tif" wi="138" he="44" img-content="dna" img-format="tif"/><!-- EPO <DP n="128"> -->
<img id="ib0186" file="imgb0186.tif" wi="138" he="211" img-content="dna" img-format="tif"/><!-- EPO <DP n="129"> -->
<img id="ib0187" file="imgb0187.tif" wi="138" he="86" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 53<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 53
<img id="ib0188" file="imgb0188.tif" wi="148" he="95" img-content="dna" img-format="tif"/><!-- EPO <DP n="130"> -->
<img id="ib0189" file="imgb0189.tif" wi="138" he="212" img-content="dna" img-format="tif"/><!-- EPO <DP n="131"> -->
<img id="ib0190" file="imgb0190.tif" wi="138" he="34" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 54<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 54
<img id="ib0191" file="imgb0191.tif" wi="143" he="147" img-content="dna" img-format="tif"/><!-- EPO <DP n="132"> -->
<img id="ib0192" file="imgb0192.tif" wi="139" he="198" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 55<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial<!-- EPO <DP n="133"> --></li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 55
<img id="ib0193" file="imgb0193.tif" wi="138" he="198" img-content="dna" img-format="tif"/><!-- EPO <DP n="134"> -->
<img id="ib0194" file="imgb0194.tif" wi="138" he="147" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 56<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 56
<img id="ib0195" file="imgb0195.tif" wi="138" he="33" img-content="dna" img-format="tif"/><!-- EPO <DP n="135"> -->
<img id="ib0196" file="imgb0196.tif" wi="138" he="211" img-content="dna" img-format="tif"/><!-- EPO <DP n="136"> -->
<img id="ib0197" file="imgb0197.tif" wi="138" he="96" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 57<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 57
<img id="ib0198" file="imgb0198.tif" wi="138" he="85" img-content="dna" img-format="tif"/><!-- EPO <DP n="137"> -->
<img id="ib0199" file="imgb0199.tif" wi="141" he="211" img-content="dna" img-format="tif"/><!-- EPO <DP n="138"> -->
<img id="ib0200" file="imgb0200.tif" wi="138" he="44" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 58<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 58
<img id="ib0201" file="imgb0201.tif" wi="138" he="136" img-content="dna" img-format="tif"/><!-- EPO <DP n="139"> -->
<img id="ib0202" file="imgb0202.tif" wi="146" he="211" img-content="dna" img-format="tif"/><!-- EPO <DP n="140"> -->
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 59
<img id="ib0203" file="imgb0203.tif" wi="139" he="189" img-content="dna" img-format="tif"/><!-- EPO <DP n="141"> -->
<img id="ib0204" file="imgb0204.tif" wi="138" he="149" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 60<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; Artificial synthetase</li><li>&lt;400&gt; 60
<img id="ib0205" file="imgb0205.tif" wi="138" he="21" img-content="dna" img-format="tif"/><!-- EPO <DP n="142"> -->
<img id="ib0206" file="imgb0206.tif" wi="138" he="215" img-content="dna" img-format="tif"/><!-- EPO <DP n="143"> -->
<img id="ib0207" file="imgb0207.tif" wi="138" he="98" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 61<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 61
<img id="ib0208" file="imgb0208.tif" wi="139" he="72" img-content="dna" img-format="tif"/><!-- EPO <DP n="144"> -->
<img id="ib0209" file="imgb0209.tif" wi="145" he="214" img-content="dna" img-format="tif"/><!-- EPO <DP n="145"> -->
<img id="ib0210" file="imgb0210.tif" wi="139" he="47" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 62<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 62
<img id="ib0211" file="imgb0211.tif" wi="139" he="125" img-content="dna" img-format="tif"/><!-- EPO <DP n="146"> -->
<img id="ib0212" file="imgb0212.tif" wi="138" he="214" img-content="dna" img-format="tif"/><!-- EPO <DP n="147"> --></li><li>&lt;210&gt; 63<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 63
<img id="ib0213" file="imgb0213.tif" wi="139" he="175" img-content="dna" img-format="tif"/><!-- EPO <DP n="148"> -->
<img id="ib0214" file="imgb0214.tif" wi="138" he="163" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 64<br/>
&lt;211&gt; 129<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Escherichia coli</li><li>&lt;400&gt; 64
<img id="ib0215" file="imgb0215.tif" wi="157" he="27" img-content="dna" img-format="tif"/><!-- EPO <DP n="149"> --></li><li>&lt;211&gt; 129<br/>
&lt;212&gt; RNA<br/>
&lt;213&gt; Escherichia coli</li><li>&lt;400&gt; 65
<img id="ib0216" file="imgb0216.tif" wi="158" he="17" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 66<br/>
&lt;211&gt; 34<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; oligonucleotide primer</li><li>&lt;400&gt; 66<br/>
atgaagtagc tgtcttctat cgaacaagca tgcg   34</li><li>&lt;210&gt; 67<br/>
&lt;211&gt; 34<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; oligonucleotide primer</li><li>&lt;400&gt; 67<br/>
cgaacaagca tgcgattagt gccgacttaa aaag   34</li><li>&lt;210&gt; 68<br/>
&lt;211&gt; 33<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; oligonucleotide primer</li><li>&lt;400&gt; 68<br/>
cgctactctc ccaaatagaa aaggtctccg ctg 33</li><li>&lt;210&gt; 69<br/>
&lt;211&gt; 32<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; oligonucleotide primer</li><li>&lt;400&gt; 69<br/>
ctggaacagc tatagctact gatttttcct cg   32</li><li>&lt;210&gt; 70<br/>
&lt;211&gt; 34<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; oligonucleotide primer<!-- EPO <DP n="150"> --></li><li>&lt;400&gt; 70<br/>
gccgtcacag attagttggc ttcagtggag actg   34</li><li>&lt;210&gt; 71<br/>
&lt;211&gt; 33<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; oligonucleotide primer</li><li>&lt;400&gt; 71<br/>
gattggcttc ataggagact gatatgctct aac   33</li><li>&lt;210&gt; 72<br/>
&lt;211&gt; 33<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; oligonucleotide primer</li><li>&lt;400&gt; 72<br/>
gcctctatag ttgagacagc atagaataat gcg   33</li><li>&lt;210&gt; 73<br/>
&lt;211&gt; 35<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; oligonucleotide primer</li><li>&lt;400&gt; 73<br/>
gagacagcat agatagagtg cgacatcatc atcgg   35</li><li>&lt;210&gt; 74<br/>
&lt;211&gt; 37<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; oligonucleotide primer</li><li>&lt;400&gt; 74<br/>
gaataagtgc gacatagtca tcggaagaga gtagtag   37</li><li>&lt;210&gt; 75<br/>
&lt;211&gt; 35<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; oligonucleotide primer</li><li>&lt;400&gt; 75<br/>
ggtcaaagac agttgtaggt atcgattgac tcggc   35</li><li>&lt;210&gt; 76<br/>
&lt;211&gt; 34<br/>
<!-- EPO <DP n="151"> -->&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; oligonucleotide primer</li><li>&lt;400&gt; 76<br/>
cgctactctc cccaaattta aaaggtctcc gctg   34</li><li>&lt;210&gt; 77<br/>
&lt;211&gt; 34<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; oligonucleotide primer</li><li>&lt;400&gt; 77<br/>
cgctactctc cccaaatata aaaggtctcc gctg   34</li><li>&lt;210&gt; 78<br/>
&lt;211&gt; 34<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; oligonucleotide primer</li><li>&lt;400&gt; 78<br/>
cgctactctc cccaaatgga aaaggtctcc gctg   34</li><li>&lt;210&gt; 79<br/>
&lt;211&gt; 34<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; oligonucleotide primer</li><li>&lt;400&gt; 79<br/>
cgctactctc cccaaagata aaaggtctcc gctg   34</li><li>&lt;210&gt; 80<br/>
&lt;211&gt; 34<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; oligonucleotide primer</li><li>&lt;400&gt; 80<br/>
cgctactctc cccaaaaaaa aaaggtctcc gctg   34</li><li>&lt;210&gt; 81<br/>
&lt;211&gt; 34<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; oligonucleotide primer</li><li>&lt;400&gt; 81<br/>
<!-- EPO <DP n="152"> -->gccgtcacag attttttggc ttcagtggag actg   34</li><li>&lt;210&gt; 82<br/>
&lt;211&gt; 34<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; oligonucleotide primer</li><li>&lt;400&gt; 82<br/>
gccgtcacag attatttggc ttcagtggag actg   34</li><li>&lt;210&gt; 83<br/>
&lt;211&gt; 34<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; oligonucleotide primer</li><li>&lt;400&gt; 83<br/>
gccgtcacag attggttggc ttcagtggag actg   34</li><li>&lt;210&gt; 84<br/>
&lt;211&gt; 34<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; oligonucleotide primer</li><li>&lt;400&gt; 84<br/>
gccgtcacag atgatttggc ttcagtggag actg   34</li><li>&lt;210&gt; 85<br/>
&lt;211&gt; 34<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; oligonucleotide primer</li><li>&lt;400&gt; 85<br/>
gccgtcacag ataaattgge ttcagtggag actg   34</li><li>&lt;210&gt; 86<br/>
&lt;211&gt; 424<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial synthetase</li><li>&lt;400&gt; 86
<img id="ib0217" file="imgb0217.tif" wi="138" he="20" img-content="dna" img-format="tif"/><!-- EPO <DP n="153"> -->
<img id="ib0218" file="imgb0218.tif" wi="138" he="211" img-content="dna" img-format="tif"/><!-- EPO <DP n="154"> -->
<img id="ib0219" file="imgb0219.tif" wi="138" he="108" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 87<br/>
&lt;211&gt; 85<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; artificial tRNA</li><li>&lt;400&gt; 87
<img id="ib0220" file="imgb0220.tif" wi="157" he="11" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 88<br/>
&lt;211&gt; 79<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; cDNA for tRNA</li><li>&lt;400&gt; 88
<img id="ib0221" file="imgb0221.tif" wi="157" he="11" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 89<br/>
&lt;211&gt; 95<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial<!-- EPO <DP n="155"> --></li><li>&lt;220&gt;<br/>
&lt;223&gt; Artificial plasmid insert</li><li>&lt;400&gt; 89
<img id="ib0222" file="imgb0222.tif" wi="157" he="10" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 90<br/>
&lt;211&gt; 42<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Homo sapiens</li><li>&lt;400&gt; 90<br/>
gacaagtgcg gtttttttct ccagctcccg atgacttatg gc   42</li><li>&lt;210&gt; 91<br/>
&lt;211&gt; 80<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; FTam 73 forward primer</li><li>&lt;400&gt; 91
<img id="ib0223" file="imgb0223.tif" wi="157" he="11" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 92<br/>
&lt;211&gt; 88<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; FTam 115 reverse primer</li><li>&lt;400&gt; 92
<img id="ib0224" file="imgb0224.tif" wi="157" he="11" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 93<br/>
&lt;211&gt; 76<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; FTam 116 forward primer</li><li>&lt;400&gt; 93
<img id="ib0225" file="imgb0225.tif" wi="157" he="11" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 94<br/>
&lt;211&gt; 75<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
<!-- EPO <DP n="156"> -->&lt;223&gt; FTam 117 reverse primer</li><li>&lt;400&gt; 94
<img id="ib0226" file="imgb0226.tif" wi="159" he="12" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 95<br/>
&lt;211&gt; 11<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial</li><li>&lt;220&gt;<br/>
&lt;223&gt; B box sequence</li><li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (8)..(8)<br/>
&lt;223&gt; n is a, c, g, or t</li><li>&lt;400&gt; 95<br/>
ggttcgantc c   11</li></ul></p></description><claims mxw-id="PCLM56985053" lang="DE" load-source="patent-office"><!-- EPO <DP n="161"> --><claim id="c-de-01-0001" num="0001"><claim-text>Wirbeltierzelle oder -zelllinie, umfassend eine Nukleotidsequenz gemäß SEQ ID NO: 87 oder SEQ ID NO: 88, wobei es sich bei der Zelle nicht um eine menschliche embryonale Stammzelle oder eine menschliche In-vivo-Zelle und bei der Zelllinie nicht um eine menschliche embryonale Stammzelllinie handelt.</claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Zelle nach Anspruch 1, wobei die Nukleotidsequenz für ein tRNA-Molekül codiert, das eine Anticodon-Erkennungssequenz aufweist, die für ein Selektorcodon spezifisch ist.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Zelle nach Anspruch 2, wobei das Selektorcodon aus der aus amber-Codon, ochre-Codon, opal-Codon oder vier oder mehr Basencodons bestehenden Gruppe ausgewählt ist.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Zelle nach Anspruch 2, wobei die Nukleotidsequenz für ein tRNA-Molekül codiert, das sich mit wenigstens einer nichtnatürlichen Aminosäure aminoacylieren lässt.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Zelle nach Anspruch 1, wobei die Nukleotidsequenz für ein tRNA-Molekül codiert, bei dem es sich um eine orthogonale tRNA (O-tRNA) handelt.<!-- EPO <DP n="162"> --></claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Zelle nach Anspruch 5, wobei die O-tRNA zur Aminoacylierung mit einer natürlichen Aminosäure oder einer nichtnatürlichen Aminosäure fähig ist.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Zelle nach Anspruch 4, wobei die O-tRNA zur Aminoacylierung mit einer natürlichen Aminosäure oder einer nichtnatürlichen Aminosäure fähig ist.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Zelle nach Anspruch 5, wobei die O-tRNA zur Aminoacylierung mit einer nichtnatürlichen Aminosäure fähig ist.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Zelllinie nach Anspruch 1, wobei die Zelllinie stabil transfiziert wurde.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Zelllinie nach Anspruch 1, wobei die Zelllinie transient transfiziert wurde.</claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Verfahren zur Produktion wenigstens eines wenigstens eine nichtnatürliche Aminosäure umfassenden Proteins in einer Wirbeltierzelle, wobei es sich bei der Wirbeltierzelle nicht um eine menschliche embryonale Stammzelle oder eine menschliche In-vivo-Zelle handelt, wobei man bei dem Verfahren:
<claim-text>in einem entsprechenden Medium die Wirbeltierzelle, welche eine Nukleinsäure umfasst, die wenigstens ein Selektorcodon umfasst und für das Protein codiert, kultiviert; wobei das Medium eine unnatürliche Aminosäure und die Wirbeltierzelle Folgendes umfasst:
<claim-text>eine O-tRNA mit einer Nukleotidsequenz gemäß SEQ ID NO: 87 oder SEQ ID NO: 88, die in der Zelle funktioniert und das Selektorcodon erkennt; und eine Orthogonale-Aminoacyl-tRNA-Synthetase (0-RS), die vorzugsweise die O-tRNA mit der unnatürlichen Aminosäure aminoacyliert.</claim-text></claim-text><!-- EPO <DP n="163"> --></claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>Verfahren nach Anspruch 11, wobei die Zelle stabil transfiziert wurde, so dass sie die O-tRNA und 0-RS umfasst.</claim-text></claim><claim id="c-de-01-0013" num="0013"><claim-text>Verfahren nach Anspruch 11, wobei die Zelle transient transfiziert wurde, so dass sie die 0-tRNA und O-RS umfasst.</claim-text></claim><claim id="c-de-01-0014" num="0014"><claim-text>Verfahren nach Anspruch 11, wobei die Zelle stabil transfiziert wurde, so dass sie entweder die 0-tRNA oder die O-RS umfasst, und transient transfiziert wurde, so dass sie die zuvor nicht transfizierte O-RS bzw. O-tRNA umfasst, so dass die Zelle immer noch sowohl eine O-tRNA als auch eine O-RS umfasst.</claim-text></claim><claim id="c-de-01-0015" num="0015"><claim-text>Verfahren nach Anspruch 11 oder Zelle nach Anspruch 8, wobei die unnatürliche oder nichtnatürliche Aminosäure aus der aus einem <i>p-</i>Acetyl-L-phenylalanin, einem <i>p</i>-Iod-L-phenylalanin, einem 0-Methyl-L-tyrosin, einem <i>p-</i>Propargyloxyphenylalanin, einem L-3-(2-Naphthyl)alanin, einem 3-Methylphenylalanin, einem 0-4-Allyl-L-tyrosin, einem 4-Propyl-L-tyrosin, einem Tri-O-acetyl-GlcNAcβ-serin, einem L-Dopa, einem fluorinierten Phenylalanin, einem Isopropyl-L-phenylalanin, einem <i>p</i>-Azido-L-phenylalanin, einem <i>p</i>-Acyl-L-phenylalanin, einem <i>p</i>-Benzoyl-L-phenylalanin, einem L-Phosphoserin, einem Phosphonoserin, einem Phosphonotyrosin, einem <i>p-</i>Bromphenylalanin, einem <i>p</i>-Amino-L-phenylalanin, einem unnatürlichen Analog einer Tyrosin-Aminosäure; einem unnatürlichen Analog einer Glutamin-Aminosäure; einem unnatürlichen Analog einer Phenylalanin-Aminosäure; einem unnatürlichen Analog einer Serin-Aminosäure; einem unnatürlichen Analog einer Threonin-Aminosäure; einer alkyl-, aryl-, acyl-, azido-, cyano-, halogen-, hydrazin-, hydrazid-, hydroxyl-, alkenyl-, alkinyl-, ether-,<!-- EPO <DP n="164"> --> thiol-, sulfonyl-, selen-, ester-, thiosäure-, borat-, boronat-, phospho-, phosphono-, phosphin-, heterocyclisch, enon-, imin-, aldehyd-, hydroxylamin-, keto- oder aminosubstituierten Aminosäure oder einer Kombination davon; einer Aminosäure mit einem photoaktivierbaren Crosslinker; einer Spin-Label-Aminosäure; einer fluoreszierenden Aminosäure; einer metallbindenden Aminosäure; einer metallhaltigen Aminosäure; einer radioaktiven Aminosäure; einer Photocaged- und/oder photoisomerisierbaren Aminosäure; einer biotin- oder biotinanaloghaltigen Aminosäure; einer ketohaltigen Aminosäure; einer Polyethylenglykol oder Polyether enthaltenden Aminosäure; einer schweratomsubstituierten Aminosäure; einer chemisch spaltbaren oder photospaltbaren Aminosäure; einer Aminosäure mit einer verlängerten Seitenkette; einer Aminosäure mit einer toxischen Gruppe; einer zuckersubstituierten Aminosäure; einer kohlenstoffverknüpften Zucker enthaltenden Aminosäure; einer redoxaktiven Aminosäure; einer α-hydroxyhaltigen Säure; einer Aminothiosäure; einer α,α-disubstituierten Aminosäure; einer β-Aminosäure; einer von Prolin oder Histidin verschiedenen cyclischen Aminosäure und einer von Phenylalanin, Tyrosin oder Tryptophan verschiedenen aromatischen Aminosäure bestehenden Gruppe ausgewählt ist.</claim-text></claim><claim id="c-de-01-0016" num="0016"><claim-text>Verfahren nach Anspruch 11, wobei das Protein ein therapeutisches Protein, ein diagnostisches Protein, ein großtechnisches Enzym oder einen Teil davon umfasst.</claim-text></claim><claim id="c-de-01-0017" num="0017"><claim-text>Verfahren nach Anspruch 11, wobei das interessierende Protein oder Polypeptid ein Protein oder einen Teil eines Proteins umfasst, das aus folgender Gruppe ausgewählt ist: Cytokin,<!-- EPO <DP n="165"> --> Wachstumsfaktor, Wachstumsfaktor-Rezeptor, Interferon, Interleukin, Entzündungsmolekül, Onkogenprodukt, Peptidhormon, Signaltransduktionsmolekül, Steroidhormon-Rezeptor, Erythropoetin (EPO), Insulin, menschliches Wachstumshormon, Alpha-1-Antitrypsin, Angiostatin, antihämolytischer Faktor, Antikörper, Apolipoprotein, Apoprotein, atrionatriuretischer Faktor, atrionatriuretisches Polypeptid, atriales Peptid, C-X-C-Chemokin, T39765, NAP-2, ENA-78, Gro-a, Gro-b, Gro-c, IP-10, GCP-2, NAP-4, SDF-1, PF4, MIG, Calcitonin, c-Kit-Ligand, CC-Chemokin, Monozyten-Chemoattraktor-Protein-1, Monozyten-Chemoattraktor-Protein-2, Monozyten-Chemoattraktor-Protein-3, Monozyten-Entzündungsprotein-1-alpha, Monozyten-Entzündungsprotein-1-beta, RANTES, 1309, R83915, R91733, HCC1, T58847, D31065, T64262, CD40, CD40-Ligand, Collagen, koloniestimulierender Faktor (CSF), Komplementfaktor 5a, Komplementinhibitor, Komplementrezeptor 1, DHFR, epitheliales neutrophilenaktivierendes Peptid-78, GROα/MGSA, GROß, GROγ, MIP-1α, MIP-1δ, MCP-1, Epidermiswachstumsfaktor (EGF), epitheliales neutrophilenaktivierendes Peptid, Exfoliating-Toxin, Faktor IX, Faktor VII, Faktor VIII, Faktor X, Fibroblastenwachstumsfaktor (FGF), Fibrinogen, Fibronectin, G-CSF, GM-CSF, Glucocerebrosidase, Gonadotropin, Hedgehog-Protein, Hämoglobin, Hepatozytenwachstumsfaktor (HGF), Hirudin, Humanserumalbumin, ICAM-1, ICAM-1-Rezeptor, LFA-1, LFA-1-Rezeptor, Insulin, insulinähnlicher Wachstumsfaktor (IGF), IGF-I, IGF-II, IFN-α, IFN-β, IFN-γ, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, Keratinozytenwachstumsfaktor (KGF), Lactoferrin, leukämiehemmender Faktor, Luciferase, Neurturin, neutrophilenhemmender Faktor (NIF), Onkostatin M, osteogenes Protein, Parathormon, PD-ECSF, PDGF, Pleiotrophin, Protein A, Protein G, pyrogene<!-- EPO <DP n="166"> --> Exotoxine A, B oder C, Relaxin, Renin, SCF, löslicher Komplementrezeptor I, löslicher I-CAM 1, löslicher Interleukin-Rezeptor, löslicher TNF-Rezeptor, Somatomedin, Somatostatin, Somatotropin, Streptokinase, Superantigen, Staphylokokken-Enterotoxine, SEA, SEB, SEC1, SEC2, SEC3, SED, SEE, Steroidhormon-Rezeptor, Superoxid-Dismutase (SOD), Toxisches-Schocksyndrom-Toxin, Thymosinalpha-1, Gewebeplasminogenaktivator, Tumorwachstumsfaktor (TGF), TGF-α, TGF-β, Tumornekrosefaktor, Tumornekrosefaktor-alpha, Tumornekrosefaktor-beta, Tumornekrosefaktor-Rezeptor (TNFR), VLA-4-Protein, VCAM-1-Protein, Gefäßendothelwachstumsfaktor (VEGEF), Urokinase, Mos, Ras, Raf, Met; p53, Tat, Fos, Myc, Jun, Myb, Rel, Östrogen-Rezeptor, Progesteron-Rezeptor, Testosteron-Rezeptor, Aldosteron-Rezeptor, LDL-Rezeptor, SCF/c-Kit, CD40L/CD40, VLA-4/VCAM-1, ICAM-1/LFA-1, Hyalurin/CD44 und Corticosteron.</claim-text></claim><claim id="c-de-01-0018" num="0018"><claim-text>Kit für die Produktion eines Proteins, das wenigstens eine unnatürliche Aminosäure umfasst, wobei das Kit einen eine Polynukleotidsequenz gemäß SEQ ID NO: 87 oder SEQ ID NO: 88 enthaltenden Behälter umfasst.</claim-text></claim><claim id="c-de-01-0019" num="0019"><claim-text>Kit nach Anspruch 18, wobei das Kit ferner wenigstens eine unnatürliche Aminosäure umfasst.</claim-text></claim><claim id="c-de-01-0020" num="0020"><claim-text>Kit nach Anspruch 18, wobei das Kit ferner Anweisungsmaterial zur Produktion des Proteins umfasst.</claim-text></claim></claims><claims mxw-id="PCLM56985054" lang="EN" load-source="patent-office"><!-- EPO <DP n="157"> --><claim id="c-en-01-0001" num="0001"><claim-text>A vertebrate cell or cell line comprising a nucleotide sequence as set forth in SEQ ID NO: 87 or SEQ ID NO: 88, wherein the cell is not a human embryonic stem cell or an <i>in vivo</i> human cell and the cell line is not a human embryonic stem cell line.</claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>The cell of claim 1, wherein the nucleotide sequence encodes a tRNA molecule that has an anticodon recognition sequence that is specific for a selector codon.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>The cell of claim 2, wherein the selector codon is selected from the group consisting of: amber codon, ochre codon, opal codon, or four or more base codons.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>The cell of claim 2, wherein the nucleotide sequence encodes a tRNA molecule that is capable of being aminoacylated with at least one non-natural amino acid.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>The cell of claim 1, wherein the nucleotide sequence encodes a tRNA molecule that is an orthogonal tRNA (O-tRNA).</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>The cell of claim 5, wherein the O-tRNA is capable of aminoacylation with a natural amino acid or a non-natural amino acid.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>The cell of claim 4, wherein the O-tRNA is capable of aminoacylation with a natural amino acid or a non-natural amino acid.</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>The cell of claim 5, wherein the O-tRNA is capable of aminoacylation with a non-natural amino acid.</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>The cell line of claim 1, wherein the cell line has been stably transfected.</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>The cell line of claim 1, wherein the cell line has been transiently transfected.</claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>A method of producing in a vertebrate cell, wherein the vertebrate cell is not a human embryonic stem cell or an <i>in vivo</i> human cell, at least one protein comprising at least one non-natural amino acid, the method comprising:
<claim-text>growing, in an appropriate medium, said vertebrate cell that comprises a nucleic acid that comprises at least one selector codon and encodes the protein; wherein the medium comprises an unnatural amino acid and the vertebrate cell comprises:<!-- EPO <DP n="158"> --> an O-tRNA having a nucleotide sequence set forth in SEQ ID NO: 87 or SEQ ID NO: 88 that functions in the cell and recognizes the selector codon; and</claim-text>
<claim-text>an orthogonal aminoacyl tRNA synthetase (O-RS) that preferentially aminoacylates the O-tRNA with the unnatural amino acid.</claim-text></claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>The method of claim 11, wherein the cell has been stably transfected to comprise the O-tRNA and O-RS.</claim-text></claim><claim id="c-en-01-0013" num="0013"><claim-text>The method of claim 11, wherein the cell has been transiently transfected to comprise the O-tRNA and O-RS.</claim-text></claim><claim id="c-en-01-0014" num="0014"><claim-text>The method of claim 11, wherein the cell has been stably transfected to comprise one of the O-tRNA or O-RS and transiently transfected to comprise the other of the O-tRNA or O-RS, such that the cell still comprises both a- O-t-RNA and an O-RS.</claim-text></claim><claim id="c-en-01-0015" num="0015"><claim-text>The method of claim 11 or the cell of claim 8 wherein the unnatural or non-natural amino acid is selected from the group consisting of: a <i>p</i>-acetyl-L-phenylalanine, a <i>p</i>-iodo-L-phenylalanine, an O-methyl-L-tyrosine, a <i>p-</i>propargyloxyphenylalanine, an L-3-(2-naphthyl)alanine, a 3-methyl-phenylalanine, an O-4-allyl-L-tyrosine, a 4-propyl-L-tyrosine, a tri-O-acetyl-GlcNAcβ-serine, an L-Dopa, a fluorinated phenylalanine, an isopropyl-L-phenylalanine, a <i>p</i>-azido-L-phenylalanine, a <i>p</i>-acyl-L-phenylalanine, ap-benzoyl-L-phenylalanine, an L-phosphoserine, a phosphonoserine, a phosphonotyrosine, a <i>p</i>-bromophenylalanine, a <i>p</i>-amino-L-phenylalanine, an unnatural analogue of a tyrosine amino acid; an unnatural analogue of a glutamine amino acid; an unnatural analogue of a phenylalanine amino acid; an unnatural analogue of a serine amino acid; an unnatural analogue of a threonine amino acid; an alkyl, aryl, acyl, azido, cyano, halo, hydrazine, hydrazide, hydroxyl, alkenyl, alkynl, ether, thiol, sulfonyl, seleno, ester, thioacid, borate, boronate, phospho, phosphono, phosphine, heterocyclic, enone, imine, aldehyde, hydroxylamine, keto, or amino substituted amino acid, or any combination thereof; an amino acid with a photoactivatable cross-linker; a spin-labeled amino acid; a fluorescent amino acid; a metal binding amino acid; a metal-containing amino acid; a radioactive amino acid; a photocaged and/or photoisomerizable amino acid; a biotin or biotin-analogue containing amino acid; a keto containing amino acid; an amino acid comprising polyethylene glycol or<!-- EPO <DP n="159"> --> polyether; a heavy atom substituted amino acid; a chemically cleavable or photocleavable amino acid; an amino acid with an elongated side chain; an amino acid containing a toxic group; a sugar substituted amino acid; a carbon-linked sugar-containing amino acid; a redox-active amino acid; an α-hydroxy containing acid; an amino thio acid; an α,α disubstituted amino acid; a β-amino acid; a cyclic amino acid other than proline or histidine, and an aromatic amino acid other than phenylalanine, tyrosine or tryptophan.</claim-text></claim><claim id="c-en-01-0016" num="0016"><claim-text>The method of claim 11, wherein the protein comprises a therapeutic protein, a diagnostic protein, an industrial enzyme, or portion thereof.</claim-text></claim><claim id="c-en-01-0017" num="0017"><claim-text>The method of claim 11, wherein the protein or polypeptide of interest comprises a protein or a portion of a protein selected from the group consisting of: a cytokine, a growth factor, a growth factor receptor, an interferon, an interleukin, an inflammatory molecule, an oncogene product, a peptide hormone, a signal transduction molecule, a steroid hormone receptor, erythropoietin (EPO), insulin, human growth hormone, an Alpha-1 antitrypsin, an Angiostatin, an Antihemolytic factor, an antibody, an Apolipoprotein, an Apoprotein, an Atrial natriuretic factor, an Atrial natriuretic polypeptide, an Atrial peptide, a C-X-C chemokine, T39765, NAP-2, ENA-78, a Gro-a, a Gro-b, a Gro-c, an IP-10, a GCP-2, an NAP-4, an SDF-1, a PF4, a MIG, a Calcitonin, a c-kit ligand, a CC chemokine, a Monocyte chemoattractant protein-1, a Monocyte chemoattractant protein-2, a Monocyte chemoattractant protein-3, a Monocyte inflammatory protein-1 alpha, a Monocyte inflammatory protein-1 beta, RANTES, I309, R83915, R91733, HCC1, T58847, D31065, T64262, a CD40, a CD40 ligand, a Collagen, a Colony stimulating factor (CSF), a Complement factor 5a, a Complement inhibitor, a Complement receptor 1, DHFR, an epithelial Neutrophil Activating Peptide-78, a GROα/MGSA, a GROβ, a GROγ a MIP-1α, a MIP-1δ, a MCP-1, an Epidermal Growth Factor (EGF), an epithelial Neutrophil Activating Peptide, an Exfoliating toxin, a Factor IX, a Factor VII, a Factor VIII, a Factor X, a Fibroblast Growth Factor (FGF), a Fibrinogen, a Fibronectin, a G-CSF, a GM-CSF, a Glucocerebrosidase, a Gonadotropin, a Hedgehog protein, a Hemoglobin, a Hepatocyte Growth<!-- EPO <DP n="160"> --> Factor (HGF), a Hirudin, a Human serum albumin, an ICAM-1, an ICAM-1 receptor, an LFA-1, an LFA-1 receptor, an Insulin, an Insulin-like Growth Factor (IGF), an IGF-I, an IGF-II, an IFN-α, an IFN-β, an IFN-γ, an IL-1, an IL-2, an IL-3, an IL-4, an IL-5, an IL-6, an IL-7, an IL-8, an IL-9, an IL-10, an IL-11, an IL-12, a Keratinocyte Growth Factor (KGF), a Lactoferrin, a leukemia inhibitory factor, a Luciferase, a Neurturin, a Neutrophil inhibitory factor (NIF), an oncostatin M, an Osteogenic protein, a Parathyroid hormone, a PD-ECSF, a PDGF, a Pleiotropin, a Protein A, a Protein G, a Pyrogenic exotoxins A, B, or C, a Relaxin, a Renin, an SCF, a Soluble complement receptor I, a Soluble I-CAM 1, a Soluble interleukin receptor, a Soluble TNF receptor, a Somatomedin, a Somatostatin, a Somatotropin, a Streptokinase, a Superantigen, a Staphylococcal enterotoxins, an SEA, an SEB, an SEC1, an SEC2, an SEC3, an SED, an SEE, a steroid hormone receptor, a Superoxide dismutase (SOD), a Toxic shock syndrome toxin, a Thymosin alpha 1, a Tissue plasminogen activator, a tumor growth factor (TGF), a TGF-α, a TGF-β, a Tumor Necrosis Factor, a Tumor Necrosis Factor alpha, a Tumor necrosis factor beta, a Tumor necrosis factor receptor (TNFR), a VLA-4 protein, a VCAM-1 protein, a Vascular Endothelial Growth Factor (VEGEF), a Urokinase, a Mos, a Ras, a Raf, a Met; a p53, a Tat, a Fos, a Myc, a Jun, a Myb, a Rel, an estrogen receptor, a progesterone receptor, a testosterone receptor, an aldosterone receptor, an LDL receptor, a SCF/c-Kit, a CD40L/CD40, a VLA-4/VCAM-1, an ICAM-1/LFA-1, a hyalurin/CD44, and a corticosterone.</claim-text></claim><claim id="c-en-01-0018" num="0018"><claim-text>A kit for producing a protein that comprises at least one unnatural amino acid, the kit comprising: a container containing a polynucleotide sequence set forth in SEQ ID NO: 87 or SEQ ID NO: 88.</claim-text></claim><claim id="c-en-01-0019" num="0019"><claim-text>The kit of claim 18, wherein the kit further comprises at least one unnatural amino acid.</claim-text></claim><claim id="c-en-01-0020" num="0020"><claim-text>The kit of claim 18, wherein the kit further comprises instructional materials for producing the protein.</claim-text></claim></claims><claims mxw-id="PCLM56985055" lang="FR" load-source="patent-office"><!-- EPO <DP n="167"> --><claim id="c-fr-01-0001" num="0001"><claim-text>Cellule ou lignée de cellules de vertébré comprenant une séquence de nucléotides telle qu'indiquée dans la SEQ ID n° : 87 ou la SEQ ID n° : 88, dans laquelle la cellule n'est pas une cellule souche embryonnaire humaine ou une cellule humaine <i>in vivo</i> et la lignée de cellules n'est pas une lignée de cellules souches embryonnaires humaines.</claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Cellule selon la revendication 1, dans laquelle la séquence de nucléotides code pour une molécule d'ARNt qui a une séquence de reconnaissance d'un anticodon, qui est spécifique d'un codon sélecteur.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Cellule selon la revendication 2, dans laquelle le codon sélecteur est choisi dans le groupe constitué par le : codon ambre, codon ocre, codon opale, ou par quatre codons de base ou plus.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Cellule selon la revendication 2, dans laquelle la séquence de nucléotides code pour une molécule d'ARNt qui est capable d'être aminoacylée avec au moins un acide aminé non naturel.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Cellule selon la revendication 1, dans laquelle la séquence de nucléotides code pour une molécule d'ARNt qui est un ARNt orthogonal (O-ARNt).<!-- EPO <DP n="168"> --></claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Cellule selon la revendication 5, dans laquelle l'O-ARNt est capable de réaliser une aminoacylation avec un acide aminé naturel ou un acide aminé non naturel.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>Cellule selon la revendication 4, dans laquelle l'O-ARNt est capable de réaliser une aminoacylation avec un acide aminé naturel ou un acide aminé non naturel.</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>Cellule selon la revendication 5, dans laquelle l'O-ARNt est capable de réaliser une aminoacylation avec un acide aminé non naturel.</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>Lignée de cellules selon la revendication 1, dans laquelle la lignée de cellules a été transfectée de manière stable.</claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>Lignée de cellules selon la revendication 1, dans laquelle la lignée de cellules a été transfectée de manière transitoire.</claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>Procédé de production dans une cellule de vertébré, dans lequel la cellule de vertébré n'est pas une cellule souche embryonnaire humaine ou une cellule humaine <i>in vivo,</i> d'au moins une protéine comprenant au moins un acide aminé non naturel, le procédé comprenant les étapes consistant à :
<claim-text>cultiver, dans un milieu approprié, ladite cellule de vertébré qui comprend un acide nucléique, qui comprend au moins un codon sélecteur et code pour la protéine ; dans lequel le milieu comprend un acide aminé n'étant pas naturel et la cellule de vertébré comprend :
<claim-text>un O-ARNt ayant une séquence de nucléotides indiquée dans la SEQ ID n° : 87 ou la SEQ ID n° : 88 qui fonctionne dans la cellule et reconnaît le codon sélecteur ; et<!-- EPO <DP n="169"> --></claim-text>
<claim-text>une aminoacyl-ARNt orthogonal synthétase (O-RS) qui aminoacyle préférentiellement l'O-ARNt avec l'acide aminé n'étant pas naturel.</claim-text></claim-text></claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>Procédé selon la revendication 11, dans lequel la cellule a été transfectée, de manière stable, pour comprendre les O-ARNt et O-RS.</claim-text></claim><claim id="c-fr-01-0013" num="0013"><claim-text>Procédé selon la revendication 11, dans lequel la cellule a été transfectée, de manière transitoire, pour comprendre les O-ARNt et O-RS.</claim-text></claim><claim id="c-fr-01-0014" num="0014"><claim-text>Procédé selon la revendication 11, dans lequel la cellule a été transfectée, de manière stable, pour comprendre l'un des O-ARNt ou O-RS et a été transfectée, de manière transitoire, pour comprendre l'autre des O-ARNt ou O-RS, de sorte que la cellule comprenne encore à la fois un O-ARNt et une O-RS.</claim-text></claim><claim id="c-fr-01-0015" num="0015"><claim-text>Procédé, selon la revendication 11, ou cellule, selon la revendication 8, dans lequel (laquelle) l'acide aminé n'étant pas naturel ou étant non naturel est choisi dans le groupe constitué par :
<claim-text>une <i>p</i>-acétyl-L-phénylalanine, une <i>p</i>-iodo-L-phénylalanine, une O-méthyl-L-tyrosine, une <i>p-</i>propargyloxy-phénylalanine, une L-3-(2-naphthyl) alanine, une 3-méthyl-phénylalanine, une O-4-allyl-L-tyrosine, une 4-propyl-L-tyrosine, une tri-O-acétyl-GlcNAcβ-sérine, une L-Dopa, une phénylalanine fluorée, une isopropyl-L-phénylalanine, une <i>p</i>-azido-L-phénylalanine, une <i>p-</i>acyl-L-phénylalanine, une <i>p</i>-benzoyl-L-phénylalanine, une L-phosphosérine, une phosphonosérine, une phosphonotyrosine, une <i>p-</i>bromo-phénylalanine, une <i>p</i>-amino-L-phénylalanine, un analogue n'étant pas naturel d'un acide aminé tyrosine ; un analogue n'étant pas naturel d'un acide aminé glutamine ; un analogue n'étant pas<!-- EPO <DP n="170"> --> naturel d'un acide aminé phénylalanine ; un analogue n'étant pas naturel d'un acide aminé sérine ; un analogue n'étant pas naturel d'un acide aminé thréonine ; un acide aminé substitué par alkyle, aryle, acyle, azido, cyano, halo, hydrazine, hydrazide, hydroxyle, alcényle, alcynyle, éther, thiol, sulfonyle, séléno, ester, thioacide, borate, boronate, phospho, phosphono, phosphine, hétérocyclique, énone, imine, aldéhyde, hydroxylamine, céto ou amino ou bien une quelconque combinaison de ceux-ci ; un acide aminé avec un agent de réticulation photo-activable ; un acide aminé à marquage de spin ; un acide aminé fluorescent ; un acide aminé de liaison à un métal ; un acide aminé contenant un métal ; un acide aminé radioactif ; un acide aminé photo-bloqué et/ou photo-isomérisable ; un acide aminé contenant de la biotine ou un analogue de la biotine ; un acide aminé contenant un groupe cétonique ; un acide aminé contenant du polyéthylène glycol ou un polyéther ; un acide aminé à substitution d'atome lourd ; un acide aminé pouvant être photo-coupé ou coupé chimiquement ; un acide aminé avec une chaîne latérale allongée ; un acide aminé contenant un groupe toxique ; un acide aminé avec une substitution de glucide ; un acide aminé contenant un glucide, lié à un carbone ; un acide aminé actif d'un point de vue redox ; un acide contenant un α-hydroxy ; un acide thio-aminé ; un acide aminé α,α-disubstitué ; un acide β-aminé ; un acide aminé cyclique autre que la proline ou l'histidine, et un acide aminé aromatique autre que la phénylalanine, la tyrosine ou le tryptophane.</claim-text></claim-text></claim><claim id="c-fr-01-0016" num="0016"><claim-text>Procédé selon la revendication 11, dans lequel la protéine comprend une protéine thérapeutique, une<!-- EPO <DP n="171"> --> protéine diagnostique, une enzyme industrielle ou une partie de celles-ci.</claim-text></claim><claim id="c-fr-01-0017" num="0017"><claim-text>Procédé selon la revendication 11, dans lequel la protéine ou le polypeptide d'intérêt comprend une protéine ou une partie d'une protéine choisie dans le groupe constitué par : une cytokine, un facteur de croissance, un récepteur de facteur de croissance, un interféron, une interleukine, une molécule inflammatoire, un produit oncogène, une hormone peptidique, une molécule de transduction d'un signal, un récepteur aux hormones stéroïdiennes, l'érythropoïétine (EPO), l'insuline, l'hormone de croissance humaine, une antitrypsine alpha-1, une angiostatine, un facteur anti-hémolytique, un anticorps, une apolipoprotéine, une apoprotéine, un facteur natriurétique atrial, un polypeptide natriurétique atrial, un peptide atrial, une chimiokine C-X-C, le T39765, la NAP-2, l'ENA-78, une Gro-a, une Gro-b, une Gro-c, une IP-10, une GCP-2, une NAP-4, un SDF-1, un PF4, un MIG, une calcitonine, un ligand de c-kit, une chimiokine CC, une protéine chimio-attractive des monocytes de type 1, une protéine chimio-attractive des monocytes de type 2, une protéine chimio-attractive des monocytes de type 3, une protéine inflammatoire monocytique de type 1 alpha, une protéine inflammatoire monocytique de type 1 bêta, RANTES, 1309, R83915, R91733, HCC1, T58847, D31065, T64262, un CD40, un ligand de CD40, un collagène, un facteur stimulant les colonies (CSF), un facteur 5a du complément, un inhibiteur du complément, un récepteur 1 du complément, la DHFR, un peptide 78 activateur des polynucléaires neutrophiles épithéliaux, une GROα/MGSA, une GROβ, une GROγ, une MIP-1α, une MIP-1δ, une MCP-1, un facteur de croissance épidermique (EGF), un peptide activateur des polynucléaires neutrophiles épithéliaux, une<!-- EPO <DP n="172"> --> toxine exfoliante, un facteur IX, un facteur VII, un facteur VIII, un facteur X, un facteur de croissance des fibroblastes (FGF), un fibrinogène, une fibronectine, un G-CSF, un GM-CSF, une gluco-cérébrosidase, une gonadotropine, une protéine de hérisson, une hémoglobine, un facteur de croissance des hépatocytes (HGF), une hirudine, une sérumalbumine humaine, une ICAM 1, un récepteur d'ICAM 1, une LFA 1, un récepteur de LFA 1, une insuline, un facteur de croissance du type insuline (IGF), un IGF-I, un IGF-II, un IFN-α, un IFN-β, un IFN-γ, une IL-1, une IL-2, une IL-3, une IL-4, une IL-5, une IL-6, une IL-7, une IL-8, une IL-9, une IL-10, une IL-11, une IL-12, un facteur de croissance des kératinocytes (KGF), une lactoferrine, un facteur d'inhibition de la leucémie, une luciférase, une neurturine, un facteur d'inhibition des polynucléaires neutrophiles (NIF), une oncostatine M, une protéine ostéogène, une hormone parathyroïdienne, un PD-ECSF, un PDGF, une pléiotropine, une protéine A, une protéine G, des exotoxines pyrogènes A, B ou C, une relaxine, une rénine, un SCF, un récepteur I du complément soluble, une I-CAM 1 soluble, un récepteur d'interleukine soluble, un récepteur de TNF soluble, une somatomédine, une somatostatine, une somatotropine, une streptokinase, un super-antigène, des entérotoxines staphylococciques, une SEA, une SEB, une SEC1, une SEC2, une SEC3, une SED, une SEE, un récepteur aux hormones stéroïdiennes, une superoxyde dismutase (SOD), une toxine du syndrome du choc toxique, une thymosine alpha 1, un activateur du plasminogène tissulaire, un facteur de croissance tumorale (TGF), un TGF-α, un TGF-β, un facteur de nécrose tumorale, un facteur de nécrose tumorale alpha, un facteur de nécrose tumorale bêta, un récepteur du facteur de nécrose tumorale (TNFR), une protéine VLA-4, une<!-- EPO <DP n="173"> --> protéine VCAM-1, un facteur de croissance endothélial vasculaire (VEGEF), une urokinase, un Mos, un Ras, un Raf, une Met ; un p53, un Tat, un Fos, un Myc, un Jun, un Myb, un Rel, un récepteur aux oestrogènes, un récepteur de la progestérone, un récepteur de la testostérone, un récepteur d'aldostérone, un récepteur de LDL, un SCF/c-Kit, un CD40L/CD40, un VLA-4/VCAM-1, un ICAM-1/LFA-1, un hyalurine/CD44 et une corticostérone.</claim-text></claim><claim id="c-fr-01-0018" num="0018"><claim-text>Trousse destinée à produire une protéine qui comprend au moins un acide aminé n'étant pas naturel, la trousse comprenant : un conteneur contenant une séquence de polynucléotides indiquée dans la SEQ ID n° : 87 ou la SEQ ID n° : 88.</claim-text></claim><claim id="c-fr-01-0019" num="0019"><claim-text>Trousse selon la revendication 18, dans laquelle la trousse comprend en outre au moins un acide aminé n'étant pas naturel.</claim-text></claim><claim id="c-fr-01-0020" num="0020"><claim-text>Trousse selon la revendication 18, dans laquelle la trousse comprend en outre des matériels d'instruction pour produire la protéine.</claim-text></claim></claims><drawings mxw-id="PDW16672044" load-source="patent-office"><!-- EPO <DP n="174"> --><figure id="f0001" num="1"><img id="if0001" file="imgf0001.tif" wi="153" he="127" img-content="drawing" img-format="tif"/></figure></drawings><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
